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Abstract 
PI3Ks have been shown to have many important functions in T cells, including in cell growth 
and survival, chemotaxis and differentiation; however, the role of SHIP-1 as a negative 
regulator of PI3K signalling has not been so thoroughly investigated. The use of knockout 
mouse models has given an insight into the role of SHIP-1 in murine T cells, but these are 
compromised by loss of function during development which impinges upon mature T cell 
function. In addition, some work has been undertaken to investigate the role of SHIP-1 in 
human leukaemic T cell lines, but it is not clear how these findings might translate to SHIP­
1’s function in normal cells. 
Therefore the work in this thesis was undertaken to investigate the role of SHIP-1 in primary 
human T lymphocytes. Initial experiments demonstrated that SHIP-1 was active both in 
unstimulated cells and in response to a variety of stimuli. Using a lentiviral method to deliver 
shRNA against SHIP-1 and a constitutively active form of SHIP-1 it was found that whilst 
constitutive activation of SHIP-1 led to cell death, silencing of SHIP-1 expression resulted in 
viable cells which failed to proliferate. Furthermore, silencing of SHIP-1 revealed its crucial 
role in the regulation of basal PI3K signalling, actin polymerisation, cell morphology and 
basal motility. Interestingly, there was no additional defect in chemotaxis, in agreement with 
findings that SHIP-1 and TAPP PH domain probes did not localise to specific regions of the 
cell membrane during chemotaxis. In addition, silencing of SHIP-1 caused an abnormal 
profile of cytokine production and in particular, CD4+ T cells were skewed towards becoming 
Tregs. 
The observations in this study suggest that whilst the role of SHIP-1 in primary human T 
cells has some similarities to its role in both murine T cells and leukaemic cell lines, there 
are also significant differences which it will be crucial to take into account when designing 
drugs to target SHIP-1. 
The final results section comprises work completed for Novartis, the sponsor of this PhD. In 
this section it was found that knockout of PI3Kγ in mice resulted in elevated production of IL­
17A and IL-17F along with abberant expression of IL-17 receptors and loss of PI3K 
signalling in response to IL-17A. These findings are of particular relevance for PI3Kγ 
inhibitors that are in clinical trials for inflammation and autoimmune diseases. 
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In this section, the immune system will be introduced and the various components of 
the innate and adaptive immune systems discussed. The Introduction will then focus 
upon T cells, examining the range of T cells subsets, their activation and chemotaxis. 
Next the phosphatidylinositol -3 kinase (PI3K) signalling pathway will be described, 
with an emphasis on its role in immune cells and its regulation by lipid phosphatases, 
including SH2 domain containing inositol phosphatase-1 (SHIP-1). In addition, the 
role of the PI3K signalling pathway in inflammation and disease will also be covered, 
using the example of airway inflammation, including the potential of PI3Ks and lipid 
phosphatases as targets for drug discovery. 
1.1 The immune system 
1.1.1 Innate immunity 
The immune system serves two main roles in the body. Firstly its searches for and 
neutralises pathogens, including extracellular pathogens, intracellular pathogens, 
fungi, and parasites such as worms. The second function of the immune system is to 
remove unhealthy, dead or cancerous cells. The immune system can be broadly 
divided into two branches; innate and adaptive immunity. The innate immune system 
consists of phagocytes (i.e. macrophages, neutrophils and dendritic cells) as well as 
mast cells, eosinophils basophils and natural killer cells. Common motifs on 
pathogens can be recognised by pattern recognition receptors on cells of the innate 
immune system (2). Phagocytes can engulf pathogens, whilst mast cells, eosinophils 
and basophils release inflammatory mediators such as histamine to trigger 
inflammation and initiate further leukocyte recruitment. Natural killer (NK) cells kill 
tumour cells or cells infected with virus that fail to present major histocompatibility 
complex I (MHCI) (3). γδ T cells may also be considered to be part of the innate 
immune system as the T cell receptor (TCR) can function as a pattern recognition 
receptor (4, 5). 
1.1.2 Adaptive immunity 
Dendritic cells can be described as a bridge between innate and adaptive immunity 
as they are professional antigen presenting cells (APCs)(6). The main components of 
the adaptive immune system are B cells and T cells. T cells may be either CD 
(cluster of differentiation) 8+ T cells, which recognise antigen presented by MHC I 
(found on all cells) and primarily kill cancerous or virally infected cells, or they can be 
CD4+ and recognise antigen presented by MHC II which is found on macrophages, 
dendritic cells and B cells (7). CD4+ T cells differentiate into a number of effector cell 
2 
Chapter 1: Introduction 
subtypes that can be classified according to their transcription factor and cytokine 
expression profile (3, 8) (Figure 1.1). 
1.2 CD4+ T cell subsets and CD8+ T cells 
1.2.1 Overview of T cell subsets 
Mosmann and Coffman were the first to describe how T helper cells could be of 
either Th1 or Th2 phenotypes (8). Broadly, Th1s, which are characterised by the 
secretion of IFNγ, aid cell mediated killing, by directing B cells’ production of 
opsonising antibodies and supporting macrophage-mediated killing. Th2s help B cells 
to make neutralising antibodies and are characterised by the production of IL-4 (9). 
More recently another subset of T helper cells has been identified, namely the Th17 
subset, which produce the signature cytokine IL-17 and encourage tissue based 
immunity, for example by triggered IL-6 production by fibroblasts (10, 11). Further T 
cells subsets include the recently identified Th9 (12, 13), and Th22s (14), which 
produce IL-9 and IL-22 respectively. Although niche functions of these cells have 
been identified their overall significance is as yet unclear. Tregs are a further subset 
of T helper cells which are suppressive upon other cell types. Tregs may develop in 
the thymus or can be developed from naïve T cells in the periphery. They may 
release signature cytokines including TGFβ and IL-10. Some would also consider 
follicular T cells to be a separate class of T helper cells (Tfh)(9).The CD4+ T cell 
subsets will now be considered in more detail. 
1.2.2 Th1 cells 
Th1 cells produce IFNγ and IL-12. In addition they produce lymphotoxin, tumour 
necrosis factor α (TNFα) and substantial quantities of IL-2. They aid B cell class 
switching to immunoglobulin G2a (IgG2a) and stimulate macrophage activity, thus 
promoting the destruction of cells infected with intracellular pathogens such as 
Listeria monocytogenes. Th1 cells are implicated in the pathology of autoimmune 
diseases, for example multiple sclerosis (15, 16). 
Th1 differentiation is initiated by IFNγ or the IL-12 family member IL-27 (whose 
receptors are expressed on naive cells) triggering the activation of signal transducer 
and activator of transcription 1 (STAT1) which upregulates the T-box transcription 
factor Tbet. Tbet induces production of IFNγ, remodels the ifnγ gene locus and also 
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Figure 1.1: CD4+ T cell subsets 
Tregs can be induced from thymocytes or from naive cells in the periphery. All other 
CD4+ subsets are induced in the periphery. T helper 1 (Th1) differentiation is 
induced by interleukin -12 (IL-12), Th2 differentiation by IL-4, and Th17 most likely by 
a combination of IL-23, IL-6 and transforming growth factor β (TGFβ). They then 
produce their signature cytokines, amongst others: interferon γ (IFNγ) is produced by 
Th1, IL-4 by Th2, IL-17 by Th17 and IL-10 and TGFβ by regulatory T cells (Tregs). 
IFNγ suppresses Th2 and Th17 differentiation and function, IL-4 suppresses Th1 and 
Th17, Treg cytokines suppress Th1, Th2 and probably Th17s. It is not clear whether 
IL-17 has suppressive actions on particular CD4+ subsets (17) although there is 
some evidence that it may regulate Th1 function (18). Signature chemokine receptors 
and transcription factors are also shown. 
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increases transcription of the β chain of the receptor for IL-12 (19). In some limited 
circumstances, STAT1 signalling may be dispensable for the generation of IFNγ 
producing Th cells (20). The transcription factor Eomes also plays an important role 
in the control of the Th1 lineage (21) as do STAT2 and STAT4. Tbet and STAT4 
contribute to a positive feed back loop by upregulating IFNγ and IL-12Rβ2, but also 
inhibit Th2 responses by downregulating the transcription factor GATA3. TCR 
signalling controls activation of the transcription factors nuclear factor of activated T 
cells (NFAT), nuclear factor κB (NfκB) and activator protein 1 (AP-1), and strong TCR 
signalling biases towards Th1 development (22). 
1.2.3 Th2 cells 
Th2 cells produce IL-4, IL-5 and IL-13: these aid B cell class switching to produce IgE 
and IgG1, help eosinophil recruitment and promote mucosal defence. Therefore Th2 
cells play a role in defence against extracellular pathogens such as helminths (23). 
Aberrant Th2 responses are implicated in allergic diseases such as asthma (9). 
Naive CD4+ T cells express the IL-4 receptor, and IL-4 stimulates the receptor to 
activate STAT6. In combination with IL-2 mediated activation of STAT5, this causes 
the cells to differentiate into Th2s as well as causing production of the transcription 
factor GATA3. GATA3 remodels the il-4 locus to facilitate increased IL-4 transcription 
upon restimulation (24), although it does not directly bind the IL-4 promoter itself (25). 
However, it can bind the IL-5 and IL-13 promoters (26). Activation of the transcription 
factors AP-1, NFAT and NFκB also aids the differentiation of Th2 cells, although 
NFAT1 also plays a part in a negative feedback loop to inhibit IL-4 production (27). 
The Th2 phenotype is reinforced by cytokine feed back loops. IL-4 induces its own 
expression, whilst the cells become unresponsive to IFNγ and IL-12. In human cells, 
some degree of plasticity remains, for example if Th1 cells are cultured under Th2 
skewing conditions, then a proportion of the cells will start to express both IFNγ and 
IL-4 (28). 
1.2.4 Th17 cells 
In order to induce differentiation towards a Th17 phenotype, TGFβ and IL-6 are 
required in mice, and IL-1 and TNFα may also play a role (29-31). Whilst IL-23 is not 
5 
Chapter 1: Introduction 
required for the generation of murine Th17 cells it is thought to aid in their expansion 
and maintenance once differentiated (31). Human Th17 generation is thought to 
require at least IL-1β, IL-23 and TGFβ, although a consensus has not been reached 
(protocols for generation of human Th17 cells are comprehensively reviewed by de 
Jong et al. (32)).   
Th17 cells are believed to be generated using STAT3 signalling, whilst STAT1 and 5 
are inhibitory upon Th17 development (33). STAT3 also binds IL-17 and IL-17F 
promoters (34). Retinoic Acid Receptor- related orphan receptor γt (RORγt) (which is 
expressed in response to STAT3) and RORα are both involved in Th17 differentiation 
and RORγt is required for the production of IL-17 and IL-17F (35). Similarly, an 
absence of RORα reduces IL-17 expression, whilst interferon regulatory factor (IRF) 
is also thought to aid Th17 differentiation (33). Development of Th17 is inhibited by 
other cytokines for example IL-2 and IFNγ (29). TGFβ facilitates expression of the IL­
23R. Note that in the absence of IL-6, TGFβ induces Tregs rather than Th17 (33). 
The Th17 cells produce IL-17A, IL-17F, IL-21 and IL-22 as well as the Th1-expressed 
cytokines TNFα and lymphotoxin β (36). Th17 cells also preferentially express the 
chemokine receptor CCR6 and its ligand, the chemokine CCL20 (also known as 
MIP3α) (37). However, Th17 cells express neither IFNγ nor IL-4 (33). Furthermore 
both IFNγ and IL-4 inhibit Th17 differentiation (11) (however there is some evidence 
of CD4+ cells that express both IFNγ and IL-17 (33)). IL-27 also negatively regulates 
IL-17 production. IL-2 signalling has been shown in mice to reduce IL-17 production 
and increase generation of Tregs (38). 
IL-17A drives a tissue based immune response to combat extracellular pathogens 
such as bacteria and fungi via the production of IL-6, IL-8, granulocyte macrophage 
colony stimulating factor (GM-CSF), matrix metalloproteinases (MMPs) and 
chemokines including CXCL1 and CXCL10 (31) to orchestrate the recruitment of 
macrophages and neutrophils to tissues (33). IL-17F has about 50% homology to IL­
17A with similar functions (31, 36, 39). IL-17A and IL-17F have been implicated in 
airway inflammation (36, 40, 41) as well as diseases including multiple sclerosis, 
psoriasis, inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and systemic 
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lupus erythromatosis (SLE) (36, 42). Furthermore, IL-17A and IL-17F are thought to 
have both pro- and anti- tumour functions, with IL-17F in particular exacerbating 
tumour growth by facilitating angiogenesis (43). 
1.2.5 Treg cells 
Tregs can be broadly divided into natural Tregs (nTregs), which are generated in the 
thymus, and inducible T regs (iTregs), which can be generated from naive T cells in 
the periphery or in vitro (44 - 46).  Tregs can be generated in vitro by TGFβ, and 
express the transcription factor forkhead box P3 (foxp3). Mutations in foxp3 in mice 
or humans, leads to Scurfy mice and IPEX syndrome (immunodeficiency, 
polyendocrinopathy, and enteropathy, X-linked syndrome) respectively (47). A key 
target of Foxp3 is the micro RNA miR155. miR155 suppresses suppressor of 
cytokine signalling 1 (SOCS1) and increases proliferation of Tregs in response to IL­
2 (48). miR155 is also upregulated in naive T cells upon activation and when 
miR155 is lost, cells are skewed towards a Th2 phenotype (49). In addition, there are 
several reports of the lipid phosphatase SHIP-1 being negatively regulated by 
miR155, indicating that loss of SHIP may have opposite effects of miR155 loss (50). 
The control of SHIP-1 by miR155 will be covered in the Discussion. 
Tregs may be further subdivided, with some researchers considering TGFβ­
producing cells as a separate class of T helper cells termed Th3, whilst those 
producing IL-10 are described as Tr1 cells. Interestingly, some cells can also express 
both foxp3 and RORγt and are therefore Tregs with the ability to produce IL-17 (51­
53). In addition, subpopulations of foxp3 positive cells have also been shown to 
express GATA3 (15) and Tbet (54) with the latter playing a particular role in the 
suppression of Th1 responses. 
1.2.6 CD8+ T cells 
CD8+ T cells are also known as cytotoxic T lymphocytes (CTLs). The main function 
of CD8+ T cells is to lyse cells that are either cancerous or infected with viruses, 
using perforins and granzymes. Granzymes are a family of serine proteases and 
CTLs produce granzyme A and granzyme B (55). CTLs also release the antiviral 
cytokines IFNγ and TNFα (although CTLs have recently been shown to secrete IL-17 
as well (56-58)). However, individual cells do not necessarily express all granzymes, 
perforins and cytokines (59). Eomesodermin drives the production of cytokines and 
cytotoxic products, although T-bet is also thought to play a role (60, 61). TCR 
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stimulation and signalling from cytokines such as IL-2 are also important in initiation 
of granzyme production (62).  
Granzymes and perforins bound to serglycin are stored in cytotoxic granules, a type 
of secretory lysosome (63). Upon TCR ligation, the secretory granules move to the 
supramolecular activation cluster (SMAC) at the immunological synapse (64). The 
granzymes enter target cells through the actions of perforins (58). The exact process 
is not clearly understood but is thought to involve perforins making pores in the target 
cell that allow calcium influx and trigger endocytosis (65). Once in the target cell, 
granzyme A can initiate caspase independent cell death by initiating mitochondrial 
damage leading to DNA damage and subsequent apoptosis (66). Granzyme B can 
activate caspases, including caspase 3 to initiate apoptosis (67). 
1.3 T cell trafficking 
1.3.1 Immune surveillance and T cell trafficking 
T cells generally encounter antigens presented by professional APCs in secondary 
lymphoid organs (SLOs) such as lymph nodes. In order for this to occur during 
normal immune surveillance, T cells must be directed to leave the blood and to 
migrate through the SLO in a manner which encourages them to encounter their 
cognate antigen, followed by egress from the lymph node, across a further 
endothelial cell barrier, to re-enter the vascular system (68). This process is 
orchestrated by chemokines (see below), selectins, integrins and sphingosine 1 
phosphate (S1P). 
Lymphocytes in the blood express selectins and α4 integrins (e.g. Very Late Antigen 
-4, VLA-4) on the tips of their microvilli. These tether to their ligands (e.g. vascular 
cell adhesion molecule-1 (VCAM-1)) on the endothelial cell wall, in the face of shear 
flow, allowing rolling to occur. This can occur spontaneously, without need of integrin 
activation. T lymphocytes also use LFA-1 during rolling, but not in making the initial 
tethering contact (69-71). Once tethered or rolling, T cells can come into contact with 
chemokines associated with the endothelium. If they express a cognate receptor for 
these chemokines, the T cell will arrest and undergo firm adhesion via LFA-1 and α4 
integrins. It will then extravasate from the blood vessel using CD31, LFA-1 and α4 
integrins. Expression of a variety of chemokine receptors allows the correct T cell to 
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be recruited and if necessary retained in a particular tissue. For example; 
lymphocytes expressing CCR7 and L-selectin will home to secondary lymphoid 
tissues by virtue of their expression of the CCR7 ligands CCL21 and CCL19. 
Expression of L-selectin and the CCR7 ligand CCL21 (and possibly CCL19) by the 
high endothelial venules (HEVs) promotes diapedis of the naïve T cells as illustrated 
in Figure 5 (72), whilst central memory T cells may undergo diapedis in response to 
CXCL12/CXCR4 signalling (73). CCL21 gradients then direct the T cell to migrate 
through the SLO for 6-24 hours, where it can interact with dendritic cells (DC), which 
may bear its cognate antigen (74), although random movement of T cells within 
SLOs has also been observed (75). Sphingosine-1 phosphate gradients promote the 
egress of T cells from SLOs, a process which is antagonised by CCR7 ligands (76). 
During an adaptive immune response, the above process is facilitated by 
upregulation of ICAM-1 and CCL21 on the HEV to encourage migration into lymph 
nodes (77). Once activated, expression of specific chemokine receptors facilitates 
migration to sites of peripheral inflammation; for example CCR9 allows homing to the 
small intestine and CCR4 and CCR10 to the skin (78). Furthermore, subsets of T 
helper cells express characteristic chemokine receptors (Th1 CXCR3 and CCR5, 
Th2 CCR4 and CCR8 (79), Th17 CCR6 (37), Th22 CCR10 (14, 80) and Tfh CXCR5. 
Tregs express a variety of chemokine receptors, but change from expressing CCR7 
to CXCR5 upon activation (81)). The signature cytokines released by these cells 
encourage tissue resident cells to release appropriate chemokines to recruit more 
cells from the same T helper subtype, thus contributing to a positive feedback loop 
during the adaptive immune response (82). 
1.3.2 The role of chemokines in the immune system 
Chemokines (chemotactic cytokines) are small proteins, approximately 8-10kDa, 
which derive their names from characteristic cysteine residues in CC, CXC C or 
CXXXC motifs at the amino terminus. There are over 50 chemokines and 18 
chemokines receptors (83, 84). Most chemokine receptors can bind different 
chemokines, and some chemokines can also act at several different receptors. 
Although some chemokines have homeostatic functions (such as CCR7 ligands), the 
majority are released from cells upon inflammation in order to recruit leukocytes (85). 
Chemokine receptors are 7 transmembrane GPCRs, coupled to Gαi (84). Classically 
viewed as forming a chemokine gradient in order to direct chemotaxis, in fact a key 
role of chemokines is to induce arrest of leukocytes on the endothelium and firm 
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adhesion through intergrin clustering and affinity changes (86, 87). In addition to the 
functional chemokine receptors, two non-signalling receptors, D6 and duffy antigen 
receptor for chemokines (DARC) have been identified. D6 serves to scavenge and 
endocytose excess inflammatory chemokines, whilst DARC scavenges excess 
chemokines and also aids the uptake of chemokines by endothelial cells for 
subsequent display to leukocytes (88, 89). 
10 
Chapter 1: Introduction 
Figure 1.2: T cell extravasation from the blood 
T cells in the blood make temporary contact with endothelial cell through the 
interaction of L-selectin and integrins with their ligands presented on the surface of 
endothelial cells. Chemokines activate multiple pathways within the cell to cause 
flattening and firm adhesion, which is mediated by the actions of LFA-1 and α4 
integrins. The cell may then crawl along the endothelial cell until it reaches a junction 
between endothelial cells, at which point it will extravasate from the blood vessel in a 
process known as diapedesis (90). 
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1.3.3 T cell activation 
T cell activation is described by a two signal model. “Signal 1” occurs when an 
antigen presenting cell presents antigen on an MHC. The MHC and antigen are 
bound by the T cell’s TCR. The MHC protein is also bound by either CD4 or CD8 on 
the T cell. “Signal 2” is initiated by the binding of costimulatory molecule on the T cell 
(typically CD28) by an appropriate ligand such as CD80/CD86 (B7) on the antigen 
presenting cell. Without signal 2, signal 1 induces anergy in the T cell, a protective 
mechanism which prevents aberrant response to self-antigen (91) (Figure 1.3). Other 
molecules can also provide a costimulatory signal, for example, ICOS, an inducible 
costimulator which is expressed on activated T cells, Lymphocyte function-
associated antigen 1 (LFA-1) and some β1 integrins including Very late antigen-4 
(VLA-4). Negative regulation of TCR signalling also occurs, firstly through termination 
of the existing signals, for example by the actions of phosphatase and tensin 
homolog (PTEN) or though recruitment of negative regulators of signalling such as 
the Dok adaptor proteins of SH2-domain-containing tyrosine phosphatase 1 (SHP1) 
to the TCR signalosome, and secondly through the actions of inhibitory co-receptors 
such as Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD­
1) (92, 93). Signal 1 and 2 initiate a range of intracellular signalling pathways in the T 
cell including PLCγ and PI3K signalling pathways (Figure 1.4). These have a number 
of crucial roles in T cell activation, perhaps the most important of which is the 
production of IL-2. IL-2 is a key factor in the survival and proliferation of T cells (94). 
Furthermore, activated T cells upregulate expression of CD25 (the IL-2 receptor α 
chain) via NFAT transcription factors, in order to increase the positive feedback loop 
(95). 
The signalling pathways that control T cell activation will now be considered in more 
detail. The T cell receptor consists of α and β chains, (which are variable in nature 
and can recognise and bind their cognate antigen), associated non-covalently with 
dimers of different CD3 proteins. Antigen binding, in the context of MHC 
presentation, leads to the phosphorylation of immunoreceptor tyrosine based 
activation (ITAM) motifs on CD3 molecules by Src kinases, thus initiating the 
formation of signalling complexes. This starts with recruitment of the adaptor protein 
zeta chain associated protein kinase 70 kDa (ZAP-70) which in turn recruits linker of 
activated T cells (LAT) (96). LAT can bind phospholipase Cγ (PLCγ), SH2 domain 
containing leukocyte protein 76 kDa (SLP-76) and the p85 adaptor subunit of PI3Ks 
as well as growth factor receptor bound protein 2 (Grb2) and Grb2-Related Adaptor  
12 
Chapter 1: Introduction 
Figure 1.3: T cell activation and costimulation 
The TCR recognises a peptide antigen when it is presented by MHC complexes. 
CD4 recognises class II MHC, expressed by professional antigen presenting cells, 
whilst CD8 recognises class I MHC, which is expressed on all cells. This signal alone 
(signal 1) induces anergy, or even death of the T cell. However, signal 2 can be 
provided by B7.1 or B7.2 on the antigen presenting cell (APC) binding CD28. CD28 
is widely expressed on T cells and direct the cell towards activation and proliferation 
(e.g. IL-2 production). ICOS is upregulated upon T cell activation, and therefore 
serves to modulate the functions of the active cell through interactions with ICOSL. 
Negative regulation of T cell responses is achieved via the interaction of B7.1 or B7.2 
with CTLA4 (the expression of which is also upregulated upon activation of T cells), 
or via Programmed Death ligand (PD-L) costimulation (97-99). 
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Downstream of Shc (GADS). Thus PI3K, inositol trisphosphate (IP3) (which leads to 
Ca2+ flux) and diacyl glycerol (DAG) signalling pathways are all controlled by the TCR 
(Figure 1.4). CD28 initiates PI3K signalling by recruitment of the p85 adaptor to the 
pYMNM motif (100). The PI(3,4,5)P3 generated serves to recruit PDK1 and Akt. In 
the case of T cell activation, two Akt signalling pathways are of particular importance. 
Firstly, inhibition of GSK3β prolongs nuclear localisation of NFAT and hence 
increases IL-2 production. Akt also activates NFκB, causing the transcription of pro 
survival genes such as Bcl-xl (B-cell lymphoma-extra large). PI(3,4,5)P3 also recruits 
Itk, thus regulating the ERK signalling pathway (101). 
Full T cell activation requires polarisation of the cell, with movement of the 
microtubular organizing center (MTOC) towards the site of contact with the APC and 
the formation of a strong synapse, in the form of a supramolecular activation cluster 
(SMAC) (102). The central SMAC is rich in TCRs, whilst the peripheral SMAC has a 
high density of integrins to facilitate adhesion (103).  
Adhesion of T cells to the endothelium or to antigen presenting cells requires actin 
polymerisation and inside-out signalling from the TCR to integrins to increase their 
affinity for their ligands. This involves the formation of signalling complexes initiated 
by recruitment of adhesion and degranulation promoting adaptor protein (ADAP) to 
SLP-76 (104, 105). ADAP binds Src kinase associated phosphoprotein 55 kDa 
(SKAP-55) and Rap1-GTP interacting adaptor molecule (RIAM) and translocates to 
the cell membrane, possibly through the interaction of RIAM’s pleckstrin homology 
(PH) domain with phosphatidylinositol 3,4 bisphosphate (PI(3,4)P2) (106). This 
complex facilitates the recruitment of Talin to the tails of the integrins. Lastly, PLCγ1 
stimulated PKD1 association with Rap1 causes its activation and hence the 
recruitment of RAPL (107, 108). RAPL initiates the clustering of integrins and 
changes in their conformation to improve their affinity for their ligands (Figure 1.5). 
Furthermore, TCR signalling can itself mediate integrin activation, whilst LFA-1 
contributes to T cell adhesion to antigen presenting cells, allowing a stable contact to 
form at the synapse (90). 
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Figure 1.4: Signalling initiated by T cell activation 
Upon TCR activation, leukocyte-specific protein tyrosine kinase (LCK) activates ZAP­
70 which phosphorylates tyrosine residues on LAT, facilitating recruitment of GADS 
and SLP-76. ZAP-70 further phosphorylates SLP-76, allowing the recruitment of 
more SH2 domain containing proteins. SLP-76 also has a proline rich domain which 
allows recruitment of SH3 domain containing proteins including PLCγ1 and ITK. The 
involvement of Gads in the signalling complex allows the recruitment of PI3K, whilst 
PLCγ1 cleaves PI(4,5)P2 to yield IP3 and DAG. IP3 acts on its receptors on the 
endoplasmic reticulum (ER) to initiate Ca2+ release, this leads to colocalisation of 
STIM with CRAC channels to allow extracellular Ca2+ to enter the cell. In addition, 
DAG triggers PKCθ activation and recruitment of RasGRP (guanyl nucleotide-
releasing protein). Protein kinase Cθ (PKCθ) activates RasGRP, which removes 
GDP from Ras, allowing it to bind GTP and thus activating it (92).  
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Figure 1.5: Integrin activation by TCR signalling 
The LAT/SLP-76 complex is assembled as described in Figure 1.4. ADAP is 
recruited to SLP-76 and complexes with RIAM and SKAP55. These then localise the 
membrane where RIAM is thought to bind PI(3,4)P2 by virtue of its PH domain. The 
complex recruits RAP1 (Repressor Activator Protein) and RAPL (regulator of cell 
adhesion and polarization enriched in lymphoid tissues) and subsequently Talin. 
PLCγ1 is recruited to the TCR signalosome, and mediates generation of DAG which 
activates PKCθ and in turn PKD1, which contributes to the recruitment and activation 
of Rap1. Talin and RAPL mediate the clustering of integrins and the conformational 
changes required to increase their affinity. 
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1.3.4 Reactive oxygen species in cell signalling 
Thus far, an examination of signalling pathways has focussed on the role of proteins 
and phospholipids. Yet other molecules can also play a key role in cell signalling. For 
example it is well known that reactive oxygen species (ROS) are generated by a 
range of phagocytic cells and have a key role in mediating microbial killing (109). 
However, ROS are also generated in a range of other cell signalling pathways, 
including TCR signalling (110, 111) and death receptor signalling (112), where they 
are key mediators of apoptosis. 
1.3.5 Resolution of the T cell response 
During the adaptive immune response there is a large proliferation of T cells (the 
expansion phase). However, as infection is resolved, many of these cells will become 
surplus to requirement and die. This can happen in two main ways: activation 
induced cell death (AICD) and activated T cell autonomous death (ACAD). AICD 
relies upon TCR stimulation and also upon cytokines particularly IL-2 (113). It is not 
currently clear how IL-2, which generally increases the survival and expansion of T 
cells, switches during the contraction phase to sensitise to AICD, although it has 
been hypothesised that IL-2 signalling drives the expression of CD95L (FasL) (114). 
TCR signals also generate ROS which can initiate a mitochondrial dependent death 
pathway and aid expression of CD95L (115). 
Death receptors can play a key role in AICD. Three main receptors are implicated: 
Fas, TNFα, and TNF-related apoptosis-inducing ligand (TRAIL) receptors (116). 
Knockout of the Fas receptor (CD95) in mice results in accumulation of T cells and 
autoimmunity (116, 117). The involvement of TNF signalling in AICD is less well 
characterised but inhibition of TNF signalling can reduce TCR-mediated cell death 
(118). Knockout of TRAIL on its own does not result in a strong phenotype, but in 
conjunction with knockout of FasL show a severe pathology (119). ACAD, also 
known as death by neglect, is a cell intrinsic process that does not require TCR 
stimulation or death receptor ligation. Instead it is triggered by Bim signalling (120) 
and a decrease in levels of Bcl-2 (through a ROS dependent mechanism (121-123)). 
Thus ACAD has been hypothesised to be the dominant mechanism at the end of the 
immune response when levels of foreign antigen are low (116). 
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1.4 The PI3K pathway 
1.4.1 PI3K in health and disease 
Phosphoinositide 3-kinases (PI3K) were discovered in the late 1980s (124, 125) and 
it is now understood that they play many important roles, including the control of cell 
growth and survival, transcriptional and translational responses, glucose and nutrient 
uptake, proliferation, migration and differentiation. However, dysregulation of PI3K in 
these processes contributes to a range of diseases including diabetes, 
cardiovascular disease, autoimmune diseases as well as cancer and inflammation 
(126-128). 
1.4.2 Structure, function and distribution of PI3K isoforms 
The class 1 PI3Ks are composed of a regulatory subunit and a constitutively 
associated catalytic subunit. The three class 1A catalytic isoforms p110α, p110β and 
p110γ each pair with one of five regulatory subunits encoded by three genes: p85α, 
its alternative transcripts p55α and p50α, p85β and p55γ (Figure 1.6). The regulatory 
subunits modulate enzymatic activity and degradation of the catalytic subunits and 
are responsible for recruitment of the complex to the plasma membrane upon 
receptor ligation.  Class 1A isoforms are activated downstream of immune cell 
receptors including the TCR, B cell receptor (BCR), costimulatory molecules and 
cytokine receptors that are phosphorylated by tyrosine kinases upon cognate 
stimulus (129, 130) (Figure 1.7).  
The class 1B catalytic isoform p110γ pairs with either of the regulatory subunits 
p84/p87 or p101 (131, 132) and is activated by G protein βγ subunits and signals 
downstream of G protein coupled receptors (GPCRs). However, there is now 
substantial evidence that some GPCRs including chemokine receptors activate class 
IA PI3Ks, particularly PI3Kβ (133-135).  Regulation of PI3K signalling is mediated by 
the 3’ phosphatase PTEN and the 5’ phosphatases SHIP-1 and SHIP-2 (136). 
Whereas PI3Kα and PI3Kβ appear to have a ubiquitous tissue distribution, PI3Kδ 
and PI3Kγ are predominantly expressed in immune cells, although PI3Kγ is also 
expressed in the heart and endothelium (137, 138) and PI3Kδ is found in neurons 
and in some cancers including melanoma and breast cancer (139, 140).  Similarly, 
PTEN and SHIP-2 are ubiquitously expressed, whilst SHIP-1 is mainly restricted to 
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leukocytes (136), although it is also found in spermatids (141) and has recently been 
reported to be expressed in the endothelium (142). 
1.4.3 PI3K signalling 
Phosphatidyl Inositol 3’ Kinases (PI3Ks) catalyse the addition of a phosphate group 
to the 3’ position of the inositol ring in phosphatidyl inositides. The Class I PI3Ks 
convert PI(4,5)P2 to PI(3,4,5)P3 (Figure 1.7). PI(3,4,5)P3 remains associated with the 
cell membrane and recruits proteins containing pleckstrin homology (PH) domains, 
thus initiating signalling cascades. PI3Ks are found in all cells of the body and play 
essential roles in processes such as proliferation and survival. In addition, PI3Ks 
have unique functions in immune cells, playing a part in chemotaxis to chemokines 
as well as antigen, cytokine and co-receptor signalling. PI3K signalling can be 
terminated by the actions of the lipid phosphatase PTEN, a 3’ phosphatase which 
hydrolyses PI(3,4,5)P3 back to PI(4,5)P2. However, PI(3,4,5)P3 is also a substrate for 
the SHIPs which covert PI(3,4,5)P3 to PI(3,4)P2. PI3K signalling activates a multitude 
of signalling pathways (Figure 1.8). Some key pathways will now be considered in 
detail. 
1.4.4 The importance of PDK-1 and other AGC family kinases in 
PI3K signalling 
The AGC family of kinases are all serine/threonine or tyrosine kinases, consisting of 
60 members, including cyclic AMP dependent protein kinase (PKA), cyclic GMP 
dependent protein kinase (PKG) and protein kinase C (PKC) from which their name 
is derived (143). There are also several members with key roles in PI3K signalling 
including PDK1 and protein kinase B (PKB/ Akt). PDK1 is constitutively active as it 
can trans autophosphorylate its activation motif and upon recruitment to PI(3,4,5)P3, 
phosphorylates many other AGC family kinases on their activation motifs, which lie 
within the catalytic domain (144). For example, Akt is recruited to PI(3,4,5)P3 and 
then phosphorylated upon Thr308 by PDK1(145). mTOR complex 2 (mTORC2) then 
phosphorylates Akt on Ser473, to allow full activation (146). S6 kinase (S6K), serum-
and glucocorticoid-induced protein kinase (SGK) and PKC, all members of the AGC 
family of kinases, also depend upon PDK1 for activation (147, 148). Therefore it can 
be seen that PDK1 serves as a master regulator of PI3K signalling. 
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Figure 1.8: Phosphatidylinositol signalling by PI3K, PTEN and SHIP 
Phosphatidylinositol (4,5) bisphosphate (PI(4,5)P2) is associated with the inner cell 
surface membrane. Upon receptor stimulation, PI3K catalyses the addition of a 
phosphate group to the 3 prime position of the inositol ring to yield 
Phosphatidylinositol (3,4,5) trisphosphate (PI(3,4,5)P3), which remains associated 
with the membrane and recruits proteins containing pleckstrin homology (PH) 
domains, the classical example of which is Akt (149). This initiates a number of 
signalling pathways as illustrated in Figure 9. Regulation of PI3K signalling is 
achieved by the actions of the lipid phosphatases PTEN and the SHIPs. PTEN 
removes the phosphate from the 3 prime position to give the original substrate 
PI(4,5)P2, whilst the SHIPs remove a phosphate group from the 5 prime position to 
generate PI(3,4)P2. Many small molecule ATP-competitive inhibitors of PI3K have 
been developed in order to control the PI3K signalling pathway. 
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Figure 1.9: PI3K signalling pathways 
PI(3,4,5)P3, the product of PI3K, remains associated with the membrane and recruits 
proteins containing pleckstrin homology domains. Akt is one such protein: an AGC 
family kinase, it adds phosphate groups to wide variety of proteins to modulate their 
action. For example, it inhibits the transcription factor p53 and forkhead box (FOXO), 
to inhibit cell death, it inhibits GSK3β to promote the cell cycle and metabolism and it 
activates the mammalian target of rapamycin (mTOR) to initiate cell growth. Other 
PH domain containing proteins that are recruited to PI(3,4,5)P3 include SGK and Tec. 
The latter, through activation of PLCγ, activates DAG and IP3 signalling pathways. 
Thus PI3K signalling can also regulate Ras, PKC and Ca2+ signalling pathways (150, 
151). 
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1.4.5 Akt as a second messenger of PI3K signalling 
Akt is another key protein in the PI3K signalling cascade: an AGC family kinase, it 
adds phosphate groups to wide variety of proteins to modulate their action. For 
example, it inhibits the transcription factor p53 and forkhead box (FOXO), to inhibit 
cell death, it inhibits GSK3β to promote the cell cycle and metabolism and it activates 
the mammalian target of rapamycin (mTOR) to initiate cell growth. Other PH domain 
containing proteins that are recruited to PI(3,4,5)P3 include SGK and Tec. The latter, 
through activation of PLCγ, activates DAG and IP3 signalling pathways. Thus PI3K 
signalling can also activate Ras, PKC and Ca2+ signalling pathways (150, 151). 
Interestingly, Akt has also been shown to have equal or greater affinity for PI(3,4)P2 
as it does for PI(3,4,5)P3 (152, 153). 
1.4.6 mTOR signalling downstream of PI3K 
Another downstream target of PI3K is mTOR, a kinase with a wide variety of 
substrates. There are two distinct complexes formed by mTOR; TORC1 and TORC2. 
TORC1 consists of Rheb (a GTPase), the GβL adaptor subunit, mLST8, PRAS40 
and the regulatory associated protein of TOR (Raptor). TORC2 consists of mSin1, 
mLST8, and protor and rapamycin-insensitive companion of TOR (Rictor) (154) 
(although recent evidence has suggested that Rictor is something of a misnomer, as 
long incubations in rapamycin (hours) can also reduce TORC2 activity (155)). mTOR 
has a host of downstream targets. In the case of TORC1, the most notable are S6K 
and 4E-BP1, with important roles in nutrient sensing, integrating signals from insulin, 
amino acids and growth factors (156-158) to prevent apoptosis and autophagy and to 
promote G0 to G1 transition, transcription and cell growth (159). A major role of 
TORC2 is to phosphorylate Akt on Ser473 conferring maximum activity (146). Akt 
phosphorylates and inactivates tuberous sclerosis complex protein 2 (TSC2), which, 
through its actions as a GAP for Rheb, is a negative regulator of TORC1 (160). 
Furthermore TORC1/S6K-mediated phosphorylation of Rictor increases 
phosphorylation of Akt by TORC2 (161).  Thus mTOR signalling is both up and 
downstream of Akt and plays a key role in PI3K signalling. 
In T cells mTOR signalling has specific roles. Notably, when mTOR is inhibited, T 
cells become anergic (162). mTOR inhibition or deletion can also promote the 
generation of Treg cells and their selective expansion (163) and inhibits development 
of Th1, Th2 and Th17 effector T cells (164). 
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1.4.7 PI3Ks in innate and adaptive immunity 
PI3K signalling occurs in response to activation of a diverse array of receptors that 
are expressed on leukocytes and are responsible for both innate and adaptive 
immune responses. PI3Ks are activated by antigen receptors, costimulatory 
receptors, Fc (fragment crystallisable) receptors, adhesion molecules, Toll-like 
receptors and cytokines receptors as well as receptors for a variety of 
chemoattractants including C5a, fMLP, chemokines and sphingosine-1-phosphate 
(S1P) (165). Given their leukocyte-restricted expression, PI3Kγ and PI3Kδ are 
thought to be the main isoforms involved in inflammatory and autoimmune diseases. 
Mice in which PI3Kδ or PI3Kγ have been either knocked out (KO) or replaced with 
kinase-inactive mutants (e.g. PI3KδD910A) are viable, fertile and generally healthy 
(134). However, as detailed in Table 1.1, when their immune system is challenged, 
they exhibit severely altered phenotypes demonstrating that PI3Kδ and PI3Kγ have 
key functions in immune cells. Whilst they serve important functions during an 
immune response to pathogens, they also play a role in many inflammatory diseases 
(134, 166). There is evidence of considerable redundancy between PI3Kδ and 
PI3Kγ as mice with a dual knockout of PI3Kγ and point mutation of PI3Kδ have a 
very severe immune phenotype, with impairment of thymocyte development and T 
cell lymphopenia as well as T cell and eosinophil infiltration of mucosal organs, 
elevated IgE levels, and a skewing toward Th2 immune responses (167). However, 
use of isoform selective PI3K inhibitors (AS-604850 and IC87114) on wild type cells 
in vitro did not increase production of Th2 cytokines, indicating that in mature T cells 
deletion of these is not sufficient to skew cells to Th2. Therefore the exact role of 
PI3K signalling in Th1/Th2 differentiation remains undetermined, particularly as Akt 
activation can induce differentiation of both subsets (168). 
PI3K signalling has a number of essential functions in cell growth, survival 
proliferation and differentiation. However, PI3K signalling also has cell-type specific 
roles. In T cells PI3K is required for activation induced by T cell receptor signalling, 
particularly when affinity for the antigen is low or costimulation is weak (reviewed 
(169)). It is not clear whether PI3K signalling is essential for CD28 signalling 
(reviewed (170)). However, some researchers have shown that the p110δ isoform is 
important in CD28-mediated expansion and differentiation, although CD28 has also 
been shown to activate PI3K independently of its ability to recuit PI3Kδ (171). Co­
inhibitory receptors have been demonstrated to interact with the p85 regulatory 
25 
Chapter 1: Introduction 
subunit of PI3Ks, and to downregulate Akt activation. PI3K signalling is also involved 
in IL-2 production by T cells (172) as well as Th1, Th2 and Th17 cytokines (173). 
1.4.8 The role of PI3Kγ in T lymphocytes 
Loss of PI3Kγ causes some defects in thymocyte development (168, 174-176). In 
CD4+ T cells PI3Kγ is dispensable for activation and proliferation, with generally 
normal TCR signalling (177), however some studies have indicated a role for PI3Kγ 
in TCR signalling and T cell activation (178). Both in vitro and in vivo activation are 
normal, though PI3Kγ-/- effector CD4+ T cells fail to migrate to sites of peripheral 
inflammation, and in vitro they fail to migrate to CCL22 despite normal expression of 
its receptor (CCR4), and their ability to polarise F-actin in response to chemokine is 
reduced (177). PI3Kγ aides chemotaxis of other leukocytes including neutrophils and 
eosinophils (175), however, it is often dispensable for T cell chemotaxis (135). A lack 
of PI3Kγ prevents hyperresponsiveness, inflammation and remodelling of the airways 
in an ovalbumin (OVA) based model of asthma, with a reduction in the levels of IL-4 
IL-5 and IL-13 (175). Furthermore, loss of PI3Kγ reduces the severity of autoimmune 
disease models such as collagen induced arthritis (CIA) and Systemic lupus 
erythematosus (SLE) (127). 
1.4.9 The role of PI3Kδ in T lymphocytes 
Loss of PI3Kδ results in murine T cells that have defective TCR signalling (179) and 
reduced proliferation (180) and differentiation to Th1 and Th2 (180). In vivo this 
results in reduced immune responses, and reduced recruitment of T cells to sites of 
inflammation (181) although on some backgrounds loss of PI3Kδ results in an 
inflammatory bowel disease (179). PI3Kδ is also important for Treg maintenance in 
the periphery, and for their suppressive functions (182) as well as the regulation of T 
helper cytokines such as IL-4, IFNγ and IL-17 (173). 
1.5 Lipid phosphatases in the immune system 
Genetic loss of PTEN or SHIP-1 can also influence the immune system. Mice 
heterozygous for PTEN and the lymphocyte-specific PTEN null mouse have a 
tendency towards overactive immune responses (Table 1.1). Similarly, knockout of 
SHIP-1 results in an inflammatory phenotype while cell-specific gene targeting of 
SHIP-1 in T cells leads to altered Th1/Th2 cytokine production (183, 184).   SHIP-1 is 
also thought to control the ratio of Tregs vs Th17 differentiation (185, 186). Together, 
this evidence underlines the importance of PI3K in maintaining a balanced and 
functional immune response and the necessity of keeping PI3K-dependent signalling  
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Table 1.1: The effect of genetic manipulation of the PI3K pathway on immune 
cell function 
Cell 
Type 
PI3Kδ KO or KD PI3Kγ KO Dual PI3KδKD/ 
PI3KγKO 
SHIP-1 KO PTEN KOi 
T cell • Defective TCR 
signalling (179) 
• ↓proliferation 
(180) 
• ↓ migration to 
sites of 
inflammation (181) 
• Decreased 
differentiation to 
Th1 and Th2 (180) 
• ↓peripheral Treg 
number and 
function (189) 
• Abberant Th1, 
Th2 and Th17 
cytokine production 
(173) 
• ↓DP T cell 
number (190) 
• ↑ proportion 
of CD8+ (190) 
• ↑ apoptosis ↓ 
survival of 
memory T 
cells(191) 
• ↓ in vivo 
cytotoxic 
response (176) 
• Impaired TCR 
signalling (178) 
• Small ↓ in 
polarisation and 
F-actin 
polymerisation 
(192) 
• ↓ in effector 
CD4+ migration 
to sites of 
inflammation 
(177) 
• Severe 
lymphopenia(167) 
• ↓ 
maturation(167) 
• ↑ peripheral 
proliferation(167) 
• ↑Th2 
cytokine(167) 
• ↓ T reg function 
(167) 
• ↓ in progenitor 
number (184) 
• ↑ In Th2 
cytokines in lung 
(193) 
• ↑ numbers in 
lung (193) 
• ↑ T reg 
numbers (185, 
194) 
• ↑Treg and 
↓Th17 in 
vitro(186) 
• T cell specific 
KO ↓ in Th2 
response, skewed 
to Th1,↑ in CD8+ 
cytotoxicity (183) 
• Heterozygote 
has 
lymphoproliferativ 
e autoimmune 
disorder (195) 
• ↑ motility (196) 
• Loss in CD8+ 
causes CNS 
disease and 
↑suceptibilty to 
EAE (197) 
• Autoreactive T 
cells , no CD28 
costimulation req’d 
(198) 
B cell • ↑IgE production 
(199) 
• Aberrant BCR 
signalling (179, 200) 
• ↓ B cell 
numbers(179)  
• ↓ proliferation 
(180) 
• ↑ apoptosis (180) 
• No strong 
phenotype 
(176) 
• ↓ B cell 
numbers(167) 
• ↓ Ig 
production(167) 
• ↓ in progenitor 
number (201) 
• ↑ in B cell 
number (201) 
• B cell specific 
KO=no phenotype 
(202) 
• ↑proliferation, 
(203) 
• ↓apoptosis (203) 
• Defective class 
switch 
recombination 
(203) 
• Heterozygote 
has immune-
complex mediated 
glomerular 
nephritis (195) 
Neutro­
phil 
• ↓ chemotaxis to 
some ligands (204) 
• ↓ GPCR (e.g. 
fMLP and C5a) 
signalling (176) 
• ↑ numbers 
(176) 
• Defects in 
respiratory 
burst (176) 
• ↓ chemotaxis 
(176, 204) 
• ↑ Infiltration and 
inflammation 
(probably result of 
lymphopenia)(167) 
• ↓ chemotaxis 
(204) 
• Spontaneous 
infiltration to lung 
(184) 
• ↑ numbers in 
blood (184) 
•↑ motility (205) 
•↓ability to 
prioritise 
chemotactic cues 
(206) 
•↑ numbers in 
lung (207) 
Eosino­
phil 
• ↑ 
numbers(176) 
• ↓ infiltration in 
vivo (208) 
• ↓ chemotaxis 
to eotaxin in 
vitro(208) 
• ↑ Infiltration and 
inflammation 
(probably result of 
lymphopenia)(167 
) 
• ↑ numbers in 
lung (193) 
Mono­
cyte/ 
Macrop­
hage 
• ↓ 
chemotaxis(209) 
• ↓ proliferation 
(209) 
• ↑monocyte 
numbers (176) 
• ↓motility and 
chemotaxis(210 
, 211) 
• Spontaneous 
infiltration to lung 
(184) 
• ↑circulating 
monocyte 
numbers (184) 
• Skewed to M2 
(alternatively 
activated) (212) 
• ↑FcR mediated 
•↑ numbers in 
lung (207) 
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phagocytosis 
(213) 
• ↓NADPH 
oxidase activity 
and early 
oxidative burst 
(214) 
• macrophage 
specific KO: 
myeloproliferative 
disease and ↑in 
both Treg and 
Th17 (202) 
Mast 
cell 
• Fail to 
degranulate in vitro 
and in vivo in 
response to FcεRI 
signaling(215) 
• No IgE/Antigen­
dependent 
hypersensitivity(215 
) 
• ↓ proliferation, 
adhesion and 
migration, (216) 
• Protected 
against passive 
cutaneous 
anapylaxis(216) 
• Fail to amplify 
activation via 
GPCR 
stimulation (e.g. 
adenosine ATP 
MIP1α) (215) 
• ↓IgE and 
antigen induced 
migration (217) 
• Fail to 
mediate 
formation of 
edema upon 
passive 
immunisation 
and antigen 
challenge (218) 
• Fail to 
degranulate in 
vitro in 
response to 
FcεRI (215) 
• Spontaneous 
infiltration to lung 
and degranulation 
(219) 
• ↑degranulation 
, (220) 
• ↑hyperplasia, 
cytokine 
production and 
asthma 
pathology(219) 
•↑survival 
(humanii) (221) 
↑cytokine 
production 
(humanii) (221) 
NK • ↓migration to 
inflammation and 
chemokines and 
S1P(222) 
• ↓migration to 
inflammation 
and 
chemokines 
(222) 
• Impaired 
development 
(223) 
• ↓numbers in 
spleen (223) 
• Impaired 
development (223) 
• ↓ cytotoxicity 
(223) 
• ↑ numbers(224) 
• Altered 
repertoire, (224) 
• ↑ expression of 
inhibitory 
receptors leading 
to ↓GVHD (224) 
• Vα14iNKT cells  
have ↓ 
development ↓ 
proliferation, 
cytokine secretion, 
tumor 
surveillance(225) 
Dendriti 
c cell 
• ↓ IL-6 production 
(226) 
• Defective in 
vitro 
chemotaxis 
(227) 
• ↓ numbers 
(227) 
• Fail to 
migrate to 
draining lymph 
nodes(227) 
• ↓ contact 
hypersensitivity 
due to 
↓migration of 
cutaneous DC 
(227) 
• ↑splenic 
DC(228) 
• ↑ myeloid DC 
from BMDC(228) 
• ↓ ability to 
induce T cell 
proliferation (228) 
• In humans, ↑ 
expression during 
aging implicated in 
↓ DC function 
(229) 
Basophil • In humans low 
expression 
correlates with 
increased 
histamine release 
(230)
i Whole animal KO of PTEN is embryonic lethal, models indicated here are cell type 
specific KO, except for the whole animal heterozygote where indicated
ii Using shRNA 
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in check. The lipid phosphatases will be discussed in greater detail in subsequent 
sections. 
1.5.1 PTEN 
PTEN was initially identified as a tumour suppressor that is lost in a wide variety of 
tumours (187). PTEN dephosphorylates the 3’ position of the inositol ring, and in vitro 
can act upon PI(3)P, PI(3,4)P2 and PI(3,4,5)P3 (188). However, most interest is 
concerned with its role in modulating the PI3K pathway and hence its actions upon 
PI(3,4,5)P3. 
The phosphatase domain of PTEN contains many residues in common with protein 
phosphatases, including a conserved catalytic cysteine residue, but in addition it has 
two lysine residues which are thought to aid binding to negatively charged 
phosphatidylinositides. PTEN also contains a lipid-binding C2 domain and a C 
terminal PDZ- binding domain (Figure 1.10). The actions of PTEN are regulated in a 
number of ways. Binding to the membrane is facilitated by the phosphatase and C2 
domains and is enhanced by an electrostatic interaction, whilst phosphorylation of 
the C terminal region of PTEN may inhibit its recruitment to the membrane. The 
presence of PI(4,5)P2 at the membrane aids PTEN phosphatase activity, possibly by 
bringing it into proximity with PI(3,4,5)P3 and also by facilitating a conformational 
change (231). Phosphorylation of PTEN on serine residues can stabilise the enzyme 
and modify its ability to interact with the membrane and other proteins. For example, 
phosphorylation of PTEN in its C terminal region results in an altered conformation 
with impaired binding to PDZ domains (55). Reversible inhibition of PTEN is 
mediated by oxidation by reactive oxygen species (ROS), resulting in the formation of 
a disulphide bond between the catalytic cysteine (cys124) with a neighbouring 
cysteine residue (cys71) (232). 
PTEN interacts with a number of proteins, for example interaction with PDZ-
containing proteins such as MAGI can reduce the degradation of PTEN. PTEN can 
also interact with certain receptors, for example the sphingosine-1-phosphate 
receptor 2 (233). Despite its ability to interact with the membrane, PTEN is 
predominantly found in the cytoplasm of unstimulated cells, where it is suggested 
that interaction with cytoplasmic structures (234) or a closed conformation may 
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Figure 1.10: Structures of PTEN and the SHIPs 
The protein interaction motifs are indicated, along with their binding partners. 
Regions lost in SHIP-1 due to alternative splicing and proteolytic cleavage of the 
protein are also shown, along with the approximate molecular weights of the resulting 
proteins. Splice variants of SHIP-1 with molecular weights of 145 and 130 kDa, have 
been reported with truncations occurring at the N terminal. In humans, the 110kDa 
protein which lacks an SH2 domain (SIP-110) was originally hypothesised to be a 
splice variant (237), but it has been postulated that this is in fact the human ortholog 
of s-SHIP which arises from use of an internal promoter and contains a unique amino 
acid sequence at the N terminal (238). However, whilst s-SHIP is reported to be 
restricted to stem cells, antibodies raised against SIP-110 also detected a 110kDa 
protein in the mature mouse B-cell lymphoma line Bal 17 (237). 
Note that in mice, a SHIP isoform with a molecular weight of 110kDa also arises from 
an out of frame splice in the C terminal region ((239) not shown). C terminal 
truncations of SHIP-1, possibly due to cleavage by calpain, result in proteins with 
molecular weights of 135,125 and 110 kDa (240). Finally, murine SHIP-1 mRNA can 
contain a 183bp deletion (282bp in humans). This results in a 135kDa protein with 
the deletion occurring in the proline rich region between the two NPXY motifs (241). 
Whilst the SHIP-1 genomic locus has been extensively characterised in mice, such a 
comprehensive study has not been undertaken for human SHIP-1. It has also been 
hypothesised that SHIP-2 splice variants may also occur (239).  
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prevent free association with the membrane. PTEN contains two PEST motifs and 
ubiquitination by Nedd 4 can target it to the nucleus or towards degradation pathways 
(235). PTEN is found in the nucleus of many cells, particularly during the G0-G1 
phase, and both PI(4,5)P2 and PI(3,4,5,)P3 have also been detected in the nucleus 
(236). 
Whilst a ubiquitous PTEN knockout is embryonic lethal, tissue specific and 
heterozygous knockouts have elucidated the functions of PTEN, many of them in the 
immune system. For example, PTEN heterozygous mice develop an autoimmune 
lymphoproliferation by 9 months of age whilst mice heterozygous for both PTEN and 
SHIP-1 exhibit a more rapid progression of lymphoproliferation (242). Furthermore 
both PTEN and SHIP-1 are frequently lost in leukaemias (243) and many 
immortalised leukaemic cell lines such as Jurkats lack one or both of these 
phosphatases (244). T cell-specific PTEN KO mice exhibit splenomegaly and an 
enlargement of the thymus. They have increased numbers of T cells and die due to 
CD4+ lymphomas. The mice display a defect in negative selection and have reduced 
positive selection of CD8+ cells. Furthermore, PTEN plays a role in peripheral 
tolerance as PTEN-/- T cells are autoreactive. They also display an increase in 
proliferation and cytokine production and a decrease in apoptosis compared to wild-
type cells (245).   
PTEN is crucial to many lymphocyte functions. Notably PTEN inhibits T cell receptor 
(TCR) signalling, necessitating a requirement for CD28 costimulation in order to 
generate a response to TCR stimulation. In addition, PTEN null T cells fail to become 
anergic in response to TCR stimulation without CD28 stimulation (246). However, 
other researchers have shown that PTEN may be more important in maintaining low 
levels of PI(3,4,5)P3 and PI(3,4)P2 in the absence of TCR signalling (247). PTEN 
expression has been shown to limit TCR and CD3-dependent phosphorylation of 
phospholipase Cγ1 (PLCγ1) and ERK and to limit Itk kinase activity. Basal levels of 
PI(3,4,5)P3 are high in PTEN null leukaemic cell lines, with a corresponding high 
level of phosphorylation of Akt (248). 
PTEN also has a role in Th2 driven inflammation, for instance its expression is 
decreased in murine models of allergic inflammation. In asthmatic mice introduction 
of PTEN cDNA via adenovirus can reduce levels of cytokines such as IL-4 and CCL5 
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(RANTES) (which are secreted by T cells), contributing to a reduction in bronchial 
inflammation and airway hyperresponsiveness (249, 250). 
1.5.2 SHIP-1 
Three forms of SHIP have been identified. SHIP-1 is confined to haematopoietic cells 
and spermatids, whilst SHIP-2 is widely expressed with high levels in the brain, heart 
and skeletal muscles (and is coexpressed with SHIP-1 in haematopoietic cells) and 
s-SHIP is limited to stem cells. SHIP-1 can metabolise the 5’ phosphate from inositol 
(1,3,4,5) tetraphosphate and PI(3,4,5)P3, and so can terminate PI3K-dependent 
signalling pathways. However, whilst many proteins containing pleckstrin homology 
(PH) domains are recruited to PI(3,4,5)P3, some, such as DAPP1 (dual adaptor of 
phosphotyrosine and 3-phosphoinositides), can interact with both PI(3,4,5)P3 and 
PI(3,4)P2, whilst the TAPPs (tandem PH domain containing protein) are recruited 
exclusively to PI(3,4)P2 (251). 
SHIP-1 possesses an N terminal SH2 domain and a C terminal proline rich domain 
as well as two NPXY motifs and a C2 domain that can bind its product PI(3,4)P2 
(Figure 1.10). The SH2 domain has been demonstrated to bind tyrosine 
phosphorylated Shc, SHP-2, Doks, Gabs and some ITIMs and ITAMs 
(immunoreceptor tyrosine-based inhibition/activation motif). The proline rich region 
can bind selected SH3 domain-containing proteins such as Src and is essential to 
SHIP-1 function (252). Meanwhile the NPXY motifs can bind PTB (phosphotyrosine 
binding) domains of Shc and Dok2 (201, 253, 254), and mutating the NPXY motifs to 
NPXF partially reduced SHIP-1 activity. NPXY motif binding requires phosphorylation 
by the Src family kinase Lyn and this phosphorylation plays a key role in its 
recruitment to the membrane and activity (255, 256). It has also been proposed that 
SHIP-1 activity is regulated by cAMP-dependent protein kinase (257). 
Multiple variants of SHIP-1 are produced. Splice variants with molecular weights of 
145, 130 and 110 kDa, have been reported with truncations occurring at the N 
terminal. This results in different binding specificities between SHIP-1 proteins. For 
example, the Grb2 SH3 domain binds exclusively to the 110kDa splice variant which 
lacks an SH2 domain, whilst Shc can bind the 145 and 135 kDa proteins (237). The 
110kDa protein is postulated by others (238) to be the human ortholog of sSHIP (see 
below), as it contains a unique N terminal amino acid sequence. C terminal 
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truncations of SHIP-1 have also been reported, possibly due to cleavage by calpain, 
resulting in SHIP1- proteins with molecular weights of 135,125 and 110 kDa. Finally, 
murine SHIP-1 mRNA can contain a 183bp deletion (282bp in humans). This results 
in a 135kDa protein with the deletion occurring in the proline rich region between the 
two NPXY motifs (241) .These truncations also result in variation in binding partners, 
for example, only 145kDa SHIP-1 can be immunoprecipitated with Shc (240).  
SHIP-1 can also aid formation of signalling complexes, for example following 
stimulation of the TCR, SHIP-1 recruits Dok2 (downstream of tyrosine kinase 2) to a 
complex containing LAT, Dok1 and Grb2, facilitating the inhibitory effects of Dok2 on 
TCR signalling (258). 
SHIP-1 KO mice have an increased proportion of CD4+ vs CD8+ cells in the spleen. 
Their peripheral CD4+ T cells display a higher percentage of the activation markers 
CD25 and CD69 but fail to produce IL-2 in response to PMA/ionomycin stimulation. 
They also produce TGFβ and express Foxp3. Finally, these lymphocytes also inhibit 
the production of IL-2 by CD4+CD25- T cells, indicating that they are Tregs (194). 
others have also found that a lack of SHIP-1 causes an increase in Treg numbers 
and this was found to limit graft vs. host disease (GvHD) (185, 259, 260). Different 
groups have variously reported that SHIP-1 KO T cells proliferate normally in 
response to TCR signalling (261) or are anergic (194). 
A substantial proportion of SHIP-1-/- mice succumb to a fatal myeloid cell infiltration of 
the lungs by 14 weeks of age, which is thought to be Th2 driven (184, 262). In 
addition, SHIP-1 null haematopoietic stem cells are hyper-responsive, for example to 
IL-3, GM-CSF and steel factor (SF). However, a T cell specific deletion of SHIP-1 
resulted in mice that failed to skew towards Th2 responses, possibly due to an 
increase in basal levels of T-bet. In addition these mice have a more efficient CD8+ 
cytotoxic response. In contrast to the mice with complete deletion of SHIP-1, T cell 
specific deletion did not result in an increased number of Tregs and the mice had a 
normal lifespan, without leukocyte infiltration of the lungs (183). Further controversy 
on this subject came from experiments using naïve T cells from whole animal SHIP-1 
knockout mice. These were found to differentiate in vitro into Tregs more easily than 
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WT cells, but failed to differentiate into Th17s under appropriate conditions. This was 
attributed to a decreased ability of IL-6 to mediate STAT3 signalling in the KO cells, 
thus biasing them away from Th17 development. 
SHIP-1 has also been shown to have a key role in controlling the response of T 
lymphocytes to oxidative stress. Leukaemic T cells which lack SHIP-1 have higher 
levels of cell death in response to reactive oxygen species than those which express 
SHIP-1, as they fail to activate the NFκB survival pathway through IKK (IκB kinase) 
mediated serine phosphorylation of IκBα, and instead must rely upon a less effective 
mechanism involving tyrosine phosphorylation of IκBα (263). In this manner, SHIP-1 
can reduce apoptosis in response to both H2O2 and signalling pathways that involve 
generation of reactive oxygen species such as Fas signalling (264).  
1.5.3 A note on SHIP-1 null mouse models 
The Krystal laboratory utilises SHIP-1 null mice with a deletion of the transcriptional 
start site and the first exon on a C57BL/6-129Sv background.  C57BL/6 mice are 
generally prone to Th1 type inflammation (265), as are 129/sv (although to a lesser 
extent (266)), (whereas balb/c are prone to Th2 driven inflammation (267, 268)). 
Despite this, the group feels that the severe lung inflammation seen in the SHIP-1 
knockout mice may be due to the strain used and therefore are in the process 
breeding the SHIP-1 deletion onto different backgrounds (A. Ming Lum personal 
communication). 
Workers at the John Hopkins School of medicine, Baltimore use SHIP-1 null mice on 
a C57BL/6-129Sv (262) background or 129/J (261) backgrounds through deletion of 
the first coding exon and part of the following intron. The Kerr group used SHIP-1 null 
mice on a C57BL/6J background, either by knockout of the enzymatic domain (exons 
10-13) or by deletion of the promoter and first exon of SHIP-1.  MxCreSHIP-1flox/flox on 
a C57BL/6J background were also used so that SHIP-1 could be deleted in mature 
animals (185). 
Finally the Bolland group generated a T cell specific knockout mouse by crossed 
mice containing a loxP-flanked SHIP-1 gene (covering exons 10-13, encoding the 
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entire enzymatic domain) with mice transgenic for Cre recombinase driven by the 
CD4 promoter (183). These mice had a C57BL/6 background. Thus it can be seen 
that a variety of models have been used to characterise the role of SHIP-1 in mice, 
albeit on a limited range of backgrounds. 
1.5.4 SHIP-1 in health and disease 
A dominant negative mutation of SHIP-1 has been reported in some acute myeloid 
leukaemia (AML) cases (269) and multilobulated nuclear formation of adult T cell 
leukaemia/lymphoma (ATLL) (270, 271) whilst SHIP-1 (along with PTEN) is reported 
to be widely inactivated in T lymphoblastic leukaemia (T-ALL). In T-ALL cell lines, 
SHIP-1 is frequently lost at the protein level (including in Jurkats). Even in the T-ALL 
cell line CEM, where SHIP-1 has been previously reported (244), it has a 
conservative mutation and protein levels are reduced. In primary T-ALL a variety of 
mutations have been reported in the SHIP-1 gene, often resulting in reduced 
expression, or expression of lower molecular weight forms (272). 
The measles virus drives expression of 110kDa splice variant of SHIP-1 (SIP110) 
(237) in order to reduce Akt activity and cell proliferation, thus facilitating suppression 
of the immune system during infection (273). SHIP-1 is also a key effector in the 
SLAM-SAP (signaling lymphocytic activation molecule/SLAM associated molecule) 
signalling pathway, and loss of the latter leads to X-linked lymphoproliferative 
disease (274).  
1.5.6 Stem cell SHIP 
Stem cell SHIP (s-SHIP) is expressed in totipotent embryonic stem cells and 
haematopoietic stem cells, whilst full length SHIP-1 is not present in stem cells. s-
SHIP is also encoded by the SHIP-1 gene Inpp5d and its transcription is controlled 
by an internal promoter. It lacks the N-terminal SH2 region of SHIP-1, but its mRNA 
has a unique 44 nucleotide sequence at the 5’ end. As with SHIP-1 (241), a 183 
nucleotide sequence can be spliced out, resulting in a doublet of 104 and 97 kDa 
being detected in western blots (928 amino acids (aa) and 867 aa rather than the full 
1191 aa of SHIP-1) (238). It has been demonstrated that s-SHIP associates with 
gp130, most probably through its interactions with Grb2. This interaction may inhibit 
both the PI3K pathway and the Ras/Mek/Erk pathway by preventing association of 
SOS with Grb2. In this way s-SHIP could modulate signalling through the leukaemic 
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inhibitory factor receptor (LIFR), which is required for growth and survival of both 
embryonic and haematopoietic stem cells (275). 
SHIP-1 null haematopoietic stem cells (HSCs) have a lower rate of spontaneous 
apoptosis than wild type cells and SHIP-1-/- mice have a larger number of HSCs. 
However, these stem cells are more likely to differentiate to myeloid cells and have a 
reduced ability to differentiate to B lymphocytes. In addition, SHIP-1-/- HSCs home 
less efficiently to the bone marrow, and this is associated with a decrease in 
expression of CXCR4 and VCAM-1 (276). 
1.5.7 SHIP-2 
SHIP-2 is a 142kDa protein with high homology to SHIP-1. Most variation occurs in 
the proline rich domain and it has only one NPXY motif, but also has a sterile alpha 
motif (SAM) domain (277). SHIP-2 can metabolise PI(3,4,5)P3 and PI(3,5)P2 as well 
as some inositol phosphates (278) and is widely expressed, with high levels found in 
a disparate range of tissues including the heart, skeletal muscle, placenta and 
fibroblasts (279). Notably SHIP-2 is coexpressed with SHIP-1 in haematopoietic cells 
and has also been detected in leukaemic cell lines.  
SHIP-2 is tyrosine phosphorylated in response to insulin and a variety of growth 
factors (280) and is known to play a role in the negative regulation of lymphocyte 
signalling. For example in T cell lines both forms of SHIP can associate with Tec and 
inhibit its activity following TCR stimulation (281). In addition, SHIP-1 and SHIP-2 
SH2 domains recognise very similar pY sequences (pY[S/Y][L/Y/M][L/M/I/V]), but 
their binding kinetics are different, with SHIP-1 having much faster association and 
dissociation rates than SHIP-2, contributing to their different actions in immune cells 
(282). 
1.5.8 The role of PTEN and SHIP-1 in T lymphocyte migration 
Directional sensing and ordered cell migration are essential to leukocyte function and 
are mediated by a variety of G-protein coupled receptors. These activate second 
messenger systems, including PI3K, resulting in the generation of PI(3,4,5)P3. During 
the process of T lymphocyte chemotaxis, chemokines, or other GPCR ligands such 
as S1P, stimulate their cognate GPCR, causing activation of G proteins (usually 
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Gαi/o) (283). This initiates polarisation of the cell, with the formation of a leading 
edge (pseudopod) and tail (uropod). 
The intracellular signalling processes leading to polarisation have mainly been 
studied in neutrophils, but are thought to occur in T cells as well. The Rac GEFS 
(guanine nucleotide exchange factor), Dedicator of cytokinesis 2 (DOCK2), Tiam1 (T 
cell lymphoma invasion and metastasis) Vav1, and p-Rex1 (phosphatidylinositol­
3,4,5-trisphosphate-dependent Rac exchange factor 1) are localised to the 
pseudopod leading to Rac1 activation and hence F-actin polymerisation (85). PI3Kγ 
also accumulates at the leading edge and regulates the activity of RacGEFs as either 
they, or their associates proteins (e.g. ELMO proteins (284)), have PH domains to 
facilitate their colocalisation (285). Loss of DOCK2 causes a reduction in the 
chemotactic ability of the cells. The effect of PI3Kγ loss or inhibition is less clear cut, 
but it is thought to reduce the chemokinetic activity of the cell (85). In activated T 
cells it has been shown to be required for basal motility but not chemotaxis whereas 
in freshly isolated T cells its inhibition has also been shown to reduce directional 
chemotaxis (286). Others have found that PI3K signalling is important for chemotaxis 
in shallow gradients, but is dispensable at higher concentrations of chemoattractant 
(287, 288). 
Reciprocal distributions of PTEN and SHIP-1 allow the maintenance of polarisation 
and facilitate directional sensing, with PTEN being distributed to the sides and back 
of the cell (289, 290) and enabling prioritisation of certain chemotactic cues (206) 
(however, even if a chemokine is uniform in distribution, the cell will still polarise and 
undergo chemokinesis). Loss of PTEN results in neutrophils with mildly increased 
actin polymerisation and speed, but slightly impaired directionality (291).  Chemotaxis 
of leukocytes has been most extensively studied in neutrophils. In agreement with 
the findings in Dictylostelium, the distribution of PTEN to the uropod during 
chemotaxis has also been observed in human neutrophils. Concurrent with this, it is 
reported that PTEN-null neutrophils have increased Akt phosphorylation in response 
to chemokines and increased F-actin polymerisation in response to fMLP. PTEN null 
neutrophils are more sensitive to chemoattractants and they exhibit enhanced 
chemotaxis with increased speed, although directional sensing is impaired, whilst in 
vivo PTEN-null neutrophils are recruited more efficiently in a mouse model of 
peritonitis (291). A similar situation is believed to occur in T lymphocytes, for example 
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PTEN negatively regulates CXCR4- mediated chemotaxis to CXCL12 as well as 
chemotaxis to insulin-like growth factor 1 (IGF-1) (292). 
Other researchers have found a limited role for PTEN in neutrophil chemotaxis and 
consider that SHIP-1 is key for the formation of the leading edge and polarisation of 
the cell. SHIP-1 null neutrophils fail to localise PI(3,4,5)P3 to the front of the cell, thus 
reducing polarity of the cell. Basal actin polymerisation is increased, and motility is 
decreased. However, during chemotaxis, whilst the speed is reduced, the ability to 
sense direction was not impaired (293). In Jurkats (which lack SHIP-1 and PTEN), 
introduction of constitutively active SHIP-1 reduces CXCL12- mediated chemotaxis. 
(294). 
1.6 Pharmacological targeting of the PI3K pathway 
The above paragraphs have outlined some of the normal physiological roles of the 
PI3K pathway in the immune system and the effects of genetic manipulation on 
individual cell function. The introduction will now examine the role of PI3Ks in 
disease. 
1.6.1 The development of PI3K inhibitors 
Initially, interest in the PI3K pathway focused on its role in cancer. PI3Kα frequently 
has activating point mutations in solid tumours, and PTEN is a well known tumour 
suppressor. Therefore early work was concerned with small molecule ATP 
competitive inhibitors of PI3Kα (295). The first compound shown to target PI3K was 
the fungal product wortmannin, which is an irreversible inhibitor (296). LY294002 was 
then developed as a specific, ATP competitive reversible inhibitor (297). The first 
isoform selective inhibitor was IC87114, which was developed by the ICOS 
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Figure 1.11: The chemotaxing cell 
Chemokines can be presented on the surface of endothelial cells. These trigger firm 
adhesion of T cells, which flatten and polarise. LFA-1 clusters in filapodia which 
protrude into the endothelial cell, helping to anchor the T cell. The T cell polarises, 
with PI3K, DOCK2 and Cdc42 (cell division control 42 kDa) signalling pathways all 
contributing to Rac1 activation and actin polymerisation at the leading edge. PI3K 
activity is confined to the pseudopod by the distribution of SHIP-1 and PTEN to the 
side and uropod (85, 283, 289).   
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Corporation. This compound has an IC50 of ~100 nM for inhibition of PI3Kδ but does 
not target the other class I PI3K isoforms (298). Class 1A selective compounds, with 
a slight selectivity for the alpha isoform, were developed by Piramed Ltd, based upon 
a compound developed by Yamanouchi Pharmaceutical Company Ltd, PI-103, and 
culminating in the development of GDC-0941, an orally available compound that has 
entered clinical trials for cancer (299).  
However, because of its important role in the immune system, it has also become 
clear that the PI3K signalling pathway plays an important part in many inflammatory 
conditions, for example in autoimmune diseases such as rheumatoid arthritis and 
multiple sclerosis, in transplant rejection, in the clearance of pathogens and even in 
myocardial infarction (300). To target the PI3K isoforms involved in inflammation, 
selective inhibition of PI3Kγ has been achieved with compounds from Serono, 
AS252424, AS605240 and AS604850 (210). Meanwhile dual inhibition of PI3Kγ and 
PI3Kδ has also been achieved with TG100-115 developed by TargeGen Inc, (301). 
Lung inflammation and allergy will now be examined in detail as an illustration of the 
role of PI3K in inflammation. Much research has been done on murine models of 
disease, both using genetic models, and small molecule pharmacological inhibitors. 
1.6.2 PI3Kγ and PI3Kδ selective inhibitors 
PI3Kδ KD mice are protected in an OVA model of asthma as they have a decreased 
production of Th2 cytokines and mucus, and are resistant to OVA-induced airway 
hyper-responsiveness, whilst  PI3Kδ KD eosinophils fail to infiltrate the lungs, even if 
transferred into wildtype recipients (302). The PI3Kδ inhibitor IC87114 (developed by 
ICOS and the first isoform specific inhibitor of PI3K to be described), was also 
effective in this model, reducing eosinophil, lymphocyte and neutrophil infiltration into 
the lungs. It also decreased Th2 cytokines, IgE, eotaxin and mucus, vascular 
permeability and hyper-responsiveness (16, 17). In addition, IC87114 has been 
shown to be effective in a canine model of allergic rhinitis (176), whilst the PI3Kδ 
selective inhibitor CAL-101 developed by Calistoga pharmaceuticals has been tested 
in a clinical trial for allergic rhinitis (303). 
In response to an OVA challenge, PI3Kγ KO mice had a greatly reduced number of 
infiltrating eosinophils, neutrophils, lymphocytes and macrophages in their 
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bronchoalveolar lavage (BAL) (304). PI3Kγ KO mice also had a decreased hyper-
responsiveness and less peribronchial smooth muscle and fibrosis compared to WT 
mice. Whilst a decrease in Th2 cytokines in the KO had been reported by some 
(175), others found no difference in IL-5 and eotaxin levels, and mucus levels that 
were comparable to those in WT mice (305). 
TG100-115 is a dual PI3Kδ/PI3Kγ inhibitor that has been successful in models of 
asthma and COPD (306). The compound was administered by aerosol as a 
preventative treatment in an OVA model of asthma and reduced infiltration of 
eosinophils and other leukocytes into the lungs. It also decreased airway hyper-
responsiveness, IL-13 levels and mucin accumulation. TG100-115 also showed 
promise as an intervention treatment in asthma models, reduced neutrophilia and 
TNFα in response to lipopolysaccharide (LPS), and was effective as an intervention 
after cigarette smoke exposure (307).  
1.6.3 Caveats of PI3K inhibition in inflammation 
It can be seen that PI3Ks have a role in driving pathological inflammation and there 
are benefits of their inhibition in inflammatory diseases. However, it is important to 
remember that they are required in normal inflammation during an immune response: 
for example PI3Kγ KO mice, or mice treated with AS605240, failed to recruit 
macrophages to the lung in response to S. pneumoniae and had impaired clearance 
resulting in progressive pneumococcal pneumonia and decreased survival (308). 
In addition, the crucial role of PI3Ks in the development and maintenance of immune 
cells may result in adverse effects of inhibitors. PI3Kδ KD (kinase dead) mice are 
skewed towards Th1 (302) and have a decrease in peripheral Treg numbers and 
function, secreting less IL-10 and failing to suppress inflammation in a colitis model 
(189) leading to the possibility that inhibition of PI3Kδ may decrease peripheral 
tolerance (309) (an additional concern with a PI3Kδ inhibitor might be spontaneous 
inflammatory bowel disease as were seen in some mouse models (179)). As 
mentioned above, mice with a dual PI3Kγ knockout and PI3Kδ inactivating point 
mutation were prone to inflammation. Pharmacological inhibiton of PI3Kδ did not 
promote T cell skewing in vitro but instead reduced production of all cytokines, and a 
PI3Kγ inhibitor had no effect either alone or in combination with a PI3Kδ inhibitor. 
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However, the authors still caution that dual inhibition of PI3Kδ and PI3Kγ may 
increase the risk of eosinophil-mediated inflammation (167, 190).  
However, recent data from preclinical trials of a PI3Kδ inhibitor CAL101 suggest that 
no adverse effects were seen in a 28 day toxicity study in dogs, although with 
prolonged treatment in rats a decrease in the size of lymph nodes, including Peyer’s 
patches, was noted (310). CAL-101, developed by Calistoga pharmaceuticals has 
also shown promise in phase I clinical trials treating haematological malignancies. 
Mostly mild or moderate side effects have so far been observed in an expanded 
study of 24 patients, with only one patient showing dose-limiting toxicity (311, 312). 
In the heart, the kinase activity of PI3Kγ is required for its role in regulating β­
adrenergic signalling. However PI3Kγ also binds phosphodiesterase 3B (PDE3B) 
and facilitates it’s degradation of cyclic adenosine monophosphate (cAMP) and in 
doing so negatively regulates contractility. Therefore PI3Kγ KO but not KD mice have 
an increase in basal cardiac contractility and are more susceptible than wildtype 
controls to cardiomyopathy, ventricular dilation and heart failure (138). However, the 
fact that the kinase function of PI3Kγ is not crucial for its role in the heart bodes well 
for ATP-competitive inhibitors of PI3Kγ as immunomodulators, as they would not be 
predicted to have cardiac side effects. 
Interestingly, recent research identifies differing roles for the two regulatory/adaptor 
subunits p84 and p101: the p84 subunit was first identified in the heart (which has 
low levels of the p101 subunit), where it associates with PDE3B and may therefore 
help to mediate the interaction of PI3Kγ with this protein. However both subunits 
were expressed in a variety of leukocytes and both could mediate interaction with Gβγ 
(132) although p84/p110γ is recruited less efficiently (131).  
Finally, many of the current small molecule ATP-competitive inhibitors also hit other 
enzymes such as mTOR or DNA dependent protein kinase (DNA-PK), which could 
potentially lead to off target side effects (reviewed (313)).  
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1.6.4 Modulation of Lipid phosphatase function 
Overexpression of PTEN (i.e. lowering the levels of PI(3,4,5)P3), was protective 
against OVA-induced asthma (25-27), and in toluene diisocyanate-induced airway 
disease, overexpression of PTEN (or use of LY294002) decreased IL-17 production, 
leukocyte infiltration, epithelial thickening, airway hyperresponsiveness and mucus 
secretion (314). In contrast, in a model of pneumonia, loss of PTEN increased the 
ability of the neutrophils to kill bacteria. Macrophage and neutrophil numbers in the 
lung were increased as were levels of chemokines and cytokines such as TNF, IL-1 
and IL-6, whilst damage to the lung and mortality were reduced (207).  
PTEN has also been suggested as a pharmacological target, although most interest 
is focussed on its role in insulin signalling, rather than in inflammation. Based on the 
fact that vanadates, particularly the bisperoxovanadiums, are potent inhibitors of 
PTEN, several selective small molecule inhibitors have been described (315). A 
possible drawback to the use of a PTEN inhibitor in the clinic is its potentially 
oncogenic action, although it will certainly be useful as a pharmacological tool (316). 
Intriguingly, thalidomide has been reported to cause limb deformities in developing 
foetuses through its actions on PTEN. It indirectly stabilises PTEN, protecting it from 
proteasomal degradation and thus suppresses Akt signalling, which in turn leads to 
increased caspase-dependent cell death. The phenotype could be rescued by either 
inhibition of PTEN or by insulin (317). Hence it can be seen that it would be desirable 
to avoid targeting non-immune cells when suppressing the PI3K pathway. 
Therefore, when seeking a target for modulation of the immune system, the 
leukocyte-restricted expression of SHIP-1 makes it an especially attractive target 
(318). Of particular note is the identification of pelorol, a meroterpenoid originally 
isolated from the marine sponge Dactylospongia elegans (319) as an activator of 
SHIP-1. A chemical synthesis from (+)-sclareolide has also been devised for pelerol 
and more potent analogues.  One of the derivatives, AQX-MN100, has been shown 
to reduce mast cell and macrophage activation in vitro, whilst in vivo it has an anti­
inflammatory action in mouse ear oedema and is effective in reducing serum TNFα in 
a murine model of endotoxic shock (320). 
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It has been indicated that structural analogues of pelorol act through allosteric 
activation of SHIP-1. It was found that PI(3,4)P2 and pelorol derivatives activate 
SHIP-1 by binding the C2 domain at the C terminal end of its phosphatase domain. 
The possibility of using an allosteric regulator reduces the chances of off-target 
effects compared to compounds that target the active site, and concurrent with this, 
the SHIP-1 activators were ineffective in SHIP-1-/- mast cells and macrophages, and 
did not affect SHIP-2 activity (321) (322). AQX-MN100 has also been shown to inhibit 
growth and trigger the apoptosis of multiple myeloma cell lines (323). A related 
compound AQX1125 is expected to enter clinical trials in 2011 as an anti­
inflammatory, with preclinical studies indicating its use in asthma and other allergic 
disease (324).  
However, the role of SHIP-1 in asthma remains unclear: knockout of SHIP-1 in mice 
caused death in up to half of mice by 10 weeks of age due to macrophage, 
neutrophil, lymphocyte, degranulating mast cell and eosinophil infiltration of the 
lungs. The KO mice had airway epithelial hypertrophy and fibrosis along with 
excessive mucus, IL-4, IL-13, eotaxin and CCL2 (30, 31), indicating the importance 
of tightly controlled PI3K signalling. However, other researchers have found that 
using an OVA model of asthma, loss of SHIP-1 decreases disease severity, with 
knockout animals having less eosinophil infiltration and decreased IgE, IL-4 and IL­
13 (325). 
1.7 Summary 
In summary, it can be seen that the immune system is a highly complicated and 
delicately balanced system. Whilst much is known about the role of T cells and the 
PI3K pathway within the immune system, there are still fundamental gaps in our 
knowledge. Firstly there is significantly less information available about SHIP-1 than 
about PI3Ks themselves, partly because SHIP-1 has been considered a less 
attractive drug target than kinases. Secondly, much of the information about PI3K 
signalling in general, and SHIP-1 in particular, has been gathered using knockout 
mice, or pharmacological tools studied in murine disease models. Therefore, the aim 
of this thesis is to investigate the role of SHIP-1 in human T cells. 
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1.8 Aims of the research 
The overall aim of the thesis was to characterise the role of SHIP-1 in human T 
lymphocytes. This could be subdivided into two main aims: 
1) To set up a lentiviral delivery system for the modulation of SHIP-1 expression in 
primary human T cells. 
2) To investigate the role of SHIP-1 in leukaemic T cell lines and in primary human T 
cells using the lentiviral expression system. In particular, there were a number of key 
objectives: 
•	 To characterise phosphorylation of SHIP-1 as a marker for its activation in 
response to a variety of stimuli in leukaemic cells lines and primary human T 
cells 
•	 To investigate the effects of SHIP-1 expression on survival of leukaemic cell 
lines 
•	 To investigate the role of SHIP-1 in primary human T cell viability, proliferation 
and signalling 
•	 To investigate the role of SHIP-1 on morphology and adhesion of primary 
human T cells 
•	 To investigate the role of SHIP-1 in chemotaxis of primary human T cells 
•	 To investigate the role of SHIP-1 on cytokine production and differentiation to 
T helper subsets 
•	 To investigate the role of SHIP-1 in CD8+ T cell cytotoxicity 
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2.1 Cell culture 
2.1.1 Leukaemic T Cell Lines 
Leukaemic cell lines (J6 Jurkats (Cancer Research UK), CCRF CEMs (Novartis) and 
HUT78s (unknown provenance) were cultured in T175 flasks at 37˚C in 95% air /5% 
CO2. The culture medium was RPMI 1640 supplemented with 10% FCS, 10 μg/ml 
penicillin and 10μg/ml streptomycin (complete media/ complete RPMI). All cell culture 
reagents were from Invitrogen unless otherwise specified. All cell culture plasticware 
was from Nunc unless otherwise specified. Cells were cultured every 2-3 days. Cells 
were maintained at a confluency of 0.5-1x106/ml and discarded after 3 months. 
2.1.2 rCD2:SHIP Jurkats 
rCD2:SHIP was previously made in the lab by ligating DNA encoding the extracellular 
and transmembrane domains of rat CD2 with the catalytic core of human SHIP, 
which was cloned into the pUHD10-3-hygromycin regulatory plasmid and stably 
transfected into Jurkats expressing a tetracycline (tet) controlled transactivator, 
allowing a tet-off inducible expression system (Figure 2.1). The expression of 
rCD2:SHIP results in the constitutive membrane localisation of the catalytic core of 
SHIP and hence its constant phosphatase activity, which depletes the cell membrane 
of PI(3,4,5)P3 and generated PI(3,4)P2 (244) (Figure 2.1). SHIP 11 Jurkat clones 
(which express rCD2:SHIP) were cultured in the presence of 2 μg/ml tetracycline. 
rCD2:SHIP Jurkats and J6 Jurkats which were to be used in the same assays as 
rCD2:SHIP Jurkats, were not allowed to exceed a density of 5x105/ml during cell 
culture. 
To induce expression of CD2:SHIP, cells were washed into complete media without 
tet and incubated for 24 hr. Samples of both were lysed and western blotted for rat 
CD2 using the monoclonal antibody OX34. However, the expression system 
appeared “leaky” with high levels of rCD2 expressed even in the presence of tet, with 
some further expression in the absence of the antibiotic. Therefore when the actions 
of CD2:SHIP are to be compared to cells lacking expression, the parental J6 cell line 
is used, rather than rCD2:SHIP Jurkats cultured in the presence of tet. 
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Figure 2.1 The tetracycline inducible gene system and rCD2:SHIP. 
Top panel: Two plasmids are stably expressed in Jurkats. The regulator plasmid 
produces a tetracycline-sensitive transactivator (tTA) which in the absence of 
tetracycline binds the tTA-dependent promoter and induces the production of 
rCD2:SHIP. If tetracycline is present, it binds the tTA and alters its conformation so 
that it is unable to bind the promoter. Redrawn from Curnock et al (326). 
Bottom panel: The chimeric protein, consisting of the catalytic core of human SHIP-1 
fused to the extracellular and transmembrane domains of rat CD2 was stably 
expressed in clones derived from the J6 Jurkat cell line, under the control of a 
Tetracycline-regulated expression system as previously described (244). 
Alternatively, it was cloned into the lentiviral pCLPS expression vector for expression 
in primary human T cells. The SHIP-1 catalytic core is located next to the cell surface 
membrane where it can metabolise PI(3,4,5)P3 to PI(3,4)P2. Expression of the 
construct can be verified by western blotting for expression of rat CD2 in human 
cells. In addition live cells can be selected for expression of the chimeric protein on 
the basis of cell surface expression of rat CD2. 
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2.1.3 HEK 293T 
Human embryonic kidney (HEK) 293T cells (A gift from Carl June, University of 
Pennsylvania, USA, hereafter, HEKs) were cultured in complete media. Cells were 
passaged every 2-3 days and allowed to reach no greater than 80% confluency.  
To passage, media was removed, cells were washed once in PBS then trypsinised 
for 1 minute at room temperature. The media was put back onto detached cells and 
centrifuged. Cells were resuspended in fresh media and seeded into a new T175 
flask. Cells were discarded after 30 passages. 
2.1.4 A20 
The A20 Mouse B lymphoma cell line (unknown provenance) was cultured in 
complete media, as for the human leukaemic T cell lines above, supplemented with 
2-mercaptoethanol (50 μM, Sigma) to provide reduced cysteines. Cells were 
maintained at a density of 1x106/ml by passaging every 2-3 days. 
2.1.5 Isolation of Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from the heparinised 
blood of healthy volunteers, by separation in Lymphoprep (Greiner Bio One). Briefly, 
10-100 ml blood was collected in heparinised (final concentration of 10 Units/ml) 
syringes. Blood was diluted 1:1 in plain RPMI and layered onto Lymphoprep in 50ml 
falcon tubes. Tubes were centrifuged at 250xg for 30 min without braking upon 
deceleration and the middle (PBMC) layer removed with a Pasteur pipette. Cells 
were washed three times in plain RPMI to remove Lymphoprep. 
2.1.6 Culture of T cells using SEB 
PBMCs obtained as above were resuspended in the initial blood volume of complete 
RPMI plus 1 µg/ml of the superantigen Staphylococcal enterotoxin B (SEB, Sigma) 
for 72hrs. Cells were then washed into double the volume of complete RPMI and 36 
U/ml IL-2 added to generate activated peripheral blood derived T lymphocytes 
(PBLs). Cells were cultured every two days, with the volume doubled each time and 
fresh IL-2 added at each passage. PBLs were used for experiments at days 9-12. 
2.1.7 Isolation of CD4+, CD8+ and naive CD4+ T cells 
PBMCs were isolated as previously described. The final wash was done in ice cold 
MACS buffer (PBS/ 0.5% BSA/ 2mM EDTA). The manufacture’s protocol was then 
followed: briefly, cells were resuspended in 40 μL MACS buffer per 107 cells and 
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antibody cocktail at 10 μl/107 cells was added, incubated at 4°C for 15 minutes then a 
further 30 μl/107 cells MACS buffer added, then 20 μl anti-biotin microbeads. 
Following a further 10 minute incubation at 4°C the cells were washed once, 
resuspended in 500 μl and applied to an LS column (Miltenyi Biotec). The column 
was washed three times and the cells that passed though were collected, and their 
purity verified by flow cytometry. Kits used were from Miltenyi Biotec MACS: naïve 
CD4+ T cell isolation kit, human 130-091-894, pan T cell, human 130-053-001, CD8+ 
T cell isolation kit II, human 130-091-154, CD4+ T cell isolation kit II human 130-091­
155. 
2.1.8 Culture of isolated T cells using CD3/CD28 beads (Th0 
conditions) 
Cells were isolated with CD4+ T cell isolation kit II human (Miltenyi Biotec) or naïve 
CD4+ T cell isolation kit as required. Cells were cultured in RPMI 1640/10% FCS/ 
10μg/ml penicillin /10μg/ml streptomycin (complete RPMI). Anti-CD3, anti-CD28 
antibody coated activating beads (hereafter CD3/CD28 beads) were used at a ratio 
of three beads to one cell (Dynabeads Invitrogen 111.31D) and IL-2 at 36 U/ml. Cells 
were cultured every 2-3 days with further media and IL-2, to maintain them at 1 x106/ 
ml. Cells were discarded after 14 days 
2.1.9 Culture of T cells under Th1 polarising conditions 
Following isolation, naive CD4+ T cells were washed twice into complete RPMI at 1 
x106/ml. CD3/CD28 beads were used at a ratio of three beads to one cell, IL-2 at 36 
units/ml, IL-12 2 ng/ml and anti IL-4 200ng/ml. Cells were cultured every 2-3 days 
with further media and half quantities of cytokines, to maintain them at 1 x106/ ml. 
2.1.10 Culture of T cells under Th2 polarising conditions 
Following isolation, naive CD4+ T cells were washed twice into complete RPMI at 1 
x106/ml. CD3/CD28 beads were used at a ratio of three beads to one cell, IL-2 at 36 
units/ml, IL-4 20 ng/ml, anti-IFNγ 5 µg/ml and anti IL-12 5 µg/ml. Cells were cultured 
every 2-3 days with further media and half quantities of cytokines, to maintain them 
at 1 x106/ ml. 
2.1.11 Culture of T cells under Th17 polarising conditions 
Following isolation, naive CD4+ T cells were washed twice into complete RPMI at 1 
x106/ml. CD3/CD28 beads were used at a ratio of three beads to one cell, IL-1β at 10 
ng/ml, IL-6 50ng/ml, anti-IFNγ 10µg/ml, anti IL-4 10µg/ml and IL-23 10ng/ml. Cells 
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were cultured every 2-3 days with further media and half quantities of cytokines, to 
maintain them at 1 x106/ ml. All cytokines were from Peprotech and all antibodies 
were from R&D. 
2.2 Electroporation and Lentiviral Methods 
2.2.1 Electroporation 
Electroporation was performed using a Microporator MP-100 and following the 
manufacturer’s instruction (Figure 2.2). Cells (either freshly isolated CD4+ T cells or 
PBMCs cultured for 10 days in the presence of SEB and IL-2) were washed in Mg2+ 
Ca2+ free PBS. Immediately before electoporation cells were washed into the 
manufacturer’s resuspension buffer R at a concentration of 2x107/ml. 0.5 μg pCLPS 
GFP plasmid was added and the mixture was pipetted into a supplied capillary 
pipette tip. A variety of parameters were used during optimisation and are indicated 
in the results. For subsequent electroporation of PH domain expression plasmids in 
freshly isolated CD4+ T cells parameter 8 was used with a single pulse of 2300V, 
with a pulse width of 20ms. Electroporation was performed using the supplied gold 
electrodes and electroporation buffer. Immediately following electroporation cells 
suspended in buffer R were pipetted into prewarmed complete media with IL-2. For 
the CD4+ T cells CD3/CD28 beads at a 1:1 ratio were also supplied. Cells were 
cultured for 48 hours before use in experiments. 
2.2.2 Overview of the lentiviral expression system 
Lentiviral expression systems are ideal for expressing proteins in difficult to transfect 
cells, when long term expression is required or when it is important that cells are not 
subjected to harsh conditions (e.g. electroporation, chemical transfection), which 
might alter their function (327, 328). Based on the HIV-1 virus, the lentiviral 
expression system utilises four plasmids. When these are simultaneously transfected 
into a HEK “packaging” cell line three of the plasmids supply the DNA necessary for 
manufacture of a viral particle, whilst the fourth plasmid is packaged into the viral 
particle (329). These viruses can then be used to infect the target cell. As they only 
contain the fourth plasmid, the infected target cell can only make proteins encoded 
by that one plasmid, and can’t assemble a viral particle (Figure 2.2).  
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Figure 2.2 The Microporator MP-100 and the lentiviral method of gene delivery 
Top panel: These images are taken from the manufacturer’s website 
(www.microporator.com). On the left is the microporator equipment. On the right is 
the pipette tip in which cells are electroporated, showing the gold electrode that is 
used to conduct electricity. The microporator is reported to offer the benefits of 
electroporation with decreased cell death. 
Bottom panel: Lentiviral plasmids were chemically transfected into HEK293T cells. 
VSVG, pREV and pGAG/POL code for the proteins necessary for the production of 
lentiviruses, which takes place in the HEK293T cells. During the construction of 
lentivirus, RNA is packaged into the virus when it includes a packaging signal (ψ). 
Hence only the expression plasmid, encoding shRNA (or rCD2:SHIP or GFP) is 
packaged into the lentivirus. This means that the lentivirus is incapable of 
reproducing. The lentivirus infects the target cell and the RNA from the expression 
plasmid is transcribed into DNA. The DNA integrates into the host cell DNA, and thus 
will be passed to daughter cells. The DNA encoding shRNA or protein can also be 
transcribed back to RNA. In the case of shRNA this is cleaved by Dicer as targets 
complementary RNA for destruction. In the case of proteins the RNA is translated 
into protein. 
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2.2.3 Use of transfer plasmids 
When using the lentiviral expression system as described above, the fourth plasmid, 
the transfer or “expression” plasmid can be any appropriate plasmid that contains a ψ 
packaging sequence. Hence, the lentiviral delivery system can be used to deliver 
DNA cloned into an expression vector or commercially available expression plasmids 
can be used with the packaging system. The following plasmids were used as 
indicated in Table 2.1: The shRNA sequences against SHIP-1 (raised against either 
the 3’ untranslated region (3’UTR) or the coding sequence (CDS) of the gene) and 
the shRNA scrambled control, (which contains at lease 4 base pair mismatches to 
any known human or mouse gene) were obtained from SIGMA and all the sequences 
are inserted into a pLKO.1-puro backbone plasmid (Table 2.1, Figure 2.3). The 
plasmid contains an ampicillin resistance element, to allow selection in E. coli and a 
puromycin resistance element to allow selection in mammalian cells. The pCLPS 
expression plasmid was used for the expression of GFP (green fluorescent protein). 
In addition rCD2:SHIP was cloned into this vector in place of GFP, as described in 
Section 2.16.4. 
2.2.4 Transfection of packaging cell line with Lentiviral plasmids 
The packaging plasmids used were: pRSV.Rev (Addgene No 12253), pMDLg/pRRE 
(Addgene No 12251) from Addgene and pVSVG (a gift from David Baltimore 
(California Institute of Technology, California, USA)). HEK 293T cells were cultured 
the day before transfection to give cells that were approximately 60% confluent on 
the day of transfection. Four hours before transfection the media on the flask was 
exchanged for 20 ml complete RPMI. Plasmids were transfected following a protocol 
provided by Olga Liu and Richard Carroll (University of Pennsylvania, Philadelphia, 
USA). On the day of transfection 1.3 ml RPMI/ 12.5 mM HEPES (4-(2-hydroxyethyl)­
1-piperazineethanesulfonic acid, Invitrogen), and Mirus LT1 Transit (219 μl) (in 
earlier optimisation experiments Fugene 6 was used as the chemical transfection 
agent) were combined without letting the transfection reagent touch the side of the 
tube. The tube was immediately vortexed for 1 second and incubated at room 
temperature for at least 5 minutes. Plasmid DNA (73 μg total: comprised of 18 μg 
pRev, 18 μg pMDLg/pRRE, 7 μg VSVG and 30 μg expression plasmid) was 
combined with H2O to take the final concentration of DNA to 0.5 μg/ml. The plasmid 
mix was then added slowly to the RPMI/HEPES/Mirus and then the tube was 
vortexed again for one second. The tube was incubated at room temperature for 30­
45 minutes. The solution was then gently pipetted up and down twice, then added to 
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Table 1.1 Lentiviral expression plasmids 
Plasmid Source Reference 
number 
Product 
pCLPS J. Riley, 
Uni. Of 
Pennsylvania, 
USA 
GFP or rCD2:SHIP 
TRCN0000 
039893 
Sigma 
MISSION 
shRNA 
1 SHIP-1 shRNA 
CCGGGCTAAGTGCTTTACGAAC 
ATTCTCGAGAATGTTCGTAAAGCACTTAGCTT 
TTTG (3UTR) 
TRCN0000 
039894 
Sigma 
MISSION 
shRNA 
2 SHIP-1  shRNA 
CCGGGCTCATTAAGTCACAGAAATTCTCGAGA 
ATTTCTGTGACTTAATGAGCTTTTTG 
(CDS) 
TRCN0000 
039895 
Sigma 
MISSION 
shRNA 
3 SHIP-1  shRNA 
CCGGGCCCATATCACCCAAGAAGTTCTCGAG 
AACTTCTTGGGTGATATGGGCTTTTTG 
(CDS) 
TRCN0000 
039896 
Sigma 
MISSION 
shRNA 
4 SHIP-1  shRNA 
CCGGGCAGAAGGTCTTCCTACACTTCTCGA 
GAAGTGTAGGAAGACCTTCTGCTTTTTG 
(CDS) 
TRCN0000 
039897 
Sigma 
MISSION 
shRNA 
5 SHIP-1  shRNA 
CCGGGCCTTCCAGATCGGAAATCAACTCGA 
GTTGATTTCCGATCTGGAAGGCTTTTTG (CDS) 
SHC002 Sigma 
MISSION Non-
Target shRNA 
Control Vector 
Non-targeting shRNA 
CCGGCAACAAGATGAAGAGCACCAACTCGAG 
TTGGTGCTCTTCATCTTGTTGTTTTT 
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Figure 2.3 The Mission shRNA vector map 
This diagram is from the Sigma website (www.sigma.com). This plasmid was used 
to express the shRNA control and SHIP-1 shRNA.  The main backbone is a pLKO.1­
puro vector and indicated on the diagram are the ampicillin (ampR) and puromycin 
(puroR) resistance elements, as well as the site for shRNA coding, the ψ packaging 
sequence and the long terminal repeats (LTR) that facilitate integration into the host 
cell DNA. 
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the flask of HEK293T. The flask was rocked gently to disperse the mixture. Cells 
were incubated for 48 hours, media containing the virus was harvested and replaced 
with fresh media. After a further 24 hours this media was also harvested and cells 
were discarded. Media was clarified by centrifugation, and then filtered using a 0.45 
µm pore filter, aliquoted into 2ml Nunc vials and stored at -80˚C. 
2.2.5 Determination of viral titre and MOI 
To determine multiplicity of infection (MOI), supernatant from GFP-virus producing 
HEKS was harvested and serial dilutions used to culture HEKS seeded at 50% 
confluency in 6 well plates 18 hours previously. After 48 hours the supernatant was 
removed, cells were trypsinised from the plate, resuspended in Fluorescence 
Analyser and Cells Sorter (FACS) buffer (PBS 0.5% BSA) and the proportion that 
were GFP positive were assessed by flow cytometry (see section 2.5.1). This was 
then used to calculate the initial number of cells infected per ml of supernatant 
applied and from that a viral titre per ml of supernatant was used to calculate the 
volume of viral supernatant required to give the desired MOI. The MOI is the number 
of viral particles per target cell. Generally, there needs to be more than one virus per 
cell as some will be degraded before infection and sometimes two viruses may infect 
a single cell. E.g. 5ml of supernatant at 1x106 virus particles /ml would be required to 
infect 5x105 cells at an MOI of 10. 
2.2.6 Construction of puromycin kill curve 
Primary CD4+ T cells cultured as above for four days were exposed to escalating 
concentrations of puromycin (Sigma). The minimum concentration required to cause 
100% cell death (verified by trypan blue staining) was assessed after 48 hours. This 
was found to be 0.3 μg/ml, Sigma’s shRNA plasmid literature suggested a range 
between 1 and 10 μg/ml, in order to select cell on the basis of puromycin resistance. 
However, the lower concentration was always found to be effective at killing 
uninfected populations. 
2.2.7 Infection of cell lines with lentivirus 
CEMs were passaged the day before transduction. 5x105 cells in 1 ml complete 
RPMI were added to a 6 well plate and 2 ml of media containing the virus was added. 
Cells were incubated overnight then media was washed and replaced with complete 
media and cells were incubated for a further 48 hours at a density of 1x106 /ml and 
then assessed for GFP by flow cytometry if required. Alternatively, in the case of 
infection with shRNA encoding lentivirus, puromycin at 10 μg/ml was used to select 
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infected cells which were then assessed for expression of SHIP-1 by Western 
blotting after a further 72 hours. 
2.2.8 Infection of primary CD4+ T cells 
PBMCs were isolated from the blood of human volunteers as described above. CD4+ 
or CD8+ T cells were then purified from the PBMCs using a Miltenyi Biotec MACs kit, 
according to the manufacturer’s instructions. The CD4+ cells were resuspended at 
1x106 /ml in complete RPMI and CD3/CD28 beads were added at a ratio of 3 
beads/cell. Cells were incubated for 24 hours. Cells were then gently pipetted to 
break up clumps, and added to 6 well plates at 1x106 cells/ well. Lentivirus was 
thawed on ice if required, then added to the T cells. Infection was performed in the 
presence of polybrene at 5 μg/ml, and in complete media supplemented with 36 U/ml 
IL-2. Cells were spinoculated for the first 90 minutes of infection by centrifugation at 
300xg. Plates were then returned to the incubator for 24 hours. The media was then 
exchanged for complete RPMI supplemented with 36 U/ml IL-2 and cells were 
cultured for a further 48 hours. At this point GFP positive cells were assessed for 
expression by flow cytometry, rCD2:SHIP expressing cells were sorted by rCD2 
expression, and shRNA expressing cells were selected by culture with puromycin 
(0.3 μg/ml) for 72 hours. Cells were used for experiments up to 14 days after 
isolation. 
2.2.9 Isolation of rCD2 positive cells 
Positive selection or rCD2:SHIP expressing primary CD4+ T cells was performed on 
the basis of cell surface expression of rat CD2 using a MACs kit according to 
manufacturer’s instructions. Briefly: three days post infection, cells were washed 
twice into MACS buffer. They were incubated for 1 hour at 4°C with anti-rat CD2 
(AbD serotec MCA154G 1:30), then washed and incubated for 15 minutes at 4°C 
with rat anti-mouse IgG2a+b microbeads (Miltenyi Biotec 130-047-201) at 20 μl/107 
cells. Cells were then washed and resuspended in 500 µL MACs buffer. Cells were 
applied to an LS column against a magnet and washed three times. The rCD2 
positive cells were retained by the column. The column was removed from the 
magnet and flushed with 5 ml MACs buffer to recover the cells. 
2.3 Cell stimulations 
Unless otherwise specified, the day before cell stimulation, primary T cells were 
removed from CD3/CD28 beads and were cultured overnight in complete RPMI in 
the absence of IL-2. SEB expanded T cells were also cultured overnight in complete 
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RPMI in the absence of IL-2. Cell lines were cultured overnight as normal. On the 
day of stimulation, cells were washed into RPMI at a concentration of 2x106 /ml in a 
volume of 0.5 ml in eppendorf tubes and incubated for an hour at 37˚C. Cells were 
stimulated as appropriate in a waterbath at 37˚C, then centrifuged for 30 seconds to 
pellet the cells, the media was aspirated and 100 μl of an appropriate lysis buffer was 
added, or an appropriate volume of fixative. 
2.4 Measurement of phosphoinositide levels 
2.4.1 PI(3,4,5)P3 
To extract lipids 5x106 CD4+ T cells (day 9-10) were used, and stimulations were 
performed as in Section 2.3.  After stimulation, cells were rinsed with 0.5 M TCA then 
twice with 5% TCA /1 mM EDTA. Neutral lipids were extracted by washing twice in 
MeOH:CHCl3 (2:1) with a 10 minute incubation each time. Acidic lipids were then 
extracted by incubating for 15 minutes in MeOH: CHCl3:12 M HCl (80:40:1) followed 
by centrifugation. The pellet was discarded and the supernatant was phase split by 
addition of CHCl3 and 0.1 M HCl. After centrifugation, the lower, organic phase was 
dried in a vacuum dryer. For the PI(3,4,5)P3 ELISA, dried lipids were resuspended in 
120 µL of the supplied PIP3 buffer and the competitive ELISA was performed 
according to the manufacturer’s instructions (Echelon Bioscience cat # K-2500). All 
chemicals used were from Sigma. 
2.4.2 PI(3,4)P2 
For assessment of PI(3,4)P2 levels, the above protocol was followed for extraction of 
lipids. After drying, lipids were resuspended in 10 μL of CHCl3:MeOH: H2O (1: 2: 0.8) 
and sonicated in an icy waterbath. The solution was spotted onto mass strip 
nitrocellulose paper (Echelon Bioscience cat # K-3400) which was prestained with 
appropriate controls, and the manufacturers instructions were followed to label 
PI(3,4)P2 with antibody and HRP-conjugated secondary antibody. The results were 
captured on X-ray film. 
2.5 Measurement of phospho- and total protein levels 
2.5.1 Western blotting 
Cells were stimulated as described in Section 2.3 and lysed in 100μL lysis buffer (50 
mM Tris-HCL pH 7.5, 150 mM NaCl, 1% Nonidet P40 (BioRad), 5 mM EDTA, 1 mM 
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sodium vanadate, sodium molybdate, 10 mM sodium fluoride, 40 μg/ml PMSF, 0.7 
μg/ml pepstatin A, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml soyabean trypsin 
inhibitor) on a rotator at 4˚C for a minimum of 1hr and then centrifuged at 600 g for 
10 minutes. 25 μl 5x sample buffer was added and samples were heated to 85˚C on 
a hot block for 10 min. Samples were briefly centrifuged then either loaded directly 
onto gels or stored at -20˚C. 10% or 7.5% (for clearer resolution of SHIP-1 variants) 
gels were poured. 15 μl of sample was loaded per lane, (5 μl for the molecular weight 
marker). Samples were stacked at 80 V and resolved at 180 V. Gels were then 
transferred onto nitrocellulose membrane (BioRad) for 1 hr at 0.8 mA per cm2 in 
semi-dry buffer. Membranes were blocked for 1 hr in TBS Tween (TBST, 20 mM Tris-
HCl, 150 mM NaCl, 0.1% Tween)/ 5% milk (Marvel). Membranes were briefly washed 
in TBST, then incubated in primary antibody overnight at 4˚C. Primary antibodies 
were used at 1:1000 dilution of stocks, in TBST with 5% BSA, 0.01% sodium azide, 
with the exception of the pY1020 SHIP-1 antibody, which was used at 1:2500 in TBST 
with 1% BSA, 0.01% sodium azide (Table 2.2). The following day, membranes were 
washed 3 times in TBST then incubated for at least 1 hour at room temperature in 
secondary antibody at 1:10,000 in TBST /1% milk. Membranes were then washed a 
further 3 times in TBST, then shaken gently for 1 minute in ECL or ECL Advance 
(Amersham Bioscience), and exposed to X-ray film (Fuji) to visualise antibody 
binding. 
All membranes were assessed for equal protein loading. If required, membranes 
were stripped of the original antibodies by rehydrating in TBST then incubating at 
60°C for 20 minutes in stripping buffer (100mM 2-mercaptoethanol, 2% SDS, 62.5nM 
Tris-HCl pH 6.7). Membranes were then washed for 3x 15 minutes in TBST, and 
reblocked, before incubation with a second primary antibody. If stripping was not 
required (because the molecular weights of the two proteins being examined were 
sufficiently different), then membranes were washed for 10 min in TBST then 
reblocked before incubation with a second primary antibody. All chemicals were from 
Sigma except where otherwise stated. 
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Table 2.2 Antibodies for western blotting and cell stimulations 
Reagent Manufacturer Product code 
SHIP-1 antibody Santa Cruz 6244 
pY1020SHIP antibody Stem Cell Technologies 01507 
AKT antibody Santa Cruz 1618 
pS473 AKT antibody Cell Signalling 9271 
ERK antibody Santa Cruz 93 
pERK antibody Cell Signalling 4377 
β‐actin –HRP conjugate Cell Signalling 5125 
rCD2 antibody (OX34) AbD Serotec MCA154GA 
Anti‐CD3 (UCHT1) eBioscience 16‐0038 
Anti‐CD28 (9.3) Gift from Carl June, University of Pennsylvania, USA  ‐
HRP conjugated anti‐rabbit Dako P0448 
HRP conjugated anti‐goat Dako P0160 
HRP conjugated anti‐mouse Dako P0447 
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Table 2.3 Flow cytometry antibodies* 
Antigen Antibody # Supplier Dilution 
used 
Fluorophore 
CD4 555346 BD Pharmingen 1:20 FITC 
CD8 FAB1509F R&D 1:10 FITC 
CD25 555431 BD Pharmingen 1:20 FITC 
CD11a 2120114 Immunotools 1:20 PE 
CD49d 21488494 Immunotools 1:20 PE 
CXCR3 FAB160P R&D 1:10 PE 
CXCR3 550967 BD Pharmingen 1:20 APC 
rCD2 MCA154F AbD Serotec 1:20 FITC 
Annexin V 10040‐15 Southern Biotec 10μL/ 106 
cells 
Cy‐5 
IL‐17 IC317IP eBioscience 1:10 PE 
IL‐4 12‐7049‐41 eBioscience 1:10 PE 
IFNγ  12‐7319‐41 eBioscience 1:10 PE 
pERM 3141 Cell Signal Technology 1:20 Unconjugated 
ERM 3142 Cell Signal Technology 1:20 Unconjugated 
*Dilutions used are of the supplied stock (which generally did not provide a concentration in 
μg/ml) 
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2.5.3 Mesoscale plate analysis of phospho- and total proteins 
In addition to western blotting, levels of phosphorylated proteins in the PI3K pathway 
were quantified, using the MSD mesoscale system (Figure 2.4). To prepare lysates, 
day 9 cells were removed from beads and cultured in complete media overnight. The 
following day they were washed into plain RPMI and incubated at 37°C for 1 hour. 
They were then stimulated as required and then lysed in the supplied Tris-based lysis 
buffer. The mesoscale plate assay was then performed according to the 
manufacturer’s instructions, with phospho (K11115D-1) and total proteins plates 
(K11133D-1) being performed in parallel. Briefly; plate were blocked for 1 hour in the 
supplied blocking buffer, then 25 μL lysate/well was placed onto the 96-well assay 
plate, pre-coated with capture antibody and incubated for 1 hour at room temperature 
before washing. Detection antibody was diluted in the supplied diluent and incubated 
for 1 hour at room temperature before washing. The supplied Read Buffer was added 
to each well and plates were read on a Mesoscale Sector 6000. 
2.6 Flow cytometry of live cells 
All flow cytometry was performed on a BD FACs Canto, using a FACs buffer of 
PBS/0.5% BSA. Cells were gated on viable population based on FSC and SSC and 
10,000 events in this population were acquired. 
2.6.1 Flow cytometric analysis of GFP expression 
For analysis of GFP expression, cell were washed once in PBS and resuspended in 
200μl PBS and assessed on a FACSCanto II with BDFacs DiVa software for 
fluorescence with excitation at 488nm, emission at 518nm.  
2.6.2 Antibody staining 
For cell surface staining by conjugated antibodies, beads were magnetically removed 
from cells. 1x106 cells were then washed twice in ice cold FACs buffer (PBS +1% 
BSA) than the conjugated antibody was added at the recommended dilution (Table 
2.3) in a volume of 50μL and incubated on ice in the dark for 30 minutes. Cells were 
then washed once and resuspended in FACs buffer on ice. For unconjugated 
antibodies, the same procedure was followed, but after washing, cells were 
resuspended in a minimum volume FACs buffer, and a conjugated secondary was 
added at 1:100 for 30 minutes, 
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Figure 2.4 The MSD mesoscale technology 
This figure is taken from the manufacturer’s website (www.mesoscale.com). Capture 
antibody is bound to dots in the bottom of wells on a 96 well plate. There are up to 10 
dots per well, allowing form 10 different analytes to be examined in a single well. 
Protein is bound by the capture antibody then detected with a labelled antibody. The 
Label emits light when excited by electricity passing through the base of the plate. 
This is recorded by a camera in the MSD sector imager machine and is automatically 
quantified. 
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before washing and final resuspension. For analysis of apoptotic cells see apoptosis 
assay. 
2.6.3 CFSE labelling 
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent dye that covalently 
binds to intracellular proteins (330). As cells proliferate, the dye is equally partitioned 
between daughter cells and thus each daughter cell will have half the fluorescence 
intensity of the original cell when assessed by flow cytometry. To perform CFSE 
assays the manufacturer’s protocol was followed. Briefly, freshly isolated CD4+ T 
cells were resuspended at 1x106 /ml in PBS /0.1% BSA. 2 µL of 5 mM CFSE solution 
(Invitrogen) was added per ml and cells were incubated at 37°C for 15 minutes. Cells 
were then washed twice in complete media, followed by another wash after 30 
minutes. Cells were then cultured as desired for seven days, before CFSE 
fluorescence was assessed by flow cytometry. For labelling of previously activated 
cells, day 7 cells were rested overnight off CD3/CD28 beads in complete media. 
Cells were resuspended at 1x106 /ml in PBS /5% BSA. 1 µL of 5 mM CFSE solution 
was added per ml and cells were incubated at 37°C for 15 minutes. Cells were then 
washed twice in complete media, followed by another wash after 30 minutes. Cells 
were cultured as required for 48 hours before CFSE fluorescence was assessed by 
flow cytometry. 
2.7 Flow cytometry of fixed cells 
Flow cytometry was performed essentially as for live cells. Cells were prepared using 
a BD cytofix/cytoperm kit (554715) which causes some alterations to FSC and SSC, 
but still allows intact cells to be distinguished from debris when gating. 1x105 cells 
were acquired from each sample with obvious debris excluded from the acquisition. 
2.7.1 Intracellular staining of pSTAT3  
Cells were stimulated as required then immediately fixed in BD cytofix for 1 hour. 
They were washed twice in BD perm/wash and incubated in 100µL volume (1 x106 
cells) for 15 minutes before addition of antibody or isotype control (1:100) overnight 
(all incubations at 4°C). Cells were then washed three times and resuspended in 
FACs buffer for flow cytometry. 
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2.7.2 Intracellular staining of actin 
Cells were stimulated as required then immediately fixed in BD cytofix for 1 hour. 
They were washed twice in BD perm/wash and incubated in 100 µL volume (1x106 
cells) for 15 minutes before addition of 50 ng/ml Phalloidin TRITC (Sigma) for 3 hours 
(all incubations at 4°C). Cells were then washed three times and resuspended in 
FACs buffer. 
2.7.3 Intracellular staining of pERM and ERM 
pERM or ERM antibody was applied as for pSTAT3, but following the last wash, were 
resuspended in 100µL BDperm/wash. Secondary antibody (Goat anti-rabbit FITC, 
Dako) was added (1:100 dilution) Cells were incubated at 4°C for 3 hours before 
being washed three times and resuspended in FACs buffer. 
2.7.4 Intracellular staining of cytokines 
On day nine-ten post isolation 1x106 cells were restimulated for 6 hours using PMA 
(50ng/ml)/Ionomycin (1 μg/ml) in the presence of Golgistop (BD), to cause the 
retention of cytokines. Cells were then fixed and the desired cytokine was stained 
using conjugated antibodies for IL-4, IFNγ or IL-17 as described for pSTAT 
2.7.5 Triple Treg stain  
For identification of Tregs the Human Regulatory T cell Staining Kit #3 (w/ PE-Cy5 
Foxp3 PCH101, FITC CD4, PE CD25; Treg Kit) from eBioscience (cat #88-8995) 
was used according to the manufacturer’s instructions. Briefly, 1x106 cells were 
resuspended in 100µL eBioscience staining buffer, and 20 µL anti-CD4 anti-CD25 
cocktail (or appropriate isotype controls) was added and cells incubated at 4°C for 30 
minutes. Cells were washed once in buffer then resuspended in 1ml eBioscience 
Fixation/permeabilization buffer for 1 hour at 4°C. Cells were then washed twice in 
Permeabilization buffer, resuspended in 100µL Permeabilization buffer/2% normal rat 
serum for 15 minutes, then 5µL anti-Foxp3 or appropriate isotype control was added 
for 1 hour. Cells were washed twice in permeabilisation buffer and resuspended in 
staining buffer for flow cytometry. Appropriate single stains were also done to allow 
manual compensation on the flow cytometer. 
2.7.6 Cell cycle analysis 
1x106 cells were washed once in PBS then fixed in 70% ice cold ethanol. Cells were 
incubated at 4°C for 1 hour then washed twice in PBS. Cells were resuspended in 
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PBS/1μg/ml RNase (Qiagen) for 30 minutes at room temperature then DNA was 
stained using PI (50 μg/ml, Sigma) for 1 hour at 4°C in PBS. Cells were washed 
twice and resuspended in PBS for flow cytometry. 
2.8 Confocal microscopy of live cells 
All confocal microscopy was performed on a Zeiss LSM 510 Meta at room 
temperature (except for chemotaxis assay, see later). To stain for rCD2, a FITC 
conjugated antibody was used at 1:100, as for flow cytometry. 1x106 cells were 
labelled for 1 hour at 4°C in PBS/ 1% BSA. Cells were then washed twice and 
resuspended in Annexin labelling buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 
mM CaCl2, 0.1% BSA). Annexin-cy5 (1:100) and PI (1 μg/ml final concentration) 
were added 5 minutes prior to imaging, at 4°C. Imaging was performed at room 
temperature. 
2.9 Confocal microscopy of Fixed Cells 
2.9.1 pERM, Actin and nuclear triple stain 
pERM was stained as for flow cytometry: 1x106 cells were stimulated as required 
then immediately fixed in BD cytofix for 1 hour. They were washed twice in BD 
perm/wash and incubated in 100µL volume (1 x106 cells) for 15 minutes before 
addition of antibody or isotype control (1:20) overnight (all incubations at 4°C). Cells 
were then washed twice in BDperm/wash and following the last wash, cells were 
resuspended in 100 µL BDperm/wash. Secondary antibody (Goat anti-rabbit FITC 
1:100 dilution), DAPI, for nuclear staining (1 μg/ml) and Phalloidin TRITC (50 ng/ml) 
for staining of polymerised actin were also used. When actin only was stained, this 
was done for three hours immediately after the fixative was washed off. Cells were 
then washed twice in BD perm/wash and once in MilliQ. They were resuspended in 
100 µL MilliQ and spun onto coverslips using a Shandon Cytospin 3 (10 minutes at 
500 rpm, low acceleration).  Coverslips were adhered to slides using Mowoil and 
allowed to set overnight. Cells were then visualised on a confocal microscope. All 
chemicals were from Sigma. 
2.9.2 ERM and nuclear dual stain  
ERM was stained as for pERM above at a 1:20 dilution of the stock antibody. During 
incubation with the secondary antibody, DAPI was used to stain the nucleus and cells 
were mounted and visualised as above. 
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2.10 Scanning Electron Microscopy 
2x106 cells were removed from beads and cultured in complete media overnight. 
They were then washed into plain RPMI for 1 hour. They were then transferred to 24 
well plates with Thermanox coverslips at the bottom of each well. They were 
incubated for a further hour, in inhibitors as necessary. Cells were fixed by replacing 
the media with RPMI /2.5% glutaraldehyde/1% tannic acid. Plates were incubated for 
2 hours at 37˚C. Coverslips were then washed with plain RPMI. Cells were postfixed 
in aqueous 1% osmium tetroxide for 1 hour at room temperature. Cells were washed 
twice in distilled water, each time incubating for 5 minutes. Coverslips were 
transferred to glass petri dishes. Cells were stained with aqueous 2% uranyl acetate 
for 1 hour in the dark. Cells were dehydrated in acetone by washing twice in 50%, 
70%, 90 % and 100% acetone, each time incubating for 5 minutes. They were then 
incubated in 1:1 Acetone: hexamethyldisilazane (HMDS) for 15 minutes, then twice in 
100% HMDS for 15 minutes. HMDS was then pipetted off, and coverslips were dried 
in a fume hood overnight. Coverslips with cells were coated in gold and cells were 
visualised on a JEOL JSM6480LV scanning electron microscope. All chemicals were 
from Sigma. 
2.11 Cell viability assays 
2.11.1 MTT assay 
Serial dilutions of H202 in RPMI were made in 96 well plates to give a volume of 
100μl. Cells at 1x106/ml in RPMI were added at 105 cells/ well (i.e. 100 μL/well), and 
incubated for 30 minutes. Plates were centrifuged for 5 min at 300 xg and the media 
was aspirated and replaced with complete media. Plates were returned to the 
incubator for 20 hours, then 20μl of MTT (Sigma) at 5 mg/ml was added to each well. 
After a further 4 hours at 37˚C media was aspirated and cells were lysed in 100 
μl/well DMSO 100%. The plate was read for absorbance at 550 nm on a Versamax 
microplate reader. 
2.11.2 Trypan Blue exclusion assay 
Cells were seeded in 96 well plates at 105 cells/well in 100μl in RPMI. TRAIL 
(Immunotools) or TNFα (Peprotech) at appropriate dilution was added in RPMI 
supplemented with 0.2% FCS (final FCS concentration 0.1%). Plates were incubated 
at 37˚C and samples were taken at 6 and 24 hours. Samples were diluted with 
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Trypan blue (1:10, Invitrogen) and 100 cells from each well were counted in a 
haemocytometer. 
2.11.3 Apoptosis assay 
Cells were treated as described in the trypan blue exclusion assay. At 6 hours, plates 
were centrifuged at 250g for 5 min, the media was aspirated and cells were 
resuspended in Annexin binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 
mM CaCl2, 0.1% BSA) plus AnnexinV-FITC (25 ng/test Apoptest A700 Dako) and 
propidium iodide (2.5 μg/ml). After a 10 minute incubation on ice cells were analysed 
by flow cytometry for emission at 518nm (FITC) and 617nm (propidium iodide). 
Compensation was performed manually. 
2.12 Cytokine assays 
2.12.1 Mesoscale 10-plex cytokine assay 
Naïve CD4+ T cells were incubated under Th0, Th1 or Th2 conditions as described 
above. After nine days the cells were washed into complete RPMI without cytokines, 
and restimulated with CD3/CD28 beads at 1:1 ratio for 16 hours in a volume of 
100μL and at a concentration of 1x106 cells/ml. After this the supernatant was 
collected and the cytokines present were analysed on an MSD mesoscale plate 
(K11010B-1) and absolute amounts calculated using a standard curve of known 
concentrations. The cytokines examined were IFN-γ, IL-1β, IL-10, IL-12 p70, IL-13, 
IL-2, IL-4, IL-5, IL-8 and TNF-α . Briefly, the protocol was as follows: Wells were 
blocked for 1 hour at room temperature with 1% w/v MSD blocker B, washed in PBS/ 
0.05% Tween-20, and 25 μL sample was added to the well. The plate was incubated 
on an orbital shaker for 2 hours and then 25 μL of the supplied detection antibody 
cocktail was added without removing the sample. The plate was incubated with 
shaking for a further two hours then washed three times with PBS/ 0.05% Tween-20 
and 150 μL of 2x MSD Read buffer T was added and the plate was read on an MSD 
Sector imager 6000. 
2.12.2 IL-17 ELISA 
Naïve CD4+ T cells were cultured under Th0, or Th17 conditions as appropriate. 
After nine days the cells were washed into complete RPMI without cytokines, and 
restimulated with CD3/CD28 beads at 1:1 ratio for 16 hours at a concentration of 
1x106 cells/ml. After this the supernatant was collected and the cytokines present 
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were analysed using an IL-17A ELISA (eBioscience cat #88-7176) and absolute 
amounts calculated using a standard curve of known concentrations. 
2.13 Adhesion assay 
The adhesion  assay was based on a protocol from Vielkind et al. (331)  Briefly, Flat-
bottom Maxisorp 96-well plates (Nunc) were coated overnight at 4°C with 
recombinant human ICAM-1 (CD54, 12.5μg/ml) (R&D ADP4-050) or fibronectin 
(10μg/ml R&D 1918-FN-02M ) in PBS. Wells were washed once with PBS and 
blocked with 2% BSA /PBS for 1 h at 37°C. The wells were washed once with PBS 
and once with plain RPMI. CD4+ T cells (day 9-10 post isolation) were labelled with 
CFSE as above. The labelled cells were added to the precoated plates at 5x105 
cells/well (input cells) in 100 µl of RPMI without phenol red supplemented with 0.1% 
BSA and were collected at the bottom of the well by centrifugation (1 minute 300xg). 
UCHT1 was added at 10µg/ml for the entire incubation or CXCL11 at 10nM for the 
last 15 minutes. The plates were incubated at 37°C for 30 min. The wells were filled 
with chemotaxis media (37°C) and covered with a plate sealer (Costar) and the 
sealed plate was turned upside down for 15 min at 37°C allowing the nonadherent 
cells to detach. While leaving the plate turned upside down, the plate sealer was 
removed. Adherent cells were then detached using 10mM EDTA and transferred to 
flat 96-well black plates (Sterilin 611F96BK). Adhesion was quantified by a 
multidetection plate reader (FLUOstar OPTIMA, BMG labtech) and the background 
adhesion (adhesion to BSA coated wells) was subtracted from the reading for each 
well. 
2.14 Migration assays 
2.14.1 Neuroprobe 
CD4+ T cells (day 8-9) were removed from CD3/CD28 beads and washed into 
complete media without IL-2 and incubated overnight. The following day they were 
washed into plain RPMI without phenol red supplemented with 0.1% BSA 
(chemotaxis media) at 3.2x106/ml and rested for 1 hour. Neuroprobe chemotaxis 
plates (ChemoTx®101-5) were preincubated with chemotaxis media for 1 hour then 
aspirated. Chemokine dilute in chemotaxis media was placed in the well in volumes 
of 29µL. A membrane with 5µm pores was placed on top. Cell suspension was 
dotted in bubbles on top of the membrane, in volumes of 25µL (Figure 2.5). The plate 
was incubated at 37°C for three hours. The bubbles were wiped from the membrane 
and the plate was centrifuged for 10 minutes at 300xg. Contents of the wells were 
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pipette into FACs tubes in a total volume of 300µL in PBS and cells were counted by 
flow cytometry. 
2.14.2 Ibidi slide videomicroscopy 
Hydrophobic uncoated μ-slides for chemotaxis (Ibidi #80301, obtained from Thistle 
Scientific) were coated with fibronectin at 45 μg/ml in PBS for 1 hour at room 
temperature and then washed twice with Milliq. This was indicated by the 
manufacturer to give a coating density of 1.5 μg/cm2. The slide and all reagents were 
warmed to 37°C to prevent formation of bubbles. The slide was filled with chemotaxis 
media, chemokine was added to the top chamber as required, in a volume of 18 μL, 
and cells (prepared as above, for the neuroprobe chemotaxis assay, but to a 
concentration of 5x106 /ml), were pipetted onto the bridge in a volume of 6μL (Figure 
2.5). A chemokine gradient was allowed to form for 15 minutes at 37°C, after which 
the cells were recorded for 15 minutes at 37°C on the LSM 510 Meta, with an image 
being taken every 15 seconds. The paths of 20 individual cells were tracked using 
the imageJ manual tracker and analysed using the imageJ chemotaxis tool. 
2.15 CD8 cytotoxicity assay 
This protocol was modified from that published by Van Gool et al. (332). Briefly CD8+ 
T cells were isolated and cultured as described above. On day 7-8 they were 
removed from beads and rested for 1 hour in complete media in the presence of 
Wortmannin (100 nM, Sigma) LY294002 (20 μM, Sigma) or ZSTK474 (1 μM, 
Zenyaku) if necessary. They were then washed into complete media without 
inhibitors. Meanwhile A20 cells were loaded with CFSE, following the protocol for 
freshly isolated T cells. In complete media, CD8+ T cells (effector cells) were 
combined in varying ratios with A20 cells (target cells) to give a total of 1x106 cells in 
a volume of 200 μL. The addition of UCHT1 at 10 μg/ml directed killing of A20 cells 
as indicated in Figure 2.6. The cells were incubated together for three hours at 37°C 
at which point cell were washed into annexin labelling buffer and incubated with 
annexin V-cy-5 (1:100) for 15 minutes. Cells were then assessed by flow cytometry 
for CFSE (i.e. discrimination of effector and target cells) and cy-5 (identification of 
apoptotic cells). 
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Cell suspension 
Filter 
Chemokine 
5 
4 
Figure 2.5. Set up of the Neuroprobe chemotaxis chamber and Ibidi chemotaxis 
slide 
Top panel; This image was taken from the manufacturer’s website 
(www.neuroprobe.com). Chemokine is placed in the well, a filter with pores is placed 
on top and then a cell suspension is pipetted onto it. Hydrophobic rings on the filter 
keep the cell suspension focussed over the well. 
Bottom panel: This image was taken from the manufacturer’s website (www.ibidi.de). 
1. Bridge on which cells are placed. 2. Upper reservoir with chemokine 3. Lower 
reservoir without chemokine. 4. and 5. Channels through which cells are pipetted. 6. 
Channel into which chemokine is pipetted. 7. Channel through which excess media is 
aspirated. 8. Stoppers to prevent evaporation. A chemokine gradient between the 
two reservoirs forms across the bridge. Cells are recorded as they move on the 
bridge. 
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CD8+ 
T cell 
CFSE-
labelled A20 
UCHT1TCR 
FcγRII 
Figure 2.6 CD8+ T cell cytotoxicity assay 
The human CD8+ T cell expresses a TCR which is bound and activated by UCHT1. 
UCHT1 is an antibody raised in mice, and hence is bound by FcγRII which is 
expressed upon the murine B cell lymphoma A20 cells. Hence the activated CD8+ T 
cell is directed to kill the A20 cell via release of granzymes and perforins. The A20 
cells are labelled with CFSE to distinguish them from the CD8+ T cells by flow 
cytometry. Labelling with an annexin cy-5 antibody (not shown) identifies apoptotic 
cells. 
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2.16 Molecular techniques 
2.16.1 PCR 
Conditions varied according to the DNA to be copied, but in brief, all reactions unless 
otherwise indicated were performed in a volume of 20μl, using Standard Taq buffer 
to 1x final concentration, 1 μl Taq (500units/ml), 1 μl dNTPs (10 mM of each dNTP) 
(all NEB) and primers at 0.5 μM (2.5 μM for mutation). Primers were from Invitrogen 
custom primers. Initial denaturation was for 10 min, followed by 20-30 cycles of 
denaturation  for 1 minute, annealing at 55˚C for 1 minute and extension at 72˚C (1 
min/ kilobase). Following PCR 5 μl of the reaction mix was diluted with 6x loading 
buffer (NEB B7021S) and visualised on a 1% agarose gel stained with ethidium 
bromide. If required PCR products were cleaned by running on a 1% agarose gel, the 
DNA band excised and purified with a gel purification kit (Qiagen). Alternatively a 
Wizard PCR cleanup kit was used. 
2.16.2 Restriction enzyme digestion and ligation of DNA 
Conditions varied according to the enzymes used, but in general digests were 
performed in reaction volumes of 10 μl with 1 μl enzyme(s) in appropriate buffer and 
BSA if required, for at least 1 hour. All enzymes and buffers were from NEB. 
Products were cleaned using gel purification. Ligations were performed in reaction 
volumes of 10 μl with 1 μl T4 ligase, 1 μl ligase buffer (both Promega) and ratios of 
insert: vector between 1:1 and 3:1 for at least 4 hours at room temperature. 
2.16.3 Transfection of E. Coli and isolation of plasmids 
For expression of most plasmids competent DS5α E. coli, were thawed from -80˚C 
on ice for 10 minutes. 5μl plasmid at 1 μg/μL was added and left on ice for a further 
20 minutes. Bacteria were then heat shocked at 42˚C for 30 seconds, then 250 μl 
SOC media was added and tubes were shaken at 200 rpm at 37˚C for 1 hour. 200 μl 
of the bacteria were plated onto ampicillin agar (100 μg/ml), and incubated overnight. 
The following day colonies were screened for appropriate plasmids using PCR. 
Colonies were used to seed 5ml of LB broth with ampicillin (100 μg/ml, Sigma) for 8 
hours, which in turn was used to seed 100 ml of LB broth with ampicillin. Plasmids 
were isolated according to manufacturer’s instructions with Qiagen mini (5 ml) or 
maxi prep (100 ml) spin columns. 
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For expression of lentiviral expression plasmids, which contain LTR and have a 
tendency to recombine with host cell DNA, Stbl3 E. coli (C7373-03 Invitrogen) were 
used. These were heat shocked as above, but for 45 seconds. After addition of SOC 
and plating, plates were incubated at 30°C for 24 hours before colonies were picked 
and screened. Colonies were then used to seed 5 ml of LB broth which was 
incubated overnight at 30°C. This was then expanded to 100 ml culture volume 
during the following day and 300 ml culture the next night. Finally, plasmids were 
isolated with a Machery Nagel Nucleobond Xtra Maxi plus kit according to the 
manufacturer’s instructions. 
2.16.4 Ligation of CD2:SHIP into lentiviral plasmid pCLPS 
In order to use this system to express rCD2:SHIP in human T cells it was necessary 
to ligate the DNA coding for rCD2:SHIP into an expression plasmid. The pCLPS 
expression plasmid encodes GFP which has previously been successfully excised 
using the BamH1 and Sal1 restriction sites. Therefore the following primers were 
designed to introduce these restriction sites to the rCD2:SHIP 
F (5’ to 3’) GCA AGG ATC CAT GAG ATG TAA ATT CCT AGG GAG 
Underlined = BamH1 restriction sequence 
R (5’ to 3’) CCA AGT CGA CTC ATG TGG CCT CTA ACC G 
Underlined = Sal1 restriction sequence 
25 cycles of PCR were performed as described in the methods and the product was 
double digested (with BamH1 and Sal1 at 37˚C with BSA in BamH1 buffer) and 
cleaned using a Wizard PCR clean up kit. The pCLPS vector was also double 
digested and ligated in a 1:1 ratio with the insert either overnight at room temperature 
or for 4 hours at room temperature. The plasmids were then transfected into DH5α 
E.Coli and colonies screened by PCR using the above primers for the presence of 
rCD2:SHIP. 
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2.16.5 RT-PCR and semi-quantitative PCR 
RNA was isolated with Trizol reagent (Invitrogen) and converted to cDNA with an 
Omniscript RT kit (Qiagen) following the manufacturer’s instructions. 1ml of Trizol 
was used to lyse 5x106 cells per point. The phases were separated using chloroform 
and RNA was precipitated using propan-2-ol, then washed in 75% ethanol. The pellet 
of RNA was air dried and then resuspended in sterile, endonuclease free water. RNA 
was quantified then quantified and 100ng reverse transcribed with Omniscript. 
Reverse transcriptase (RT) buffer, dNTP mix (final concentration 0.5mM each dNTP), 
Oligo-dT primer (final concentration 1μM) RNase inhibitor (10Units/ reaction) and 
Omniscript Reverse Transcriptase (4Units/ reaction) were combined with 100ng RNA 
and reverse transcribed at 37°C for 1 hour. Negative controls contained no RT.  PCR 
for SHIP-1 was performed at 55°C and for β-actin at 60°C, each at 30 cycles, as 
described above, the primers used were  
SHIP-1 5’-AAGAGAGAAGGCTTCTGCCA-3’ (F),  
5’- CAGGAACCGGAGAATGTTCA-3’ (R). 
β Actin 5’- TAGGCACCAGGGTGTGATGG-3’ (F),  
5’-CATGGCTGGGGTGTTGAAGG-3’ (R).  
2.17 Materials and Methods for murine experiments 
2.17.1 Animals 
PI3Kγ-/- mice on both 129sv and BALB/c backgrounds were bred under specific 
pathogen free conditions at Charles River (UK), or under comparable conditions at 
Novartis, UK (Horsham) (333). PI3Kγ kinase dead mice were bred at the University 
of Basel (138). Control wild-type mice were produced at Charles River (UK). Animals 
were housed at 24oC in a 12 hours light-dark cycle. Food and water were accessible 
ad libitum. The studies reported here conformed to the UK Animals (scientific 
procedures) Act 1986. 
2.17.2 In vivo challenge and assessment of BAL cytokines 
Animals were lightly anaesthetised with gaseous isofluorane, then instilled with 50μl 
of LPS (Sigma) at 0.1 mg/kg intra-nasally.  Bronchoalveolar lavage with 4 x 0.3 ml 
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PBS was performed at various time points following challenge, and IL-17 content 
determined via ELISA (R&D). Further studies used 1 mg/ml recombinant IL-17A 
(Peprotech) as a stimulus, resulting in a 50 μg challenge, 5hrs after which 
bronchoalveolar lavage was analysed for cell influx and KC, MIP2, IL-6 and IL-5 
content via ELISA (R&D). N.B. This experiment was performed by Matt Thomas. 
2.17.3 Splenocyte isolation and culture 
Splenocytes were isolated from the spleens of mice and disrupted by passing 
through a 40μm cell stainer (BD Falcon). Mononuclear cells were obtained by density 
gradient centrifugation (Ficoll Paque Plus, Sigma), and cultured in complete growth 
medium (RPMI supplemented with 10% FCS, 100 U/ml streptomycin, 100 μg/ml 
penicillin, and 2mM L-glutamine and 50μM 2-ME (all Invitrogen)) at 1x106 cells/ml +/-
100μg/ml LPS for 2, 4 and 6 days*. CD4+ T cells were enriched using MACS CD4+ T 
cell isolation kit (Miltenyi Biotec) to achieve >90% purity. CD4+ T cells were activated 
using either plate-bound anti-CD3 and anti-CD28 (bound overnight at 1μg/ml)* or 
murine CD3/CD28 T cell expander Dynabeads (Invitrogen).at 1:1 ratio to cells, which 
were maintained in culture at 1x106/ml. For culure under Th0 or Th17 conditions, 
cells were isolated as above, but using a MACS naïve CD4+ T cell isolation kit 
(Miltenyi Biotec). Cells were then cultured in RPMI supplemented as above and with 
murine CD3/CD28 T cell expander Dynabeads (Invitrogen) at 3:1 ratio to cells for 7 
days. For Th0 conditions, no other cytokines were added. For Th17 conditions cells 
were cultured as for Th0, supplemented with rhTGFβ1 ng/ml, rmIL-6 20 ng/ml rmIL­
23 10 ng/ml, rmIL-1β 10 ng/ml, anti IL-410 μg/ml and anti IFNγ μg/ml (all cytokines 
were from Peprotech and all antibodies were from R&D). The cells were maintained 
at approximately 1 x106/ml by doubling the culture volume (and addition of further 
cytokines for Th17 conditions) on days 3 and 5 post isolation. 
2.17.4 Assessment of cytokines in culture and proliferation 
CD4+ T cells were maintained in culture at 1x106/ml and IL-2*, IL-4*, IL-5*, IL-6, 
IFNγ* and IL-17A were assessed in cell culture supernatants using Quantikine 
ELISAs (R&D) at 48 hours except where otherwise specified. IL-17F was assessed 
using a Duoset ELISA kit (R&D) at 48 hours except where otherwise specified. 
Proliferation was assessed by tritiated thymidine incorporation at 48 hours*. * The 
indicated experiments were performed by Matt Thomas 
2.17.5 Mouse Dermal Fibroblast Culture and IL-6 production. 
Mouse dermal fibroblasts were cultured in CNT-05 media (Millipore). Cells were 
seeded at 3x103/well in 96 well plates and cultured for 48hrs before the addition of 
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CD4+ T cell supernatant. Cells were cultured for a further 24hrs before harvest of 
supernatant and measurement of IL-6 by ELISA as above. For IL-17A neutralisation, 
a blocking antibody was used at 1μg/ml (R&D MAB421). 
2.17.6 Flow cytometry 
Cells were labeled in PBS (Invitrogen) supplemented with 0.5% BSA (Sigma) by 
adding the amount of flurophore-conjugated antibody recommended by the supplier. 
IL-17RA, IL-17RC and isotype control antibodies were from BD Pharmingen. Viable 
cells were gated based on forward and side scatter.  For intracellular staining for IL­
17, cells were restimulated for 6 hrs using CD3/CD28 in the presense of Golgistop 
(BD Biosciences) then fixed and stained in Cytofix/Cytoperm reagents (BD 
Biosciences) according to the manufacturer’s instructions Anti-IL-17A and isotype 
control antibodies were from BD Biosciences. Flow cytometric analysis was 
performed using a FACSCanto II (BD Biosciences). 
2.17.7 Cell stimulations and Akt ELISA 
Cells were rested for 1hr in RPMI, then stimulated with IL-17A or IL-17F, cells were 
then lysed and phospho-AKT (S473) was measured by ELISA kit following the 
manufacturer’s instructions (Invitrogen). 
2.18 Statistics 
All statistical tests were performed using Graphpad Prism 4 software.  For the 
majority of comparisons, a Student’s paired T Test was used and results were taken 
to be statistically significant at p<0.05. Where multiple observations were performed 
in the same experiment, a one way ANOVA with repeated measures was used where 
possible. Otherwise a Holmes correction was used. 
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Characterisation of SHIP-1 activation in T cell lines 
and primary human T cells and its pro-survival role in 
cell lines 
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3.1 Background and objectives 
Previous work has identified SHIP-1 as being present in primary T cells, but lost in 
some leukaemic T cell lines (244). Furthermore, SHIP-1 has been shown to be an 
important negative regulator of T cell signalling, for example in response to 
chemokines (294). It has also been shown to play an important role in protecting cells 
against death in response to oxidative stress (334). However, much of this work 
utilised cell lines. Therefore, the first aim of this section was to investigate SHIP-1 
activation in primary human T lymphocytes and leukaemic T cell lines. The second 
aim was to characterise its protective role in T cell lines challenged with a range of 
pro-apoptotic stimuli. 
3.2 Expression of SHIP-1 in primary human T cells and T cell 
lines 
The first experiments were necessary to validate to the expression of SHIP-1 or a 
constitutively active SHIP-1 protein in cell lines and primary human cells. It has 
previously been reported that whilst primary T cells express SHIP-1, this expression 
is lost in some leukaemic cell lines such as Jurkats (244). However, to confirm this, 
activated primary human T cells, and the leukaemic cell lines CEMs, HUT78s and 
Jurkats were western blotted for SHIP-1. It was found that primary T cells and all of 
the cell lines apart from the Jurkats expressed SHIP-1 (Figure 3.1). 
To investigate the effects of SHIP-1 expression, a constitutively active SHIP mutant, 
rCD2:SHIP was used. rCD2:SHIP is a chimeric protein, consisting of the extracellular 
and transmembrane domains of rat CD2 fused to the phosphatase domain of human 
SHIP-1. The protein is constitutively localised to the cell surface membrane and 
hence the SHIP-1 phosphatase domain is suitably situated to metabolise PI(3,4,5)P3. 
This protein was expressed in Jurkats using a tet-off expression system as described 
previously (244). This experimental system allowed comparision of Jurkats which 
express no SHIP-1, with the rCD2:SHIP Jurkats which have a constitutively active 
SHIP-1 phosphatase domain. However, western blotting for the expression of rCD2 
in transfected cells indicated that expression was “leaky”, i.e. that some rCD2:SHIP 
was expressed even in the presence of tetracycline (Figure 3.1). Therefore for further 
experiments with rCD2:SHIP Jurkats, WT Jurkats were used as controls (rather than 
rCD2:SHIP Jurkats in the presence of tetracycline). 
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3.3 Characterisation of SHIP-1 activity in human T cells 
3.3.1 Phosphorylation of SHIP-1 in response to receptor stimulation 
Upon activation of signalling cascades, SHIP-1 is recruited to the membrane and is 
then tyrosine phosphorylated upon Y1020, which lies in the second of the NPXY motifs 
towards the C terminal of SHIP-1. A polyclonal antibody from Stem Cell Technologies 
recognises phosphorylation of this site, which may be taken as a marker of SHIP-1 
activation as when phosphorylated, this motif is able to bind the phosphotyrosine 
binding (PTB) domains of Shc (254) and Dok2 (201). It was therefore investigated 
whether ligands for different receptors expressed on T cells and known to regulate 
PI3K, also regulated SHIP-1 phosphorylation, or whether SHIP-1 phosphorylation 
and PI3K activation were differentially regulated. 
Phosphorylation of SHIP-1 in response to chemokines was observed in both primary 
T cells and CEMs. Phosphorylation of SHIP-1 on Y1020 was observed in response to 
stimulation of CD3 (part of the TCR complex), by the monoclonal antibody UCHT1 
(10μg/ml) or CD28 (a costimulatory receptor), by the monoclonal antibody 9.3 
(10μg/ml) as previously shown (335) (Figure 3.2). This phosphorylation was most 
consistently observed in response to CD3 stimulation, whilst the response to CD28 
appeared transient. The chemokines CXCL10 (IP10), CXCL11 (ITAC), CCL22 
(MDC), CCL17 (TARC) and CXCL12 (SDF) at 10 nM also induced phosphorylation of 
SHIP-1, although this was weaker than that induced by CD3 stimulation (Figure 3.2). 
It was also observed that phosphorylation of SHIP-1 did not correlate with 
phosphorylation of Akt. For example the phosphorylation of SHIP in primary T cells in 
response to CXCL10 is more sustained than that of Akt. 
3.3.2 SHIP-1 is phosphorylated in response to oxidative stress 
It has been demonstrated in Jurkats that reintroduction of SHIP-1 can protect against 
death caused by ROS generated by exposure of the cells to H2O2 (334). Therefore, it 
was appropriate to examine the ability of ROS to induce phosphorylation of SHIP-1 in 
primary human T cells. Application of H2O2 to activated primary human T cells or 
CEMs resulted in tyrosine phosphorylation of SHIP-1 (Figure 3.3). This was observed 
at concentrations as low as 3 μM, however at low concentrations of H2O2 the 
phosphorylation was sometimes weak and transient, whilst at higher concentrations 
of the level which results in substantial cell death (as determined by Annexin/PI 
staining, see below), phosphorylation was very strong and sustained. 
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Figure 3.1 SHIP-1 and rCD2:SHIP expression. A. SHIP-1 is present in activated 
primary human T cells, and some cell lines. 1x 106 untreated cells were lysed and 
western blotted as described in the Methods for expression of SHIP-1 using an 
antibody that recognises the N terminal of the protein. B. rCD2:SHIP Jurkats express 
the rCD2:SHIP protein.1x 106 rCD2:SHIP Jurkats cultured in the presence or 
absence (for 48 hours) of tetracycline (2 μg/ml) were lysed and western blotted for 
expression of rat CD2. The results shown are representative of three separate 
experiments. 
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A. CEMs 
B. Activated primary human T cells 
Figure 3.2 SHIP-1 is phosphorylated in response to CD3, CD28 and chemokine 
receptor stimulation A. 1x 106 CEMs were treated with 10 nM CXCL10, CCL22, 
CCL17, and CXCL12, or 10 μg/ml anti CD3 (UCHT1) or anti-CD28 (9.3) antibody for 
the indicated times, lysed and western blotted as described in Methods for 
phosphorylated SHIP-1 and pan-ERK to determine equal loading. B. Activated 
primary human T cells were treated with 10 nM chemokines or 10 μg/ml anti CD3 or 
anti-CD28 antibody for the indicated times lysed and western blotted as described in 
Methods for phosphorylated SHIP, phosphorylated S473 Akt and pan-Akt to determine 
equal loading. The results shown are representative of three separate experiments. 
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3.3.3 SHIP-1 is phosphorylated in response to TRAIL and TNFα 
Given that H2O2 was a robust signal for SHIP-1 phosphorylation it was thought 
possible that a physiological stimulus known to generate ROS could also induce 
SHIP-1 phosphorylation. Therefore, it was decided to examine the phosphorylation of 
SHIP-1 in response to stimulation of death receptors, as these are known act partly 
through the generation of ROS (336, 337). However, whilst TRAIL induced a strong 
phosphorylation of SHIP-1 in activated primary human T cells, the phosphorylation 
that was induced by TNFα was weak and transient at best (Figure 3.3). 
3.3.4 SHIP-1 is phosphorylated in response to ATP and bpVphen 
Next it was investigated whether SHIP-1 phosphorylation is induced by stimulation 
purinergic receptors as their signalling pathways can also utilise ROS. Application of 
ATP at 10 μM, also induced SHIP-1 phosphorylation (Figure 3.3) in activated primary 
human T cells. The effects of bpVphen were also investigated, as this compound has 
been reported in the literature to inhibit PTEN (probably though oxidation of a 
cysteine residue in it catalytic site) and activate SHIP-1 to cause an increase in both 
PI(3,4,5)P3 and PI(3,4)P2 (232, 338, 339). In line with this, bpVphen was found to 
cause a strong phosphorylation of SHIP-1 and also to phosphoylate Akt (figure 3.3). 
3.4 Phosphorylation of SHIP-1 correlates with its translocation 
to the membrane 
As described above, SHIP-1 is reported to be phosphorylated upon its recruitment to 
the membrane. However, this phosphorylation is not essential for enzymatic activity 
in vitro (340), nor for its association with the Src kinase Lyn at the cell membrane, as 
inhibition of the kinase activity of Lyn using PP2 inhibits SHIP-1 phosphorylation but 
not its association with Lyn (341). It was therefore necessary to verify that 
phosphorylation of SHIP-1 may be taken as a marker for its recruitment to the cell 
membrane it T cells. To do this, CEMs were left untreated, or exposed to H2O2, then 
fixed, permeabilised and stained for SHIP and pY1020 SHIP-1 as described in 
Methods and visualised using a confocal microscope. pY1020 SHIP-1 was absent from 
unstimulated cells, but localised to the cell membrane upon H2O2 treatment (Figure 
4). Staining with the SHIP-1 antibody was less successful but implied that SHIP-1 
was distributed throughout the cytosol in unstimulated controls, and recruited to the 
cell membrane upon stimulation, with little remaining in the cytosol. 
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Figure 3.3 H2O2, TRAIL TNFα, ATP and bpVphen cause phosphorylation of 
SHIP-1 1x 106 Activated primary human T cells were exposed to various 
concentrations of H2O2 for 5 minutes (A) or the indicated times (B). Samples were 
western blotted for pSHIP (pY1020) as described in the methods, then for ERK (A) or 
SHIP-1 (B) to ascertain equal loading. C. 1x 106 Activated primary human T cells 
were treated with 0.1μg/ml TRAIL for 1 minute. Samples were western blotted for 
pSHIP, then for ERK D. 1x 106 Activated primary human T cells were treated with 
1ug/ml TNFα for 5 minutes (strongest phosphorylation seen from n=4 with 1mM H2O2 
from same experiment for comparison). Samples were western blotted for pSHIP-1, 
then for ERK. 1x 106 activated primary human T cells were stimulated with 10μM 
ATP for 1 minute (E) or 30µM bpVphen for 30 seconds (F). Samples were western 
blotted for pY1020 SHIP-1 and pS473 Akt then for ERK (E) or S6 (F). The results shown 
are representative of three separate experiments. 
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5μm 
Figure 3.4 H2O2 causes phosphorylation and translocation of SHIP-1  2x 106 
CEMs were left unstimulated (control) or stimulated with 1mM H2O2 for 5 minutes, 
after which cells were prepared for imaging with a confocal microscope as described 
in the methods. Cells were stained with either an antibody recognising the SHIP-1 N 
terminal or pY1020 SHIP-1 (green). Images shown are typical examples from the 
experiment, which was the most successful of three separate experiments (in terms 
of cell permeabilisation and antibody staining). 
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3.5 Phosphorylation of SHIP-1 is inhibited by the Src inhibitor 
PP2, but not by LY294002 
SHIP-1 has been shown to be phosphorylated by Lyn, a member of the Src kinase 
family, for example in response to M-CSF in THP-1s and FcγRIIb stimulation in B 
lymphocytes (341).  Therefore it was desirable to establish whether the same was 
true in T cells for the ligands investigated above. 
Activated primary human T cells or CEMs were preincubated for 30 min with 10μM 
PP2, a non-selective Src kinase inhibitor. This inhibited phosphorylation in response 
to CD3, H2O2 and ATP even at high concentrations (e.g. 3mM ATP). It was also able 
to reduce the basal phosphorylation seen in activated primary human T cells, which 
appeared to vary between donors (Figure 3.5). In addition, to investigate whether 
SHIP-1 phosphorylation was PI3K dependent (for example, if PI(3,4,5)P3 is required 
for the formation of the signalling complexes which recruit of SHIP-1 to the cell 
surface prior to its phosphorylation), activated primary human T cells or CEMs were 
preincubated for 30 min with 20μM LY294002, a PI3K inhibitor. This failed to inhibit 
tyrosine phosphorylation of SHIP-1 in response to H2O2, ATP, and CD3. 
3.6 Experiments using Jurkats expressing CD2:SHIP 
3.6.1 CD2:SHIP protects against H2O2 induced cell death 
The generation of ROS is well known as an antimicrobial defence. However, ROS 
have also been reported as being important in a variety of signal transduction 
pathways, including TCR signalling (342) and death receptor signalling (343). It has 
also been shown that expression of SHIP-1 protected leukaemic T cells against 
ROS-induced cell death (263). To investigate this, the responses of the rCD2:SHIP 
Jurkat line to apoptotic stimuli were compared to those of wild type Jurkats. As 
described above, rCD2:SHIP Jurkats express a membrane localised SHIP-1 
phosphatase domain, whilst wild type Jurkats entirely lack SHIP-1 expression. When 
measured with an MTT-based assay, the survival of (rCD2:SHIP Jurkats) following 
exposure to H2O2 was increased compared to that of the parental Jurkat cell line 
(Figure 3.6) (334). Because the MTT assay is redox based, there was concern that it 
would result in skewed results if ROS were still present. Therefore, cells were also 
assessed for annexin V binding at 6 hours after exposure to H2O2. This also 
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Figure 3.5 PP2 but not LY294002 inhibits SHIP-1 phosphorylation. 1x 106 
activated primary human T cells were preincubated for 30 minutes in 10 μM PP2 or 
20 μM LY294002 (LY) as indicated, then exposed to A. H2O2 for 1 minute or B. 3 mM 
ATP or 10 μg/ml anti-CD3 (UCHT1) for 5 minutes. Samples were western blotted for 
pSHIP-1 as described in the methods, then for ERK to ascertain equal loading. The 
results shown are representative of three separate experiments.   
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indicated that SHIP-1 significantly protected against H2O2 –induced cell death 
(p<0.05 ANOVA with repeated measures followed by Bonferroni post hoc analysis 
p<0.01 at all concentrations of H2O2). 
3.6.2 CD2:SHIP protects against TRAIL-induced cell death 
As described earlier, ROS are generated in many disease states and signalling 
pathways, however, there is no consensus on what concentration of H2O2 may 
correspond to physiological levels of ROS in healthy or diseased tissue. Therefore 
the ability of CD2:SHIP to protect against cell death in response to death receptor 
signalling was examined, as death receptors are known to rely upon generation of 
ROS and it has been reported that introduction of full length SHIP-1 into Jurkats 
could protect against FasL-induced cell death (264). The expression of TRAIL 
receptors is known to vary between Jurkat clones, however, in a trypan blue 
exclusion assay, TRAIL induced moderate levels of cell death in Jurkats. 
Furthermore, CD2:SHIP expression did protect against cell death in this instance 
(Figure 3.7 A, B). It was observed that with the trypan blue that after 24 hr there are 
higher basal levels of dead cells after 24 hr, probably because they are only in 0.1% 
FCS (higher levels of FCS are reported to interfere with death receptor signalling). 
However, the numbers of dead cells in the control samples were similar between 
Jurkats and rCD2:SHIP Jurkats. 
3.6.3 CD2:SHIP fails to protect against TNFα-induced cell death 
To further examine the protective role of SHIP-1 in death receptor signalling, the 
effects of TNFα were examined. In the first instance, TNFα induced cell death was 
examined by trypan blue exlusion at 6 and 24 hours (Figure 3.7 C, D). However there 
was no difference in cell survival between the Jurkat and rCD2:SHIP cell lines. In 
addition the number of cells was assessed using an MTT assay, with the SHIP core 
again conferring no benefit (Figure 3.7 E).  
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Figure 3.6 SHIP-1 protects against cell death in response to H2O2. Jurkats and 
rCD2:SHIP Jurkats were incubated with H2O2 at the indicated concentrations for 30 
minutes, then washed into complete media. A. Cell metabolism (as a measure of cell 
number) was assessed with MTT after 24 hrs in a 96 well plate assay as described in 
the Methods. Cell survival was significantly enhanced by the presence of rCD2:SHIP. 
B. Cells treated as above were labelled with AnnexinIV-FITC antibody and 1x105 
cells per point were analysed by flow cytometry after 6 hrs (n=3 +/- SEM, p<0.05 2 
way ANOVA with repeated measures followed by Bonferroni post hoc test n=3). 
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Figure 3.7 SHIP-1 protects against cell death in response to TRAIL but not 
TNFα. Jurkat and rCD2:SHIP Jurkats were incubated  with 0.1μg/ml or 1μg/ml TRAIL 
for 6hr and 24 hr, before cell viability was assessed using trypan blue. A higher 
percentage of cells expressing rCD2:SHIP survived at both time points and both 
concentrations of TRAIL (*p<0.05 2 way ANOVA with repeated measures followed by 
Bonferroni post hoc test n=3). Jurkat and rCD2:SHIP Jurkats were incubated  with 
0.3, 1 or 3μg/ml TNFα for C. 6hr and D. 24 hr, before cell viability was assessed 
using trypan blue. No difference was observed between percentage survival of the 
two cell types at either time point or concentrations of TNFα (2 way ANOVA with 
repeated measures n=3). E. Jurkat and rCD2:SHIP Jurkats were incubated  with 
indicated concentrations of TNFα for 24hr, before cell viability was assessed using 
an MTT assay (typical results from n=3) 
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3.7 Summary 
•	 SHIP-1 is expressed in primary human T cells, CEMs and HUT78s, but not 
Jurkats. 
•	 SHIP-1 is activated in response to CD3 and CD28 receptor stimulation and in 
response to chemokines, ATP, TRAIL, bpVphen and H2O2. 
•	 Phosphorylation of SHIP-1 correlated to its recruitment to the cell surface 
membrane. 
•	 Phosphorylation can be inhibited by PP2 but not LY294002. 
•	 Expression of a membrane localised SHIP-1 phosphatase domain protects 
against the death of Jurkats in response to ROS and TRAIL. 
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4.1 Background and objectives 
The first results section examined the role of SHIP-1 in leukaemic T cell lines and 
also investigated its activation in primary cells. However, one of the main aims of the 
thesis was to examine the function of SHIP-1 in primary T cells. Therefore the first 
aim of this section was to set up a lentiviral delivery system for use with primary 
human T lymphocytes in order to modulate expression of SHIP-1, either by silencing 
expression using shRNA, or by driving expression of the rCD2:SHIP protein used in 
the previous chapter. The second aim was to investigate the effect of these 
interventions on cell viability and signalling. Others have shown that the PI3K 
signalling pathway is a key modulator of actin polymerisation and of cell motility and 
chemotaxis (85, 344, 345), hence the final aim was to investigate the effects of SHIP­
1 silencing on actin polymerisation. 
4.2 Choice of delivery system 
In the absence of commercially available compounds targeting SHIP-1, investigation 
of its actions in cells required a genetic approach. As reported elsewhere it is 
extremely difficult to introduce siRNA into primary T cells using either chemical 
transfection or electroporation (286, 346), without compromising viability. 
Furthermore rates of transfection are low, and the effect is transient. Previous 
experiments had been performed in the laboratory using Amaxa nucleofector 
technology, with disappointing results (286). Newer electroporation technology had 
since become available, and was investigated. As shown in Figure 4.1 
electroporation of primary human T cells with a GFP expression plasmid resulted in 
low expression levels using an optimised protocol and an MP-100 Microporator. 
Microporation of freshly isolated CD4+ T cells gave a maximum of 10% of cells 
successfully expressing GFP and viable (death rates were between 30 and 95%). 
Microporation of day 10 Staphylococcal enterotoxin B (SEB) activated T cells was 
less successful and resulted in 80-98% cell death with a maximum of 3% of cells 
being viable and expressing GFP. Therefore it was decided to use a viral delivery 
system which can give higher rates of infection for introduction of shRNA and 
rCD2:SHIP (although the microporator was used to deliver tagged PH domains, see 
Chapter 5). Lentiviruses are particularly advantageous as they can infect non dividing 
cells (347, 348).  
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Condition Voltage 
Pulse 
width 
Number of 
Pulses 
1 0 0 0 
2 2000 20 1 
3 2050 20 1 
4 2100 20 1 
5 2150 20 1 
6 2200 20 1 
7 2250 20 1 
8 2300 20 1 
9 2350 20 1 
10 2400 20 1 
11 2450 15 1 
12 2500 15 1 
13 2000 15 2 
14 2050 15 2 
15 2100 15 2 
16 2150 15 2 
17 2200 15 2 
18 2250 15 2 
Figure 4.1 Electroporation allows delivery of DNA to primary T cells 
with low efficacy (Continues on next page) 
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Figure 4.1 Electroporation allows delivery of DNA to primary T cells with low 
efficacy (cont’d) The Microporator MP-100 was used to electroporate cells. CD4+ 
were freshly isolated, whist PBMCs were cultured for 10 days in the presence of SEB 
and IL-2. Cells were washed into the supplied electroporation buffer at 2x107 cells/ml 
in a volume of 10μL (i.e. 2x105 cells/sample) and pulsed with 0.5 μg pCLPS GFP 
using the parameters described in the table. Cells were then cultured on CD3/CD28 
beads and IL-2 (for CD4+) or with IL-2 (SEB activated T cells) for 48 hours. Cells 
were then washed into FACs buffer and GFP expression was assessed by flow 
cytometry of 1 x105 cells. FSC and SSC were used to identify viable cells. 
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4.2 Set up of Lentiviral delivery system 
4.2.1 GFP encoding virus can infect Jurkat cells  
Viral particles were assembled as described in the Materials and Methods. Briefly, 
packaging plasmids and an expression plasmid were chemically transfected into 
HEK293T cells and virus was manufactured by the cells and released into the 
supernatant. During optimisation, the pCLPS GFP expression vector was used, as 
expression of GFP could be easily monitored. To check that the chemical 
transfection of HEKS with the lentiviral expression and packaging plasmids was 
optimal, transfected cells were assessed for GFP expression by flow cytometry and 
found to be over 95% transfected (Figure 4.2A). Initially, the GFP lentivirus that was 
produced by transfected HEKS was used to infect Jurkat cells, as these are a rapidly 
proliferating cell line and therefore very easy to infect. As expected, over 95% 
infection levels could be achieved (Figure 4.2B).  
4.2.2 Calculation of viral titre and demonstration of replication 
incompetence 
Serial dilutions of the supernatant containing virus applied to HEKs were used to 
calculate viral titre, to be used to calculate the multiplicity of infection (MOI) values 
used below (Figure 4.3A). In the illustrated example ~ 20% of 4x105 cells were 
infected by 3 ml of a 1:10 dilution meaning that each ml of undiluted supernatant 
contained approximately 2.7 x105 viral particles. In addition, as a safety precaution, 
supernatant from infected HEKs was applied to uninfected HEKs. This failed to result 
in new infection, indicating that the virus was replication incompetent (Figure 4.3B).  
4.2.3 Primary human T cells can be infected with high efficacy 
using lentivirus 
Having successfully established the lentiviral expression system in leukaemic cell 
lines, primary human T cells were then targeted. CD4+ T cells were isolated using a 
MACS untouched CD4+ or CD8+ isolation kits ( which bind all other cells and retain 
them in the column and allow the desired cells to pass through), and activated for 24 
hours using CD3/CD28 beads, then exposed to lentivirus for 24 hours. Initial rates of 
infection were fairly low (~13%) but spinoculation (centrifugation of the cells during 
infection) increased the rate of infection to ~30% (Figure 4.4A) and use of polybrene 
at 5 μg/ml further increased efficacy to ~ 45% (Figure 4.4B). Maximal efficacy was 
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GFP 
950.2 
5 93.3 
A. HEK Untransfected HEK GFP transfected 
B Jurkat uninfected Jurkat GFP infected 
GFP 
Figure 4.2 The Jurkat leukaemic cell line can be infected with high efficacy 
using lentivirus. 
A. HEK293T cells were cultured to 60% confluency and transfected with viral 
plasmids as described in the Materials and Methods. After 48 hours cells were 
trypsinised and resuspended in FACs buffer and 1x105 viable cells/sample were 
assessed by flow cytometry for GFP expression The percentage of cells that were 
gated as positive for GFP expression are indicated on each histogram B. Uninfected 
controls or Jurkats were infected with virus containing the pCLPS GFP as described 
in the Materials and Methods using 3 mls of supernatant from HEK293T cells to 
infect 1x106 cells. 1x105 viable cells/sample were assessed by flow cytometry for 
GFP expression three days post infection. Results are representative of three 
independent experiments. 
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GFP 
A. HEK Uninfected 
HEK infected undiluted HEK infected 1:10 HEK infected 1:100 
GFP 
69.3 23.4 11.5 
0 
GFP 
0 
B Supernatant from uninfected cells Supernatant from infected cells 
Figure 4.3 GFP can be effectively and safely expressed using lentivirus.  
A. HEK293T cells were exposed to serial dilutions of media containing GFP virus, in 
order to calculate viral titre. Cells were plated at 2x105/well in a 6 well plate and 
allowed to double over 24 hours to give 4x105/well. Cells were exposed to 3ml of 
neat supernatant from virus-producing HEK-293T cells, or 1:10 or 1:100 dilutions. 
After 48 hours assessed by flow cytometry for GFP expression of 1x105cells/point. B. 
Inability to replicate in HEK293T cells. GFP-encoding lentivirus was used to infect 
HEK293T cells. After a 48-hour incubation this supernatant was removed and used 
to culture uninfected HEK293T cells. After 48 hours this second set of cells was 
assessed by flow cytometry for GFP expression i) control HEKs ii) HEKs cultured 
with supernatant from infected HEKS. Results are representative of two independent 
experiments. 
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A. CD4+ uninfected CD4+ GFP CD4+ GFP spinoculated 
5 13.6 31.1 
GFP 
B. CD4+ uninfected CD4+ GFP CD4+ GFP polybrene 
5 41.6 47.4 
GFP 
C. CD4+ uninfected CD4+ GFP Fugene CD4+ GFP Mirus 
1.9 62.2 80.9 
GFP 
Figure 4.4 Optimal infection rates in primary human T cells require 
spinoculation and polybrene. 
Primary human CD4+ were isolated and activated for 24 hours as described in the 
Materials and Methods. They were then infected at a MOI of 5 for 24 hours with 
lentivirus encoding GFP. Cells were then washed into complete media with IL-2 and 
cultured as normal. 1x105 viable cells/sample were assessed by flow cytometry for 
GFP expression three days post infection. A. During infection, cells were cultured in 
an incubator for the full 24 hours or were spinoculated (centrifuged at 30°C, 300xg) 
for the first 90 minutes then cultured in an incubator for the remainder of the 24 
hours. B. During infection, cells were spincoculated as above. In addition, infection 
was in the absence or presence of 5 μg/ml polybrene. C. CD4+ T cells were infected 
as above but at an MOI of 10 using virus prepared by transfecting HEK293 T with 
either Fugene 6 or Mirus transit LT1. All samples were analysed three days post 
infection for GFP expression using flow cytometry of 1x105 viable cells/ point. Results 
are representative of two independent experiments. 
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achieved by improving production of the lentivirus by ensuring supercoiled DNA, 
optimal seeding densities of HEK293T cells and switching from Fugene to Mirus 
chemical transfectant (this increased the viral titre to approximately 1x106/ml without 
need of ultracentrifugation) (Figure 4.4D). Three days and seven days post infection 
cells were assessed by flow cytometry and confocal microscopy respectively. CD4+ 
and CD8+ cells were found to have similar rates of infection (~80%) and similar 
levels of expression of GFP (Figure 4.5A). Confocal microscopy indicated that 
infected cells had a normal morphology and were otherwise unaffected by exposure 
to lentivirus (Figure 4.5B). 
4.3 Expression of rCD2:SHIP reduces PI3K signalling and 
adversely affects viability 
CD4+ T cells were infected with lentivirus encoding rCD2:SHIP (a constitutively 
active form of SHIP),  expressed in the pCLPS plasmid. Rat CD2 was detected in 
infected cells by western blot and also by flow cytometry. Approximately 30-40% of 
cells were found to be infected three days post infection. Cells were sorted by 
expression of rCD2 using MACS columns to gain a population that was over 80% 
positive (Figure 4.6). 
Uninfected cells and cells infected with a GFP-expressing virus appeared healthy 
whereas rCD2:SHIP infected cells were mostly dead six days post infection as 
confirmed by flow cytometry and confocal microscopy. Therefore the cells were 
examined three days after infection and were observed to have a higher percentage 
of apoptotic cells than control cells. The levels of pAKT, as an indicator of PI(3,4,5)P3 
levels (because sufficient numbers of cells for direct measurement of lipids were not 
obtained), were also assessed using cells at this timepoint (i.e., whilst there were still 
some viable cells). rCD2:SHIP CD4+ T cells three days postinfection had much lower 
basal phosphorylation of AKT and further phosphorylation was not induced in 
response to the chemokine CXCL11 (Figure 4.7). 
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5.2 85.9 
4.5 78.2 
GFP 
A CD4+ control CD4+ GFP 
CD8 control CD8+ GFP 
Control GFP 
CD4+ 
CD8+
10μm 
B 
Figure 4.5 Primary human T cells can be infected with high efficacy using 
lentivirus 
CD4+ and CD8+ cells were isolated from PBMCs from the same donor and cultured 
with anti-CD3/CD28 antibody coated beads (at a ration of 3 beads:1 cell) and IL-2 for 
24 hours, after which they were exposed to GFP lentivirus as described in the 
methods. Cells were assessed for expression of GFP by A. flow cytometry after 3 
days (live cells were washed into FACS buffer and 1x105 viable cells were analysed 
immediately) and B. confocal microscopy after 6 days (live cells were washed into 
chemotaxis media at 1x105/ml and 100μL samples aliquoted into coverslip-bottomed 
chambered slides and imaged on an LSM510 Meta confocal microscope). Results 
are representative of three independent experiments. 
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10.2 11.6 
32.2 4.3 
81.0 
rCD2 
100kDa 
75kDa 
ERK 
Infected, positively sorted B C rCD2:SHIP 
A Isotype control Uninfected 
Infected rCD2:SHIP Infected, negatively sorted 
rCD2 
Figure 4.6 Expression of rCD2:SHIP by CD4+ and their selection by magnetic 
cell sorting 
A. Cell populations were analysed for rCD2 expression by flow cytometry using FITC 
anti rCD2 and acquisition of 1x105 viable cells. Sorting indicates the population that 
were sorted by MACS magnetic separation-negatively selected (uninfected) cells and 
positively selected (infected) cells. B. Western blot of uninfected and infected CD4+ 
cells for rCD2 expression and ERK (despite loading more protein into the uninfected 
lane, no rCD2 was detected). 
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A Control, uninfected Infected, rCD2:SHIP, positively sorted 
B. Uninfected GFP rCD2:SHIP C. 
pS473 AKT 
S6 
Control CD2SHIP 
- + - + 3nM CXCL11 2’ 
20μm 
Figure 4.7 Expression of rCD2:SHIP reduces PI3K signalling and adversely 
affects viability 
A. Control uninfected cells and cells infected with lentivirus encoding rCD2:SHIP 
were cultured for three days (i.e., four days post isolation) and infected cells were 
then magnetically sorted for expression of rCD2:SHIP.  CD4+ T cells were stained for 
annexin IV and propidium iodide and their viability was assessed by flow cytometry of 
1x105 cells/sample. B. Control uninfected cells, and cells infected with lentivirus 
encoding GFP or rCD2SHIP were cultured for three days (i.e., four days post 
isolation) and rCD2:SHIP infected cells were then magnetically sorted for expression 
of rCD2:SHIP. Cells were cultured for a further three days then stained for annexin IV 
(yellow) to identify dead cells.  Control and rCD2SHIP cells are also stained for rCD2 
(green) as described in the Materials and Methods. Samples were aliquoted onto 
chambered coverslips and analysed on an LSM 510 Meta confocal microscope. C. 
Day four post isolation control and rCD2:SHIP cells prepared as in part A were 
stimulated with CXCL11. 1x106 cells per sample were lysed and samples were 
diluted to equal concentrations of protein before being western blotted with the 
indicated antibodies as described in the Materials and Methods. S6 was blotted to 
indicate protein loading. Results are representative of three independent 
experiments. 
103 
Chapter 4: Results Section II 
4.4 Lentiviruses expressing shRNA can be used to silence 
SHIP-1 expression in primary human T cells  
shRNAs against SHIP-1 encoded in a lentiviral expression plasmid were obtained 
from SIGMA, along with scrambled short hairpin control. These plasmids also encode 
a puromycin resistance element. CEM cells were infected with SHIP-1 shRNAs 
encoded by a variety of sequences as indicated in the Materials and Methods. All 
were found to reduce expression of SHIP-1 at the protein level. Upon infection of 
CD4+ T cells, infected cells were selected on the basis of puromycin resistance 
(using a concentration of 0.1 μg/ml, previously validated as described in the Materials 
and Methods). SHIP-1 shRNA (SHIP-1 shRNA 3) reduced SHIP-1 at the protein level 
whilst PTEN expression appeared to be upregulated (Figure 4.8). 
4.5 Effect of silencing SHIP-1 in primary T cells 
4.5.1 SHIP-1 silencing does not affect viability of T cells but 
reduces proliferation  
Because of the key roles of PI3K signalling in cell growth and survival, it was thought 
prudent to check the viability of infected cells. CD4+ and CD8+ cells were infected 
with lentivirus encoding scrambled shRNA or SHIP-1 shRNA and selected on the 
basis of puromycin resistance and then their viability was assessed by PI and 
annexin staining seven days post isolation. Example plots of CD8+ and CD4+ T cells 
and bar graphs from pooled experimental data (Figure 4.9) demonstrate that SHIP-1 
knockdown does not affect viability of T cells. The viability of the cells after 6 hours in 
0.1% serum was also examined, as this was considered the maximum amount of 
time they would be in low serum or BSA during future experiments. Again loss of 
SHIP-1 did not increase the percentage of apoptotic cells. 
The next experiment analysed the ability of SHIP-1 knockdown cells to proliferate in 
response to CD3/CD28 stimulation by labelling the cells with the fluorescent probe 
CFSE and using flow cytometry to track the dilution of the CFSE as the cells divide. 
Firstly cells were labelled with CFSE immediately upon isolation and then activated 
and infected with lentivirus encoding scrambled shRNA or SHIP-1 shRNA as 
described in the Materials and Methods. CFSE intensity was the examined seven 
days post-isolation. Figure 4.10A shows fewer peaks of CFSE when SHIP-1 
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A SHIP‐1 shRNA 
C 1 2 3 4 5
150kDa SHIP-1 
Akt175kDa 
B Control shRNA C SHIP shRNA 
SHIP-1 
β-actin
 Control shRNA C SHIP shRNA 
PTEN 
ERK 
SHIP-1150kDa 
50kDa 
37kDa 
Figure 4.8 Lentiviruses expressing shRNA can be used to silence SHIP-1 
expression in primary human T cells. A. Control CEM cells were left uninfected (C) 
or infected with lentiviruses encoding short hairpin RNA against SHIP-1. 1-5 
represent different shRNA sequences as detailed in the Materials and Methods. After 
3 days cells were selected with puromycin and after a further three days cells 1x106 
cells were lysed and samples were diluted to equal concentrations of protein before 
being immunoblotted with antibodies against SHIP-1 and Akt1. Next CD4+ T cells 
were left uninfected (Control), infected with a scrambled short hairpin lentivirus 
(shRNA C) or SHIP-1 shRNA. A. mRNA was isolated from at 5x106 cells/point as 
described in the methods, Rt-PCR was used to obtain cDNA and semi-quantitative 
PCR used to determine expression of SHIP-1 and β-actin mRNA. B. 1x106 cells were 
lysed and samples were diluted to equal concentrations of protein before being 
immunoblotted with antibodies against SHIP-1 and PTEN. Equal loading was verified 
by levels of ERK. 
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Figure 4.9 Silencing of SHIP-1 does not affect viability of T cells 
CD4+ (A) or CD8+ (B) T cells were infected with lentivirus as indicated and cultured 
for a total of nine days before being stained with Annexin-Cy5 and propidium iodide 
as described in the Materials and Methods. Viability was assessed by flow cytometry 
of 1x105 cells/sample. For the bar graph of pooled data for CD4+ T cells, cells were 
incubated in 10% FCS or 0.1% FCS for 6 hours before labelling (n=3 +/- SEM). 
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A shRNA control SHIP‐1 shRNA 
CFSE 
B shRNA control SHIP‐1 shRNA 
C shRNA control SHIP‐1 shRNA 
PI 
CFSE 
Figure 4.10 Silencing of SHIP-1 expression results in decreased proliferation.   
A. Freshly isolated CD4+ T cells were loaded with CFSE and infected with lentivirus 
encoding shRNA as indicated. Proliferation was monitored by assessing CFSE 
intensity by flow cytometry on day 7 using 1x105 viable cells per sample. B. Day 6 
shRNA control or SHIP-1 shRNA infected CD4+ were rested overnight by removing 
them from CD3/CD28 beads, then loaded with CFSE on day 7 and restimulated with 
CD3/CD28 beads for 48hrs. CFSE content was then assessed by flow cytometry as 
above. C. shRNA control cells and SHIP-1 shRNA infected cells were fixed and 
permeabilised seven days post isolation and stained with propidium iodide as 
described in the methods. Propidium iodide concentration was then assessed by flow 
cytometry of 1x105 cells/ sample. Histograms are from a single experiment 
representative of at least three independent experiments. 
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expression is silenced, and furthermore these peaks are of a higher intensity. This 
indicates that SHIP-1 silenced cells underwent fewer divisions i.e. that proliferation 
was reduced. Secondly cells were isolated, activated, infected and cultured as 
described in the methods for six days. They were then removed from the CD3/CD28 
beads and rested in complete media overnight. On day seven they were loaded with 
CFSE and restimulated for 48 hours. Figure 4.10B shows that upon restimulation 
between days 7 and 9, a proportion of shRNA control cells undergo a division, in 
contrast, none of the SHIP-1 silenced cells has divided.  Propidium iodide staining 
can be used on permeabilised cells to determine the stage of cell cycle. Cells in G0 or 
G1 have one set of chromosome pairs per cell, whilst during S phase DNA is being 
synthesised and cells contain an increased amount of DNA as the phase progresses 
and therefore stain more intensively with propidium iodide. During G2 and M phase, 
two sets of chromosome pairs are present in each cell and so when these cells are 
stained with propidium iodide they fluoresce at twice the intensity when analysed by 
flow cytometry. Figure 4.10C demonstrates that unlike the shRNA control cells, 
SHIP-1 shRNA cells have undergone cell cycle arrest by day seven post isolation, 
with fewer of these cells having two copies of DNA. 
4.5.2 Loss of SHIP-1 is not sufficient to sensitise T cells to TRAIL 
It has been reported in the literature that primary T cells do not undergo apoptosis in 
response to TRAIL, although leukaemic cell lines are known to do so. As 
demonstrated in the previous results section that introduction of rCD2:SHIP could 
protect against cell death in response to TRAIL in Jurkats, it was possible that loss of 
SHIP-1 might sensitise primary cells to TRAIL. To investigate this, cells were 
exposed to TRAIL for 6 hours, at concentrations known to cause substantial 
apoptosis of Jurkats. However, this did not affect the viability of T cells, even when 
SHIP-1 expression was silenced (Figure 4.11). 
4.6 PI3K signalling in the absence of stimulation is increased 
by silencing of SHIP-1 
4.6.1 Basal PI(3,4,5)P3 levels are increased by silencing of SHIP-1 
Having verified loss of protein expression using SHIP-1 shRNA, the effects on PI3K 
signalling were investigated, beginning with its proximal target, PI(3,4,5)P3 
production. An anti-CD3 antibody, UCHT1, was used as a stimulus and 10µg/ml was 
confirmed as an optimum concentration by examining Akt phosphorylation in 
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Figure 4.11 Silencing of SHIP-1 does not sensitise primary T cells to TRAIL 
CD4+ cells were infected with lentivirus as indicated and cultured for a total of nine 
days. Cells were then incubated in 0.1% serum and the indicated concentrations of 
TRAIL for 6 hours before being stained with Annexin-Cy5 and propidium iodide. 
Viability was assessed by flow cytometry of 1x105 total cells (n=3 +/- SEM) 
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response to a range of concentrations.  The PI(3,4,5)P3 ELISA successfully 
determined the amount of PI(3,4,5)P3 (Figure 4.12). Levels in control cells were low 
but were increased upon stimulation with UCHT1. Pretreatment with the PI3K 
inhibitor LY294002 had no effect upon basal levels, but prevented an increase in 
response to UCHT1. The shRNA control had basal and stimulated levels of 
PI(3,4,5)P3 very similar to control cells. SHIP-1 shRNA cells had an increase in levels 
of PI(3,4,5)P3 under basal conditions and a further raise in PI(3,4,5)P3 was observed 
upon treatment with UCHT1. No PI(3,4)P2 (the product of SHIP-1 metabolism of 
PI(3,4,5)P3) was detected in the mass blot in any of the control samples, probably 
because the lipid was not present in sufficient quantities. A spot was observed in the 
UCHT1 treated SHIP-1 shRNA sample, which would be unexpected as without SHIP­
1 one would expect a decrease in PI(3,4)P2 levels. However, a spot was also 
observed in the PI(3,4,5)P3 control, indicating that the antibody was cross-reacting 
with PI(3,4,5)P3, which, it was known from the PI(3,4,5)P3 mass ELISA, was most 
abundant in the UCHTI stimulated SHIP-1 shRNA sample (this cross-reaction had 
also been reported on the manufacturer’s website, and the mass blot has since been 
withdrawn from sale). 
4.6.2 Basal phosphorylation of AKT and other PI3K-dependent 
proteins levels is increased by silencing of SHIP-1 
Further downstream signalling events were then examined using an MSD mesoscale 
plate to examine phosphorylation of multiple proteins. Again, UCHT1 was used as a 
stimulus. The timecourse was verified by western blotting for pAkt in control cells. 
Cells infected with a virus expressing a scrambled short hairpin control showed no 
change in phosphorylation of AKT or its downstream targets p70S6K and GSK3β 
under basal or stimulated conditions compared to control cells (Figure 4.13). 
However, levels of basal phosphorylation were increased in SHIP-1 shRNA cells. 
(pooled data from three experiments). Both controls and SHIP-1 shRNA cells 
responded to stimulation by increased phosphorylation of the proteins, however the 
additional phosphorylation induced by UCHT1 was not greater in the SHIP-1 shRNA 
cells i.e. SHIP-1 controlled the basal levels of phosphorylation. Basal Akt 
phosphorylation was also observed to be increased by western blot (Figure 4.13). 
These results correlated well with the observed changes in PI(3,4,5)P3 levels. A 
small increase was observed in the levels of ERK phosphorylation when SHIP-1 was 
silenced, when assessed by western blot either in unstimulated cells, or those 
exposed to anti-CD3 or CXCL11 (Figure 4.14). 
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4.6.3 Basal polymerisation of actin is increased by silencing of SHIP-1 
Because PI3K signalling has been implicated in the control of actin polymerisation, 
and ultimately in cell motility, levels of polymerised actin were also assessed by 
staining with phalloidin. Control cells and shRNA control cells had very little 
polymerised actin under resting conditions, and this polymerised actin was localised 
to discreet areas of the cells. In contrast, SHIP-1 silenced cells displayed an increase 
in basal polymerisation of actin and the actin appeared to be distributed in a 
homogenous manner around the cell membrane when examined by confocal 
microscopy. However, all cells displayed an increase in actin polymerisation after 
exposure to CXCL11 (ITAC) (expression of CXCR3, the receptor for CXCL11 was 
unaffected by silencing of SHIP-1, see Figure 5.8). The increase in basal actin 
polymerisation was also verified by flow cytometry and SHIP-1 silenced cells were 
found to have approximately 75% more polymerised actin than control cells in 
unstimulated conditions (Figure 4.15). 
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pAKT 
S6 
pERK1/2
 0 30 10 3 1 0.3 
A B 
C Membrane layout Membrane 
Lane # Lane # 
1 2 3 1 2 3 
Sample in lane 1 
Control 
Control + UCHT1 
Ly Control 
Ly Control + UCHT1
Figure 4.12 Measurement of PI(3,4,5)P3 and PI(3,4)P2 levels. 
A. Assay was optimised by investigating the ability of varying concentrations of 
UCHT1 to induce phosphorylation of Akt and ERK in day 10 CD4+ T cells. 1x106 
cells/point were treated as indicated with UCHT1 then lysed and western blotted for 
pS473 Akt pERK and S6 as described in the Materials and Methods. B. CD4+ Cells 
were infected with lentivirus as indicated and cultured for a total of ten days 2x106 
cells per point were stimulated as indicated in the legend (LY294002 (Ly) 20µM 1 hr 
preincubation, UCHT1 10µg/ml 10 min,) in RPMI. Lipids were extracted following the 
manufacturer’s protocol. Briefly, cells were collected in trichloroacetic acid (TCA), 
washed in TCA/EDTA, neutral lipids were extracted in methanol/chloroform, acidic 
lipids were extracted in methanol/chloroform/HCl. The phases were then split and the 
organic phase was dried under vacuum and resuspended in appropriate buffer for 
each assay. For measurement of PI(3,4,5)P3 levels a mass ELISA (Eschelon 
biosciences K-3800) was used. C. Cell extracts prepared from cells treated as in part 
B were analysed for PI(3,4)P2 levels using a mass blot (Eschelon biosciences-
withdrawn). Data is from one experiment representative of two independent 
experiments. 
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Figure 4.13 PI3K signalling in the absence of stimulation and in response 
to the CD3 stimulatory antibody UCHT1 is increased by SHIP-1 silencing 
A. CD4+ Cells were cultured for a total of ten days. 1x106 cells per point were 
stimulated as indicated in the legend with UCHT1 (10 μg/ml) then lysed and 
western blotted for pS473 Akt and ERK as described in the Materials and 
Methods. B. CD4+ Cells were infected with lentivirus as indicated and cultured for 
a total of ten days. Cells were stimulated with UCHT1 (10 μg/ml) as indicated at 
4x105 cells per point. Cells were lysed using the manufacturer’s lysis buffer 
(MSD). Levels of phosphorylated proteins (pS473AKT, pT421/S424 p70S6K and pS9 
GSK3β) were assessed using an MSD mesoscale plate and normalised to levels 
of total protein in each sample, then as a fold change compared to levels in the 
unstimulated control (n=3 +/-SEM). 
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pAkt75kDa 
β-actin 50kDa 
B C shRNA control SHIP shRNA
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- +  - + CXCL11
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pERKS6
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Figure 4.14 Phosphorylation of Akt and ERK in response to UCHT1 and 
CXCL11. CD4+ T Cells were infected with lentivirus as indicated and cultured for a 
total of 9-10 days. A. 1x106 cells per point were stimulated as indicated with UCHT1 
(10μg/ml) then lysed and western blotted for pS473 Akt and β actin as described in the 
Materials and Methods. B. 1x106 cells per point were stimulated as indicated in the 
legend with UCHT1 (U) at 10μg/ml or 9.3 (9)(anti-CD28 antibody) at 10μg/ml for 5 
minutes then lysed and western blotted for pERK and S6 as described in the 
Materials and Methods. C. 1x106 cells per point were stimulated as indicated in the 
legend with CXCL11 for 2 minutes at 3nM, then lysed and western blotted for pS473 
AKT, pERK and pan S6 as described in the Materials and Methods. Results are 
representative of at least two independent experiments. 
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A
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B 
shRNA control SHIP-1 shRNA 
Figure 4.15 Actin polymerisation in resting cells is increased by silencing of 
SHIP-1 expression. CD4+ T cells were infected with lentivirus as indicated and 
cultured for a total of ten days. 1x106 cells per point were stimulated with CXCL11 
(10nM 2 minutes) as indicated, then fixed with BD cytofix/cytoperm and polymerised 
actin was stained with Phalloidin-TRITC (typical example representative of three 
independent experiments) B. Unstimulated cells were fixed and stained as above and 
analysed by flow cytometry at 1x105 cells per point, pooled data n=5 mean +/- SEM * 
P<0.05 Student’s paired T test. 
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4.7 Summary 
•	 This section of the results demonstrated the successful set up of a lentiviral 
delivery system. 
•	 Lentiviral- mediated introduction of an active form of SHIP-1 resulted in cell 
death. 
•	 When the lentivirus was used to silence SHIP-1 expression, cells were viable 
(and remained insensitive to TRAIL), but had decreased proliferation. 
•	 Silencing of SHIP-1 increased levels of PI(3,4,5)P3 and increased levels of 
phosphorylation of proteins in the PI3K signalling pathway under resting 
conditions. 
•	 Resting levels of actin polymerisation were also increased upon silencing of 
SHIP-1. 
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The effect of silencing SHIP-1 expression on cell 
morphology, adhesion and motility 
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5.1 Background and objectives 
It was seen in the previous section that loss of SHIP-1 led to an increase in basal 
PI3K signalling pathways in primary human CD4+ T cells and an increase in basal 
actin polymerisation. Hence the first aim of this section was to characterise any 
subsequent morphological changes, in SHIP-1 silenced cells. The second aim was to 
investigate the effect of silencing SHIP-1 expression on cell motility, which 
encompassed adhesion, basal motility and chemotaxis.  
5.2 Cell morphology and expression of adhesion molecules, 
but not adhesion, are altered by SHIP-1 knockdown 
5.2.1 Scanning electron microscopy reveals loss of microvilli upon 
silencing of SHIP-1 
As well as the disordered actin polymerisation, when the SHIP-1 silenced cells were 
examined by confocal microscopy they also appeared smaller than their control 
counterparts. Therefore, SEM was undertaken to see if any further morphological 
changes were observed. It was seen that control cells had microvilli projections and 
upon treatment with 10nM CXCL11 (ITAC) (2 minutes) polarisation of the cells was 
observed, as they formed ruffles and lost microvilli expression. After a prolonged 
exposure to chemokine (1hr), cells no longer appeared motile but exhibited a 
rounded morphology (Figure 5.1) and interestingly they had not regained microvilli 
expression (n.b. some cells appeared resistant to exposure to chemokine, or were 
only affected transiently, as they were observed to have microvilli after 1 hour 
incubation in chemokine (Figure 5.2)).  
Treatment with the PI3K inhibitor LY294002 (20μM), for 1 hour, did not affect 
expression of microvilli (Figure 5.1). Nor did the Src kinase inhibitor, PP2 (10 μM, 1 
hour), (which can inhibit the phosphorylation of SHIP-1), alter expression of microvilli. 
In contrast, bpVphen, which activates SHIP-1 but inhibits PTEN, resulting in an 
increase in both PI(3,4,5)P3 and PI(3,4)P2 (338), at two different concentrations (3 
and 30 μM, 1 hour) resulted in loss of the majority of microvilli from the cell surface. 
Treatment with LY294002 could not prevent microvilli loss in response to chemokine 
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Control cells 
Untreated LY294002 20 μM PP2 10 μM bpVphen 3μM 
bpVphen 30 μM CXCL11 10 nM 2 min CXCL11 10 nM 60 min LY294002 20 μM then 
CXCL11 10 nM 60 min 
shRNA control cells 
Untreated LY294002 20 μM CXCL11 10 nM 2 min CXCL11 10 nM 60 min 
SHIP‐1 shRNA cells 
Untreated LY294002 20 μM CXCL11 10 nM 2 min CXCL11 10 nM 60 min 
Figure 5.1 Cell morphology is altered by SHIP-1 silencing. 
CD4+ T cells were infected with viruses encoding shRNA as previously and cultured 
for a total of nine days. The cells were washed into RPMI and incubated for 1 hour in 
inhibitors as indicated on thermanox coverslips in 24 well plates at 5x105/ well. They 
were then stimulated with CXCL11 as indicated and then fixed and dehydrated and 
mounted for SEM as described in Materials and Methods. Images are taken from a 
single experiment, representative of three independent experiments. N.B. In some 
samples magnification has been adjusted to include whole cell in field of view, please 
refer to individual scale bars on images. White bar indicates 2μm in all pictures. 
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Control cells     Control plus LY294002 20 μM 1 hour 
Control cells plus bpVphen 3 μM 1 hour    Control plus CXCL11 10 nM 1 hour 
Control cells plus CXCL11 10 nM 1 hour  plus CXCL11 10 nM 1 hour 
Figure 5.2 Additional SEM images of T cells indicating further points of interest  
Overview of morphology: CD4+ Cells were cultured for 9 days. The cells were 
washed into RPMI and incubated for 1h in inhibitors as indicated on thermanox 
coverslips in 24 well plates at 5x105/ well They were treated as indicated and then 
fixed and dehydrated and mounted for SEM as described in Materials and Methods. 
Images are taken from a single experiment, representative of three independent 
experiments. 
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(cells on this slide were damaged during preparation, the apparent increase in cells 
size is due to flattening after dehydration as indicated by cracks in the cell). shRNA 
control cells exhibited the same morphology as control cells, expressing microvilli in 
the absence of stimulation which were unaffected by exposure to LY294002. They 
polarised as previously described in response to CXCL11, and upon prolonged 
exposure they returned to a rounded morphology with near total loss of microvilli. 
SHIP-1 silenced cells lacked microvilli under resting conditions, being fairly spherical 
in appearance. Upon a short exposure to chemokine, they exhibited a normal ability 
to polarise, and again became rounded, without microvilli, upon long exposure to 
chemokine. Furthermore, LY294002 was unable to rescue the phenotype in resting 
SHIP-1 silenced cells (Figure 5.1). 
Figure 5.2 indicates additional points about the morphology of the cells. The first 
image demonstrates that a range of morphologies are seen in control cells, with 
some lacking microvilli or appearing polarised. Even with LY294002 treatment (20μM 
1 hour), some elongated cells can be observed. Polarised cells were also observed 
upon exposure to bpVphen (3μM 1 hour), despite loss of microvilli in non-polarised 
cells. Upon a prolonged exposure to chemokine (CXCL11 10nM 1 hour), some cells 
were still polarised whilst others exhibited a rounded morphology with loss of 
microvilli (these images are of cells found on the same slide). Furthermore, in every 
experiment, not all control cells lost microvilli upon prolonged exposure to 
chemokine. This may have been attributable to low expression of CXCR3. 
5.2.2 Phosphorylation of ERM is decreased when expression of 
SHIP-1 is silenced 
The next set of experiments examined the mechanism by which microvilli were lost 
when SHIP-1 expression was silenced. Microvilli are formed when ERM 
(Ezrin/Radixin/Moesin) proteins link the actin cytoskeleton to the surface membrane. 
It has been reported in the literature that microvilli are rapidly lost upon activation of 
the cell due to Rac1-mediated ERM dephosphorylation (349-351). When control cells 
were stained for phosphorylated ERM and examined by confocal microscopy, it was 
indeed found that pERM had a punctuate distribution that would correlate with its 
localisation to microvilli. LY294002 treatment (20μM, 1 hour) did not affect the 
localisation or abundance of pERM in control cells. SHIP-1 silenced cells had very 
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Actin Nucleus pERM Light Phase Overlay 
(Phalloidin‐TRITC) (DAPI) 
Isotype control 
10μm 
Control 
shRNA control 
SHIP‐1 shRNA 
Control + LY294002 
Figure 5.3 SHIP-1 silencing results in loss of ERM phosphorylation 
(Figure continues on next page) 
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Actin Nucleus pERM Light Phase Overlay 
(Phalloidin‐TRITC) (DAPI) 
Control 
Control+ NSC23766 
10μm 
shRNA control 
shRNA control + NSC23766 
SHIP‐1 shRNA 
SHIP‐1 shRNA + NSC23766 
Figure 5.3 (continued from previous page, see next page for legend) 
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Actin Nucleus pERM Light Phase Overlay 
(Phalloidin‐TRITC) (DAPI) 
Control+ CXCL11 
Control+ NSC23766+ CXCL11 
10μm 
shRNA control + CXCL11 
shRNA control+ NSC23766+ CXCL11 
SHIP‐1 shRNA + CXCL11 
SHIP‐1 shRNA+ NSC23766+ CXCL11 
Figure 5.3 (continued from previous page, see next page for legend) 
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Figure 5.3 (cont’d) CD4+ T cells were cultured as described in Materials and 
Methods and infected with lentiviruses encoding shRNA as indicated. On day 9-10 
5x105 cells/ point were rested in RPMI for 1hr with or without the Rac1 inhibitor 
NSC23766 100 μM (Calbiochem) and LY294002 20 μM. Cells were then stimulated 
with CXCL11 10nM for 10 minutes as indicated, the fixed with BD cytofix/cytoperm. 
Cells were stained overnight with pERM (pT567Ezrin/ pT564Radixin/ pT558Moesin, Cell 
Signal Technology) or Rabbit IgG control in BD Perm/Wash at 4˚C, then washed 
twice and stained with Anti rabbit-FITC, Phalloidin-TRITC and DAPI for three hours at 
room temperature. Cells were further washed in Perm/Wash then in Milliq and 
mounted on coverslips and imaged on an LSM 510 Meta confocal microscope. 
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little pERM although one or two very small microvilli could be observed on some cells 
(Figure 5.3). As Rac1 has been shown to mediate ERM dephosphorylation, and 
SHIP-1 has been shown to act upstream of Rac, inhibiting Ras activation both 
through its catalytic and non catalytic functions (352-354), the effect of the Rac1 
inhibitor NSC23766 (100μM, 1 hour) was also investigated. The inhibitor caused 
some aberrant morphology in control cells, which had generally lost their spherical 
appearance, although microvilli remained. When applied to SHIP-1 knockdown cells, 
the Rac1 inhibitor caused an increase in pERM, which did not appear localised to 
microvilli and it was not sufficient to completely restore the morphology of the cells to 
that of control cells. Phosphorylated ERM was largely lost from control cells upon 
exposure to CXCL11, as documented in the literature. Upon exposure to CXCL11, 
control cells retained more of their pERM, localised to microvilli, when treated with 
the Rac1 inhibitor. SHIP-1 silenced cells, pretreated with the Rac1 inhibitor also 
retained some phosphorylated ERM. When ERM phosphorylation was quantified by 
flow cytometry (Figure 5.4A), it was seen that whilst NSC23766 was sufficient to 
block ERM dephosphorylation in shRNA control cells treated with CXCL11, it did not 
fully restore ERM phosphorylation in SHIP-1 knockdown cells.  
To ensure that the lack of phosphorylated ERM in the cells was not due to a lack of 
ERM proteins themselves, confocal microscopy and flow cytometry of ERM were 
undertaken. Images of individual cells indicated that ERM was present in both 
shRNA control cells and SHIP-1 shRNA cells (Figure 5.5 A). In the shRNA control 
cells the majority appeared localised in peaks on the cell surface membrane i.e. in 
microvilli. In contrast, upon silencing of SHIP-1, ERM was broadly distributed within 
the cell. Upon stimulation with CXCL11 (10 nM, 2 minutes), both shRNA control and 
SHIP-1 shRNA cells polarised, and ERM was localised to the cell membrane. ERM 
showed some evidence of being localised to the leading edge and uropod. Flow 
cytometry verified that there was no change in the levels of total ERM protein present 
in SHIP-1 silenced cells (Figure 5.5 B). 
5.2.3 Expression of CD11a but not CD49d is reduced when SHIP-1 
expression is silenced 
Because many adhesion molecules are preferentially expressed upon the tips of 
microvilli, which are lost when SHIP-1 expression is silenced, the expression of two 
key 
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Figure 5.4 Quantification of ERM phosphorylation by flow cytometry reveals 
significant loss of phosphorylation upon silencing of SHIP-1. 
CD4+ T cells were cultured as described in Materials and Methods and infected with 
lentiviruses encoding shRNA as indicated. On day 9-10 cells were treated as 
previously, with a 1 hour preincubation of the Rac inhibitor NSC23766 at 100μM for 1 
hour, followed by a 2 minute application of 100nM CXCL11 for 2 minutes where 
indicated. Cells were fixed and stained for pERM and assessed by flow cytometry at 
1x105 cells/ point as described in the Materials and Methods. Results are from a 
single experiment. 
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A DAPI ERM Visible Overlay 
shRNA Control 
SHIP‐1 shRNA 
shRNA Control+ CXCL11 
SHIP‐1 shRNA 
SHIP‐1 shRNA+CXCL11 
10μm 
Figure 5.5 Levels of ERM protein are unaffected by silencing of SHIP-1 (figure 
continues on next page) 
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Figure 5.5 (cont’d) A. Confocal microscopy: CD4+ T cells were cultured for 10 days 
as described in the Materials and Methods.1x106 cells/point were left unstimulated or 
stimulated with CXCL11 10nM 2 minutes. Cells were fixed and stained with ERM 
antibody and DAPI and mounted on coverslips for confocal microscopy. B. CD4+ T 
cells were cultured as above, then fixed and stained for ERM. Cells were washed into 
FACS buffer and 1x105 cells/sample were assessed by flow cytometry for the 
presence of ERM. Results are from a single experiment +/- SD. 
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Figure 5.6 Expression of Adhesion molecules CD11a and CD49d. 
(figure continues on next page) 
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Figure 5.6 Expression of adhesion molecules CD11a and CD49d (cont’d) CD4+ T 
cells were cultured as described in Materials and Methods and infected with 
lentiviruses encoding shRNA as indicated. On day 9-10 cells were washed into 
serum free RPMI for 1 hour then stained for cell surface expression of CD11a and 
CD49d. Expression was analysed by flow cytometry of 1x105 viable cells/ point. 
Histograms are representative of three independent experiments and bar graphs are 
pooled data from three independent experiments, error bars are SEM, *p<0.05 
Student’s paired T Test. MFI- mean fluorescence index 
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adhesion molecules was assessed. CD11a is also known as LFA-1A, which, along 
with CD18 forms LFA-1 (αLβ2) (355). All cells stained positive for this adhesion 
molecule (Figure 5.6). However, it was noted that SHIP-1 shRNA cells expressed 
CD11a at lower levels than control or shRNA control cells (p<0.05). CD49d (α4, 
which along with CD29/β1 forms VLA-4 (356)), was expressed on an equivalent 
percentage of cells and at an equivalent levels, regardless of SHIP-1 silencing. 
5.2.4 Adhesion to fibronectin and ICAM is unaffected by silencing 
of SHIP-1 
With the reduction of expression of CD11a in mind, the ability of the cells to adhere to 
fibronectin or ICAM coated plates was investigated and found to be unaffected by 
silencing of SHIP-1. Fibronectin (357) is a dimer that can be present in the plasma or 
as part of the extracellular matrix and can be adhered to by many different integrins 
including VLA-4(α4β1) (358), whilst ICAM1 (CD54) is present on leukocytes and the 
endothelium and is bound by LFA-1 (αLβ2) (359). In fact there was a non-significant 
trend towards increased adhesion in the SHIP-1 silenced cells. Similarly, when cells 
on a fibronectin coated plate were exposed to CXCL11 or UCHT1, there was an 
increase in adherence of all cells, including SHIP-1 silenced cells (Figure 5.7). 
5.3 Basal motility but not chemotaxis, is reduced by silencing 
of SHIP-1 
Due to the observed morphological changes in SHIP-1 silenced cells, coupled with 
evidence from SHIP-1-/- neutrophils (which have a reduced basal motility), and SHIP­
1-/- murine T cells (which have a normal basal motility but increased chemotaxis 
towards CXCL12) (293, 360), it was thought likely that the SHIP-1 silenced T cells 
might exhibit altered motility. Therefore their basal motility and their ability to 
chemotax to the chemokine CXCL11 (ITAC) was assessed. 
5.3.1 CXCR3 expression is unaffected by silencing of SHIP-1 
First, the expression of CXCR3, the receptor for CXCL11, was assessed by flow 
cytometry and it was found that expression was unaltered by either shRNA control or 
SHIP-1 silencing in the case of CD4+ T cells. However in CD8+ T cells CXCR3 
expression showed evidence of being reduced by silencing of SHIP-1 (Figure 5.8). 
Therefore, further efforts proceeded using CD4+ T cells. 
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Figure 5.7 Adhesion of cells is not adversely affected by silencing of SHIP-1 
CD4+ T cells were cultured as described in Materials and Methods and infected with 
lentiviruses encoding shRNA as indicated. On day 9-10 cells were labelled with 
CFSE and their ability of cells to adhere to ICAM or fibronectin coated 96-well plates 
was assessed by analysis on a plate reader as described in the Materials and 
Methods. CXCL11 at 10nM or UCHT1 at 10μg/ml was applied for 15 minutes as 
indicated (n=3 +/- SEM). 
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Figure 5.8 Expression of CXCR3 is unaffected by SHIP-1 silencing in CD4+ T 
cells, but is reduced in CD8+ T cells. 
CD4+ or CD8+ T cells were cultured as described in Materials and Methods and 
infected with lentiviruses encoding shRNA as indicated. On day 9-10 cells were then 
examined by flow cytometry at 1x105 viable cells/ point to determine the cell surface 
expression of CXCR3, the receptor for CXCL11. A. Typical flow cytometry plots for 
CD4+ T cells. B. CD4+ T cells: bar graph is pooled data from three independent 
experiments, error bars are SEM. C. Typical flow cytometry plots for CD8+ T cells. 
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5.3.2 Basal motility in a neuroprobe chamber is reduced by 
silencing of SHIP-1 
The first assay to assess basal motility and chemotaxis utilised a Neuroprobe 
chemotaxis chamber. In this assay varying concentrations of chemokine were placed 
in the bottom wells of a 96 well plate, and a filter with 5μm pores was placed on top. 
CD4+ T cells in suspension were pipetted onto the filter and allowed to migrate 
through the pores to the chemokine. The number of cells which migrated in a 
Neuroprobe chemotaxis plate in the absence of chemokine was significantly reduced 
by silencing of SHIP-1 (p<0.05).  This reduction in basal motility reduced the number 
of cells that chemotaxed to CXCL11 at all concentrations (0.3-30 nM), although the 
chemotactic index (the number of cells that migrated to chemokine divided by the 
number that migrated basally) was unaffected (Figure 5.9). 
5.3.3 Basal motility on a fibronectin coated slide is reduced by 
silencing of SHIP-1 
Reduced motility can be due to a number of factors. For example the cells may be 
immobile, or they may fail to commit to migrating in a particular direction, effectively 
moving in circles, or they may form pseudopods but fail to commit to the most 
promising one (287, 288). Therefore in order to investigate the findings from the 
Neuroprobe assay in more detail, an Ibidi chemotaxis slide was used, on which the 
cells could be recorded and their individual paths tracked and analysed as discussed 
in Materials and Methods. It was found that the basal motility of the cells was also 
reduced on a fibronectin coated Ibidi chemotaxis slide, with a reduction in 
accumulated distance travelled (total path length), Euclidean distance travelled 
(straight line distance from start to end point), and average velocity in the absence of 
chemokine. However, only a difference in Euclidean distance travelled was observed 
during chemotaxis towards CXCL11 (100 nM) (Figure 5.10, Figure 5.11). When the 
data were expressed as a chemotatic index the findings mirrored those using the 
Neuroprobe chemotaxis assay, with the Euclidean Index being unaffected by 
silencing of SHIP-1 (Figure 5.11). However, the indices for the accumulated distance 
and velocity were increased by silencing of SHIP-1. A higher concentration of 
chemokine was used in this experiment compared to the previous experiment as the 
final concentration reaching the cells is less than a third of that used. 
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Figure 5.9 Basal motility is reduced by silencing of SHIP-1 expression but 
chemotaxis is unaffected. 
CD4+ T cells were cultured as described in Materials and Methods and infected with 
lentiviruses encoding shRNA as indicated. On day nine the chemotactic ability of the 
cells was assessed in a neuroprobe chemotaxis chamber for 3 hours at 37˚C as 
described in the Materials and Methods A. Results from a single experiment typical of 
three independent experiments. i. Percentage cells migrated ii. Chemotactic index 
normalised to basal level for each shRNA. B. Pooled data from four independent 
experiments +/- SEM *p<0.05 Student’s T Test. 
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shRNA control SHIP‐1 shRNA 
Basal 
CXCL11 
(100 nM) 
Figure 5.10 Chemotaxis on fibronectin coated surface is reduced by SHIP-1 
silencing CD4+ T cells were cultured as described in Materials and Methods and 
infected with lentiviruses encoding shRNA as indicated. The chemotactic ability of the 
cells was assessed after nine days of culture using a fibronectin coated Ibidi 
chemotaxis slide for 15 minutes at 37˚C as described in the Materials and Methods. 
20 individual cell tracks were analysed from a single experiment typical of three 
independent experiments, using imageJ. Where CXCL11 was used, the source is 
indicated by a green bar and black tracks are from cells that have migrated towards 
it, red tracks indicate cells that have migrated away.  
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Figure 5.11 Chemotaxis on fibronectin coated surface is reduced by SHIP-1 
silencing II CD4+ T cells were cultured as described in Materials and Methods and 
infected with lentiviruses encoding shRNA as indicated. The chemotactic ability of the 
cells was assessed after nine days of culture using a fibronectin coated Ibidi 
chemotaxis slide for 15 minutes at 37˚C as described in the Materials and Methods. 
Data was analysed using ImageJ and is pooled from three independent experiments. 
*p<0.05 **p<0.01 
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5.4 Summary 
•	 CD4+ T cells in which SHIP-1 has been silenced have an aberrant 
morphology with a loss of microvilli which could not be restored by PI3K 
inhibition 
•	 SHIP-1 silenced cells also lack phosphorylated ERM 
•	 ERM phosphorylation could be partially restored in SHIP-1 silenced cells 
using a Rac1 inhibitor (Figure 5.12) 
•	 Expression of CD11a, but not CD49d, was slightly reduced by silencing of 
SHIP 
•	 The ability to adhere to ICAM or fibronectin was not affected by silencing of 
SHIP 
•	 CXCR3 expression was unaffected in CD4+ T cells but was reduced in CD8+ 
T cells when SHIP-1 expression was silenced 
•	 In two different assays, basal motility of CD4+ T cells was reduced, but 
chemotaxis was unaffected when expression of SHIP-1 was silenced. 
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Figure 5.12: Summary of effects of SHIP-1 silencing on microvilli loss 
Silencing of SHIP-1 leads to increased PI3K signalling which in turn can lead to 
increased Rac1 activation and ERM dephosphorylation, culminating in microvilli 
collapse. However the microvilli loss is insensitive to PI3K inhibition and is only 
partially ameliorated by Rac1 inhibition. This suggests that SHIP-1 negatively 
regulates microvilli collapse through its scaffolding functions, independently of its 
phosphatase activity. This theory will be examined fully in the Discussion. 
140 
Chapter 6: Results Section IV 

Chapter 6: Results Section IV 

Localisation of PH domain probes and 
phosphorylated SHIP-1 during chemotaxis 
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6.1 Background and objectives 
It has been previously reported that PI3K signalling localises to the leading edge of 
the cell and that lipid phosphatases are required to maintain this polarisation and to 
aid prioritisation of chemotactic cues by aiding commitment to the most promising 
emerging pseudopod (287). The TAPP PH domain has specificity for PI(3,4)P2 whilst 
the Akt PH domain can be recruited to both PI(3,4)P2 and PI(3,4,5)P3. It has 
previously been demonstrated that when either domain is conjugated to a fluorescent 
reporter, their localisation can be tracked (293). In cell lines they have been shown to 
be recruited to the cell membrane upon receptor stimulation. Furthermore the Akt PH 
domain has been shown to localise to the leading edge of chemotaxing neutrophils. 
The results in the previous chapter demonstrated that loss of SHIP-1 results in a 
decreased basal motility of primary human T cells. Therefore the aim of this chapter 
was to investigate the role of SHIP-1 in primary T cell chemotaxis in more detail by 
examining the localisation of fluorescently-tagged PH domains and phosphorylated 
SHIP-1 in T cells during chemotaxis. 
6.2 Localisation of TAPP PH domain probes 
6.2.1 TAPP PH weakly localises to pseudopods in motile primary T 
cells 
To investigate the localisation of PI(3,4)P2 in primary human CD4+ T cells, the GFP 
TAPP PH reporter was electroporated into cells. The TAPP PH domain is specific for 
PI(3,4)P2 and therefore its localisation can be taken as a marker of SHIP-1 activity 
(251, 361). Transfection rates were modest (Section 4.2), and expression was 
weaker than with lentivirus (see Chapter 4), but cells appeared viable and healthy. 
However, only weak localisation of the probe to the leading edge was seen when the 
cells were basally motile on a fibronectin coated slide (Figure 6.1), or chemotaxing 
towards CXCL11 (Figure 6.2). The probe appeared to be located in pseudopods and 
at the leading edge but did not appear to have definitive membrane localisation. 
Similarly, a range of other stimuli including bpVphen and CD3/CD28 beads failed to 
induce definitive membrane localisation of the probe (Figure 6.3), despite the fact 
that both of these conditions were demonstrated in Chapter 3 to induce 
phosphorylation of SHIP-1. To test for defects in the probe an RFP-TAPP PH probe 
was also used. This probe was very weakly expressed and demonstrated a largely 
uniform cellular distribution, both in resting cells and upon stimulation with H2O2 
(Figure 6.4). 
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Figure 6.1 TAPP PH-GFP localisation in T cells during basal motility on 
fibronectin-coated slide 
CD4+ T cells were electroporated with TAPP-PH-GFP as described in Materials and 
Methods and on day 2 post isolation were resuspended in chemotaxis media and 
placed in a fibronectin coated Ibidi chemotaxis slide. Cells were allowed to settle for 
15 minutes, after which motile cells were recorded using video microscopy on an 
LSM510 Meta confocal microscope at 37°C. Images are of a single cell 
representative of cells recorded in two independent experiments. 
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Figure 6.2 TAPP PH-GFP localisation in T cells during chemotaxis to CXCL11 
CD4+ T cells were electroporated with TAPP-PH-GFP as described in Materials and 
Methods and on day 2 post isolation were resuspended in chemotaxis media and 
placed in a fibronectin coated Ibidi chemotaxis slide loaded with 100 nM CXCL11 in 
the top chamber as described in Materials and Methods. Cells were allowed to settle 
for 15 minutes, after which motile cells were recorded using video microscopy on an 
LSM510 Meta confocal microscope at 37°C. Images are of a single cell 
representative of cells recorded in two independent experiments. 
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Figure 6.3 TAPP PH-GFP localisation in T cells 
CD4+ T cells were electroporated with TAPP-PH-GFP as described in Materials and 
Methods and on day 2 post isolation were resuspended in chemotaxis media and 
placed in a chambered coverslip and allowed to settle for 15 minutes before 
stimulation was applied as indicated. Cells were recorded using video microscopy on 
an LSM510 Meta confocal microscope at 37°C. Images are representative of cells 
recorded in two independent experiments. 
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Figure 6.4 TAPP PH-RFP localisation in T cells 
CD4+ T cells were electroporated with TAPP-PH-RFP as described in Materials and 
Methods and on day 2 post isolation were resuspended in chemotaxis media and 
placed in a chambered coverslip and allowed to settle for 15 minutes before 
stimulation was applied as indicated. Cells were recorded using video microscopy on 
an LSM510 Meta confocal microscope at 37°C. Images are representative of cells 
recorded in two independent experiments. 
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There was a barely discernable localisation of the probe to pseudopods in the 
presence of 10nM CXCL11 (Figure 6.4). 
6.2.2 Mutant TAPP PH is diffusely distributed in primary human T 
cells 
In the next set of experiments a mutant TAPP PH probe was used, which due to a 
R212L mutation, is unable to bind PI(3,4)P2 (244). This was clearly excluded from the 
nucleus, unlike the wildtype probe, but did not localise to the membrane upon 
stimulation with H2O2, CD3/CD28 beads or CXCL11 (10nM). Treatment with 
LY294002 (20μM) for 1 hour did not alter distribution, with the probe remaining 
excluded from the nucleus (Figure 6.5). 
6.2.3 Akt PH localises to the membrane in primary T cells 
Next, cells were transfected with a GFP tagged Akt-PH protein.  The PH domain of 
Akt is reported to have affinity for both PI(3,4,5)P3 and PI(3,4)P2 (362) and it’s 
localisation is therefore indicative of PI3K irrespective of SHIP-1 activity. This was 
diffuse in resting cells but localised to the membrane in cells adhered to fibronectin, 
motile cells stimulated with 10nM CXCL11, or those stimulated with CD3/CD28 
beads (Figure 6.6) indicating the activity of PI3K at the cell membrane under these 
conditions. In contrast a mutant Akt PH (R25C) domain remained diffuse upon 
stimulation (Figure 6.7). 
6.3 Phosphorylated SHIP-1 is diffusely distributed in motile T 
cells 
As the experiments with TAPP PH domain probes had failed to show strong 
enrichment of the probe to the cell surface membrane, it was next investigated 
whether phosphorylated SHIP-1 could be identified at the membrane in motile cells. 
Control CD4+ T cells were left unstimulated or stimulated with CXCL11 (10nM, 2 
minutes), fixed, stained for pY1020SHIP-1 and DAPI and visualised by confocal 
microscopy. Similar to the results seen with CEMs in the first results section, in 
unstimulated cells there was very little phosphorylated SHIP-1 present. Upon 
chemokine stimulation the cells polarised and there was an increase in the amount of 
phosphorylated SHIP-1. However, it showed a similar distribution to the TAPP PH 
domain probes, i.e. it did not strongly localise to the cell surface membrane, although 
some weak localisation to emerging pseudopods could be seen (Figure 6.8). 
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CXCL11 10 nM 5’ Fibronectin coated coverslip LY294002 20 μM 1 hour preincubation 
Figure 6.5 Mutant TAPP PH-RFP localisation in T cells 
CD4+ T cells were electroporated with TAPP-PHR212L-RFP as described in Materials 
and Methods and on day 2 post isolation were resuspended in chemotaxis media 
and placed in a chambered coverslip and allowed to settle for 15 minutes before 
stimulation was applied as indicated. Cells were recorded using video microscopy on 
an LSM510 Meta confocal microscope at 37°C Images are representative of cells 
recorded in two independent experiments. 
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Figure 6.6 GFP Akt PH domain localises to membrane upon stimulation of 
CD4+ T cells. 
CD4+ T cells were electroporated with Akt-PH-GFP as described in Materials and 
Methods and on day 2 post isolation were resuspended in chemotaxis media and 
placed in a chambered coverslip and allowed to settle for 15 minutes before 
stimulation was applied as indicated A. At rest in chambered coverslip B. CD3/CD28 
bead 5 minutes C. On fibronectin coated coverslip D. 10nM CXCL11 on fibronectin 
coated coverslip 5 minutes. Cells were recorded using video microscopy on an 
LSM510 Meta confocal microscope at 37°C. Images are representative of cells 
recorded in two independent experiments. 
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Figure 6.7: Mutant GFP Akt-PH domain remains diffuse 
CD4+ T cells were electroporated with Akt-PHR25C-GFP as described in Materials and 
Methods and on day 2 post isolation were resuspended in chemotaxis media and 
placed in a chambered coverslip and allowed to settle for 15 minutes before 
stimulation was applied as indicated. Cells were recorded using video microscopy on 
an LSM510 Meta confocal microscope at 37°C. Images are representative of cells 
recorded in two independent experiments. 
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Figure 6.8 Phosphorylated SHIP-1 is present in motile cells but is broadly 
distributed 
CD4+ T cells were isolated and cultured as described in the Materials and Methods. 
On day 10 post isolation 1x106 cells/ point were left unstimulated or stimulated with 
CXCL11 for 2 minutes. Cells were then fixed and stained for pY1020 SHIP-1 and DAPI 
and mounted on coverslips and imaged by confocal microscopy as described in the 
Methods. Results are from a single experiment. 
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6.4 Summary 
•	 The TAPP PH domain was weakly recruited to the leading edge and 
emerging pseudopods on motile CD4+ T cells 
•	 A mutant TAPP PH domain failed to localise to specific areas of the cells, but 
was excluded from the nucleus 
•	 The Akt PH domain was weakly recruited to the leading edge of motile CD4+ 
T cells and was also recruited to the membrane upon stimulation 
•	 A mutant Akt PH domain failed to localise to specific areas of the cells 
•	 Phosphorylated SHIP-1 is diffusely distributed in the motile cell 
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7.1 Background and Objectives 
Knockout of SHIP-1 in mice leads to changes in T cell development and function. In 
the whole animal knockout there is an increase in Tregs (185) and the cells are 
biased towards a Th2 phenotype that drives lung inflammation (184). In vitro, T cells 
from these animals are prone towards skewing towards Tregs at the expense of 
Th17 development (186). In contrast, when SHIP-1 is deleted only from T cells, a 
change in the levels of Tregs or Th17 was not observed. However, cells were more 
susceptible to skewing of Th1 at the expense of Th2 (183). In addition, the CD8+ T 
cells from these animals had an increased cytotoxic capacity (183). 
Given the contradictions between these two models, it is not clear what the role of 
SHIP-1 might be in mature human T cells. Therefore, the aims of this results section 
were to investigate the ability of T cells to skew to Th1, Th2, Th17 and Treg 
phenotypes and also to investigate the cytotoxic actions of CD8+ T cells when SHIP­
1 expression is silenced. 
7.2 Ability to skew to Th1, Th2, Th17 and Treg phenotypes is 
altered by SHIP-1 silencing 
7.2.1 Skewing requires isolation of naïve CD4+ T cells 
Previous experiments had been performed using pan CD4+ T cell isolation. Upon 
flow cytometry of these freshly isolated cells, a subpopulation was found to express 
CD25, a marker for Tregs and activated cells (37) (Figure 7.1 A,B). In addition, it 
would be expected that some Th1, Th2 and Th17 would also be found in the pan 
CD4+ T cell population. Therefore, in order to start out with unbiased population, a 
naïve CD4+ T cell isolation kit was used to isolate cells for the following experiments. 
Naïve CD4+ T cells were found to be infected with lentivirus encoding for GFP at 
equal or greater percentage than pan CD4+ T cells, when infected cells were 
analysed for GFP expression by flow cytometry (Figure 7.1 ) 
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Figure 7.1 Expression of CD25 by freshly isolated pan CD4+ and infection of 
naïve CD4+ with GFP. Pan human CD4+ T cells were isolated by magnetic 
separation as described in Materials and Methods. A. Two distinct populations were 
gated by flow cytometry based on FSC (cell size) and SSC (granularity). B. The 
populations identified in part A were stained for either CD4 or CD25 expression as 
described in the Materials and Methods i. P1 (red) ii P3 (green). 1 x 105 viable cells 
were acquired for each point. C. Naïve or pan CD4+ T Cells were isolated by 
magnetic separation and infected with GFP encoding lentivirus after 24 hours of 
activation. Three days post infection GFP expression was assessed by flow 
cytometry of 1 x 105 viable cells. 
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7.2.3 Th1 skewing is unaffected by silencing of SHIP-1 
Using a combination of cytokines and neutralising antibodies as described in the 
Materials and Methods, shRNA control cells were successfully polarised under Th1 
conditions to release the signature Th1 cytokine IFNγ, but SHIP-1 silenced cells 
failed to release increased IFNγ. However, this result was not statistically significant, 
due to the variation in amount of IFNγ released by shRNA control cells between 
different donors (Figure 7.2). Moreover, intracellular staining for IFNγ showed that an 
equivalent percentage cells still stained positive for IFNγ under Th1 conditions when 
SHIP-1 expression was silenced (Figure 7.3).   
Levels of other secreted Th1 cytokines were also measured. IL-12p70, which was 
increased in Th1 conditions by both shRNA control and SHIP-1 silenced cells, with 
silencing of SHIP-1 have no effect on its production. The production of IL-1β was 
increased under skewing Th1 conditions by both shRNA control cells and SHIP-1 
silenced cells, however there was a non-significant trend under Th0, Th1 and Th2 
conditions for less IL-1β to be produced by SHIP-1 silenced cells. IL-8 (CXCL8) and 
TNFα may both be considered as Th1 cytokines (363) and followed the same trends 
as IFNγ with shRNA control cells successfully polarised under Th1 conditions to 
produce increased levels of IL-8 and TNFα, but SHIP-1 silenced cells failed to 
increase production of these cytokine under Th1 conditions (although this was 
statistically non-significant). IL-2 has been characterised as a Th1 cytokine (8) but is 
also key for proliferation of all T cells and for the development and maintenance of 
Tregs (364). IL-2 production was higher under Th0 and Th1 conditions than it was 
under Th2 conditions, however levels varied considerably between donors and no 
firm conclusions could be drawn about the effect of SHIP-1 silencing on IL-2 
production. 
7.2.4 Th2 skewing is altered by silencing of SHIP-1 
The levels of four secreted Th2 cytokines were analysed, including the signature 
cytokine IL-4. Using a combination of cytokines and neutralising antibodies as 
described in the Materials and Methods, shRNA control T cells were successfully 
polarised under Th2 conditions to release the signature Th2 cytokine IL-4. Levels of 
secreted IL-4 were increased approximately four fold by Th2-skewed shRNA control 
cells vs Th0 shRNA control cells (Figure 7.4). Silencing of SHIP-1 expression 
resulted in a dramatic increase in levels of secreted IL-4 production under Th2 
conditions (a further five-fold 
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Figure 7.2 Expression of Th1 cytokines is altered by silencing of SHIP-1 
Naïve CD4+ T cells were infected with shRNA encoding lentiviruses and cultured in 
Th0, Th1 or Th2 conditions as described in Materials and Methods for 8 days. Cells 
were then washed three times and resuspended in complete media with CD3/CD28 
beads in a 1:1 ratio for 16 hrs at 1x 106/ml after which supernatant was collected and 
cytokines were analysed using a mesoscale 10 plex plate following the 
manufacturer’s instructions. Data is pooled from at least 4 independent experiments. 
Error bars are SEM. For clarity, only shRNA and SHIP-1 shRNA results are shown. 
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Figure 7.3 Staining of IFNγ and IL-4 in T cells shows increased skewing to Th2 
upon silencing of SHIP-1 
Naive CD4+ T cells were infected with shRNA encoding lentiviruses and cultured 
under Th1 or Th2 conditions as described in Materials and Methods for 9 days. Cells 
were then washed into complete media and incubated on CD3/CD28 beads for 6 hrs 
in the presence of Golgistop. Cells were then fixed and stained for the appropriate 
cytokine and expression assessed by flow cytometry of 1x105 cells/ point. Plots are 
representative of three separate experiments. 
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Figure 7.4 Expression of Th2 cytokines is altered by silencing of SHIP-1 
Naïve CD4+ T cells were infected with shRNA encoding lentiviruses and cultured in 
Th0, Th1 or Th2 conditions as described in Materials and Methods for 8 days. Cells 
were then washed three times and resuspended in complete media with CD3/CD28 
beads in a 1:1 ratio for 16 hrs at 1x 106/ml after which supernatant was collected and 
cytokines were analysed using a mesoscale 10 plex plate following the 
manufacturer’s instructions. Data is pooled from at least 4 independent experiments. 
Error bars are SEM. For clarity, only shRNA and SHIP-1 shRNA results are shown.* 
p<0.05 Student’s paired T Test with Holmes correction. 
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increase p<0.05. Upon use of a Holmes correction to take into account the three 
paired T-tests performed the probabilities of the observed difference in IL-4 
production remained less than 0.05). Upon intracellular staining for IL-4 there was an 
increase in the percentage of SHIP-1 silenced cells staining IL-4 positive under Th2 
conditions (15% vs. 9% of shRNA control cells under Th2 conditions) (Figure 7.3).  In 
contrast, whilst there was a large increase in production of both IL-5 and IL-13 by 
shRNA control cells under Th2 conditions (5 and 15 fold respectively vs. production 
under Th0 conditions), SHIP-1 silenced cells failed increase production by the same 
amount (3 and 5 fold respectively vs. Th0 conditions p= n.s.). IL-10 is produced by 
Th2s and suppresses the production of Th1 cytokines, however it is also produced by 
some Tregs (365). Levels of secreted IL-10 were not affected by silencing of SHIP-1. 
7.2.5 Th17 skewing is facilitated by silencing of SHIP-1 
Naïve CD4+ were isolated from PBMCs and cultured under Th0 or Th17 conditions 
or Th17 conditions with the addition of IL-23 as described in the Materials and 
Methods. Levels of secreted IL-17 were assessed by dot blot. Some IL-17 was 
present in the supernatant from Th0 cells, possibly indicating the presence of Th17 
cells which had been generated by the donor, or that had spontaneously skewed. 
Culture of cells under Th17 skewing conditions caused an increase in production of 
IL-17A but culturing with IL-23 did not cause a further increase in production (Figure 
7.5). However, for the following experiments IL-23 was include in the skewing media 
as there was some evidence in the literature that it might aid the maintenance of a 
Th17 phenotype (32). In the next experiment, control, shRNA control or SHIP-1 
silenced cells were cultured under Th0 or Th17 conditions and levels of secreted IL­
17 were assessed by dot blot. Exposure to control shRNA further increased IL-17A 
production under Th17 skewing conditions, possibly due to additional cytokines 
derived from the HEK supernatant. A further increase in production was caused by 
silencing of SHIP-1 expression (Figure 7.6). When these results were quantified by 
ELISA, the same results were seen, although they did not achieve statistical 
significance. Concomitant with this an increase in IL-17A positive cells was detected 
when SHIP-1 expression was silenced under Th17 conditions (shRNA control cells 
22% positive, SHIP-1 silenced cell 34% positive for IL-17A). 
7.2.6 STAT3 phosphorylation is not affected by silencing of SHIP-1 
STAT3 is a key transcription factor, required for the generation of Th17s and the 
production of IL-17, and requires phosphorylation in order to be active (366). IL-6 
signalling can lead to phosphorylation of STAT3, in naïve T cells and sometimes in 
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Th0  Th17   Th17+IL-23 

Short exposure 

Longer exposure 

Figure 7.5 IL-17 expressing cells can be generated from naïve human CD4+ T 
cells 
Primary human T cells were skewed in vitro to produce IL-17. Naïve CD4+ T cells 
were isolated from PBMCs as described in the Methods and cultured with CD3/C28 
beads under Th0 conditions (IL-2), Th17 conditions (IL-1β, IL-6, anti IFNγ, anti-IL-4) 
or in Th17 conditions plus IL-23, for five days. Then the culture volume was doubled 
and cells were cultured for a further nine days in the presence of IL-2. After this time 
cells were counted and each culture was determined to have equal numbers of cells 
at 1x 106/ml. 5 μL of supernatant was spotted onto nitrocellulose membrane and 
blotted for IL-17.  
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Figure 7.6 Th17 skewing is increased by silencing of SHIP-1 
Naive CD4+ lymphocytes were infected with lentivirus to deliver shRNA and cultured 
under appropriate skewing conditions as described in Materials and Methods for 8 
days. Cells were then washed three times and resuspended in complete RPMI with 
CD3/CD28 beads (1:1 ratio bead:cell) for 16 hrs at 1x 106/ml. Following this 
supernatant was collected and levels of IL-17A were assessed by dot blot or ELISA, 
following the manufacturer’s protocol. A. Dot blot is representative of three 
independent experiments B. ELISA data is pooled from three independent 
experiments, error bars are SEM. C. For intracellular staining, cells were restimulated 
as above, but for 6 hours only, in the presence of Golgistop. Cells were then fixed 
and stained with anti-IL-17A and analysed using flow cytometry of 1x 105 cells/ point, 
plots are representative of three independent experiments. 
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activated T cells (366). Control, shRNA control or SHIP-1 silenced CD4+ T cells were 
cultured under Th0 or Th17 conditions and then STAT3 phosphorylation was 
assessed in fixed cells by flow cytometry. STAT3 phosphorylation was low in all Th0 
cells (Figure 7.7). However, an increase was observed in cells exposed to control 
shRNA compared to uninfected cells. No further increase was detected when SHIP-1 
expression was silenced. Furthermore, application of IL-6 did not affect levels of 
STAT3 phosphorylation in either control shRNA control or SHIP-1 silenced cells as 
assessed by flow cytometry. 
7.2.7 Silencing of SHIP-1 leads to an increase in the percentage of 
Tregs 
Naïve CD4+ T cells were isolate from PBMCs, infected with shRNA control or SHIP-1 
shRNA encoding lentiviruses and cultured under Th0 conditions as described in the 
Materials and Methods. After nine days cells were assessed for surface expression 
of CD25, a marker of Tregs and activated T cells (37), by flow cytometry. Expression 
of CD25 was detected upon approximately 60% of control cells, compared to ~75% 
of shRNA control cells (Figure 7.8). Approximately 80% SHIP-1 shRNA treated cells 
were positive for CD25 but this increase was not statistically significant compared to 
shRNA controls. However, SHIP-1 shRNA cells had expressed higher levels of CD25 
per cell (p<0.05), as indicated by the increase in mean fluorescence and 
demonstrated in the histograms. 
Further to this, triple staining for CD4, CD25 and foxp3 (the key transcription factor 
for Treg development (367)) was used to identify Treg populations. In line with 
previous results (185, 186), it was seen that there was an increase in CD25high foxp3+ 
cells upon infection with SHIP-1 shRNA from approximately 5% of control and 
shRNA control cells to 15% of SHIP-1 silenced cells (p<0.05). Infection with control 
shRNA did not affect the percentage of cells that were foxp3 positive compared to 
uninfected controls. 
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Figure 7.7 STAT3 phosphorylation is not increased by silencing of SHIP-1. 
Naive CD4+ lymphocytes were infected with lentivirus to deliver shRNA as indicated 
and cultured as described in Materials and Methods for 8 days under Th0 conditions. 
Cells were then removed from CD3/CD28 beads, rested for 1 hr and stimulated with 
IL-6 (100ng/ml 1 min) as indicated, then fixed and stained for STAT3 
phosphorylation, which was assessed by flow cytometry of 1x105 cells/ point. 
Representative histograms are shown, along with pooled data from three 
independent experiments, error bars are SEM 
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Figure 7.8 CD25 and foxp3 expression are increased when SHIP-1 expression is 
silenced Naive CD4+ T lymphocytes were infected with lentivirus to deliver shRNA as 
indicated and cultured under appropriate Th0 conditions as described in Materials and 
Methods for 9-10 days. A. Cells were then washed and stained for extracellular expression of 
CD25 and assessed by flow cytometry of 1x105 cells/ sample Histograms are representative 
of three independent experiments B. Bar graphs are pooled data from three independent 
experiments, completed as in part A, error bars are SEM. * p<0.05, Student’s paired T Test. 
C. Cells were cultured for 9-10 days as described in Materials and Methods and infected with 
lentivirus as indicated. Cells were then washed and stained for extra cellular expression of 
CD25 and CD4 then permeabilised and stained for foxp3 and assessed by flow cytometry of 
1x105 cells/ sample Histograms are representative of three independent experiments D. Bar 
graphs are pooled data from three independent experiments performed as in part C, error 
bars are SEM. * p<0.05, Student’s paired T Test. 
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7.3 CD8+ T cell cytotoxicity is not potentiated by silencing of 
SHIP-1 
7.3.1 Establishment of a model system to evaluate human CD8+ T 
cell cytotoxicity 
It had been reported in the literature that loss of SHIP-1 caused murine CD8+ T cells 
to have an increase in their cytotoxicity (181). Using murine T cells it is standard 
practice to investigate cytotoxicity using transgenic T cells that are specific for OVA 
and to target their killing towards OVA expressing cells. Clearly this was not possible 
using human T cells. Therefore a modified protocol was devised based upon 
protocols from Grant et al. and Sloan et al. (368, 369). In this experiment A20 murine 
B cell lymphoma cells were labelled with CFSE to enable them to be distinguished 
from T cells using flow cytometry. UCHT1 (an antibody which is raised in mice) was 
used to stimulate the TCR on the CD8+ T cells and the invariant chain of the 
antibody was bound by Fc receptor on the A20 cells in order to direct the killing of the 
CD8+ towards the target cells (as illustrated in the Materials and Methods). Cells 
were incubated for three hours and then stained with cy-5 conjugated annexin V and 
assessed by flow cytometry. It can be seen that target cells on their own have a 
proportion that are apoptotic. Upon coculture for three hours with either UCHT1 or 
CD8+ T cells, the percentage of viable cells is not affected. However upon addition of 
both UCHT1 and CD8+  T cells to the target cells, the percentage staining positive 
for annexin is increased (from 31% to 83% at effector to target 5:1 ratio) (Figure 7.9 
A). A lower ratio of effector:target 1:2 was used for subsequent experiments in order 
that an increase in efficiency of killing could be detected. Cytotoxicity was not 
affected by pretreatment (followed by washing before addition to the assay) of 
effector cells with wortmannin in line with other reports that PI3K is not required for 
cytotoxicity of CD8+ T cells (370) (wortmannin was used as it is irreversible and 
would therefore be expected to still inhibit PI3K activity during the cytotoxicity assay, 
although it had been washed from the media) (Figure 7.9 B). In addition 
preincubation with the PI3K inhibitors LY294002 and ZSTK474 did not affect 
cytotoxicity. 
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7.3.2 Silencing of SHIP-1 does not increase CD8+ T cell 
cytotoxicity 
The assay was then repeated using shRNA control CD8+ T cells and SHIP-1 
silenced CD8+ T cells at a 1:2 effector to target ratio. It was found that upon addition 
of UCHT1, SHIP-1 shRNA CD8+ T cells did not kill a higher percentage of A20 cells 
than the shRNA control cells, and in fact the percentage of target cells killed by the 
CD8+ T cells dropped from 24 to 9% upon silencing of SHIP-1. It was also noted that 
this assay resulted in a higher percentage of the SHIP-1 shRNA CD8+ staining 
positive for annexin (Figure 7.9 C). 24% of the SHIP-1 silenced cells became annexin 
positive in the presence of A20 plus UCHT1, compared to 10% of shRNA controls. 
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Figure 7.9 Cytotoxicity of CD8+ T cells is not increased by SHIP-1 silencing 
CD8+ lymphocytes were infected with lentivirus to deliver shRNA as indicated and 
cultured as described in Materials and Methods for 9-10 days. Cells were then set up 
in a cytotoxicity assay as described in the Materials and Methods. A20 cells were 
labelled with CFSE to distinguish them by flow cytometry. A20 and CD8+ T cells 
were cultured together as indicated with or without UCHT1. Cells were then washed 
into annexin staining buffer, labelled with cy-5 conjugated annexin and 1x105 total 
cells acquired per point by flow cytometry A.UCHT1 directs CD8+ T cells to kill target 
A20 cells i. CFSE labelled target cells ii CFSE labelled target cells plus UCHT1 iii 
Effector CD8+ plus CFSE labelled target cells (5:1 ratio). iv. Effector CD8+ plus 
CFSE labelled target cells plus UCHT1 (4:1 ratio). B. PI3K inhibitors do not affect 
CD8+ cytotoxicity. Cells were prepared as above, except CD8+ T cells were 
preincubated with PI3K inhibitors (wortmannin 100nM, LY294002 20μM, ZSTK474 
1μM) for 1 hour before being cocultured with A20 cells at E:T ratio of 1:2. n=3 +/- 
SEM. C. Cytotoxicity of CD8+ T cells is not increase by SHIP-1 silencing i. shRNA 
control effector cells plus CFSE labelled target cells (1:2 ratio) ii. shRNA control 
effector cells plus CFSE labelled target cells plus UCHT1 (1:2 ratio)  iii. SHIP-1 
shRNA effector cells plus CFSE labelled target cells(1:2 ratio)  iv. SHIP-1 shRNA 
effector cells plus CFSE labelled target cells plus UCHT1(1:2 ratio). Results are from 
a single experiment. 
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7.4 Summary 
•	 Th1 skewing and Th1 cytokine production were unaffected by silencing of 

SHIP-1

•	 IL-4 production under Th2 conditions was increased but that of IL-5 and IL-13

was decreased upon silencing of SHIP-1

•	 The percentage of cells staining positive for IL-4 increased upon silencing of

SHIP-1

•	 The proportion of naïve cells differentiating into Tregs under Th0 conditions 

increased upon silencing of SHIP-1 

•	 Th17 skewing and IL-17 A production was increased upon silencing of SHIP­

1 

•	 CD8+ cytotoxicity was reduced when SHIP-1 expression was silenced, and 
the cells had an increased tendency to die during cytotoxic targeting of A20 
cells 
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Chapter 8: Results section VI 

The role of PI3Kγ in murine IL-17 production 
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8.1 Background and Objectives 
IL-17A and IL-17F are produced by CD4 + T cells (Th17 cells), γδ T cells (371), 
CD8+ T cells (57, 372), natural killer T cells, macrophages and neutrophils (31, 371). 
IL-17 is produced in response to IL-23 by γδ, CD4+ and CD8+ T cells (373, 374) and 
can also be produced in an innate immune response, for example in response to 
complement C5a signalling (375), or toll-like receptor engagement (374). 
IL-17A drives a tissue based immune response to combat extracellular pathogens 
such as bacteria and fungi via the production of IL-6, IL-8, GM-CSF, MMPs and 
chemokines including CXCL1 and CXCL10 (31) to orchestrate the recruitment of 
macrophages and neutrophils to tissues (33). IL-17F has about 50% homology to IL­
17A with similar functions (31, 36, 39). IL-17A and IL-17F have been implicated in 
airway inflammation (36, 40, 41) as well as diseases including multiple sclerosis, 
psoriasis, inflammatory bowel disease (IBD), rheumatoid arthritis and systemic lupus 
erythromatosis (SLE) (36, 42). It has been suggested that IL-17A and IL-17F may 
have different functions in vivo, for example IL-17A may play a larger role in arthritis 
and EAE models, whilst IL-17F may be more important in IBD (376, 377). IL-17 
receptors have been shown to play critical roles in autoimmune diseases, for 
example, IL-17RA-/- deletion in mice prevented progression to chronic destructive 
synovitis in a model of arthritis (378). Furthermore, IL-17A and IL-17F are thought to 
have both pro- and anti- tumour functions, with IL-17F in particular exacerbating 
tumour growth by facilitating angiogenesis (43). 
For these reasons there is great interest in targeting the IL-17 pathway in disease 
(376). A range of therapeutic strategies are being developed to target the Th17 
signalling axis (376). An anti IL-17-mAb, AIN457, is the most clinically advanced of 
several IL-17 neutralising antibodies (376) and is currently in clinical trials for use in 
Crohn’s disease and psoriasis. 
PI3Kγ is predominantly expressed in haematopoetic cells as described in the 
Introduction. PI3Kγ aides chemotaxis of leukocytes including neutrophils and 
eosinophils, and a lack of PI3Kγ prevents hyperresponsiveness, inflammation and 
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remodelling of the airways in an OVA based model of asthma (175). There are some 
defects in thymocyte development in PI3Kγ null mice (168, 174-176). Both in vitro 
and in vivo activation of T cells are normal, although PI3Kγ-/- effector CD4+ T cells 
fail to migrate to sites of peripheral inflammation, and in vitro they fail to migrate to 
CCL22 (177). Furthermore, loss of PI3Kγ reduces the severity of autoimmune 
diseases such as CIA and SLE (127). 
The class 1B catalytic isoform p110γ pairs with either of the regulatory subunits 
p84/p87 or p101 and is activated by G-protein βγ subunits and signals downstream 
of GPCRs (131, 132). However, PI3Kγ can also be directly activated by Ras (379), 
and is bound by Ras on both its Ras binding domains and by an association of Ras 
with the catalytic domain of PI3Kγ (380). All isoforms of GTP- Ras can activate PI3Kγ 
(381). 
It has been previously reported that loss of PI3Kδ kinase activity, or dual loss of 
PI3Kγ and PI3Kδ kinase activity can affect production of Th1 and Th2 cytokines (168, 
180), however, no investigation into the role of PI3K isoforms in the production of IL­
17 had been performed. Therefore the aim of this results section was to profile the 
effect of loss of PI3Kγ on IL-17 production and to gain an understanding of the role of 
PI3Kγ in IL-17 receptor signalling. 
8.2 Lack of PI3Kγ causes an increase in IL-17A production 
This work started from experiments performed by Matt Thomas at Novartis, which 
are shown in Figure 8.1: 
“BALB/c mice were exposed to LPS, and BAL levels of cytokine were measured over 
48hr. An increase in IL-17A production was observed in PI3Kγ-/-animals after 24hrs, 
rising to 6-fold higher levels by 48hrs (Figure 8.1 A). Levels of IL-1β and TNFα did 
not differ significantly between wild-type (WT) and knockout animals (data not 
shown). Splenocyte cultures stimulated with LPS in vitro also resulted in a significant 
enhancement in IL-17A production in cells lacking PI3Kγ (Figure 8.1 B). Similarly T 
cells from PI3Kγ kinase dead knock-in animals, or PI3Kγ knockouts of a different 
background strain (129sv) also displayed increased levels of IL-17A production 
(Figure 8.1 C). More detailed analysis of wild-type and PI3Kγ-/- CD4+ T cells 
172 
Chapter 7: Results section VI 
stimulated with anti-CD3 and anti-CD28 demonstrated a near identical degree of 
proliferation and comparable production of IL-2, IL-4, IL-5, IL-6 and IFNγ, despite a 
30-fold increase in IL-17A levels (Figure 8.1D).”  
8.3 IL-17A produced by PI3Kγ T cells is functional 
It was thought that the IL-17 produced by PI3Kγ-/- CD4+ T cells might not be 
functional and hence might fail to activate a negative feedback pathway. The assay 
to determine functionality used wild-type mouse dermal fibroblasts (MDF) which 
produce IL-6 in a concentration-dependent manner in response to IL-17A. They also 
produce IL-6 in response to IL-17F but the concentrations of IL-17F required are ~2 
logs higher (Figure 8.2 A, B). 
Wild-type and PI3Kγ-/- CD4+ T cells were stimulated with CD3/CD28 T cell expander 
Dynabeads overnight to generate IL-17lo wild-type and IL-17hi PI3Kγ-/- supernatants. 
When supernatants were applied to the MDF, they produced IL-6 in accordance with 
the increased IL-17A content - with more IL-6 production being induced by PI3Kγ-/­
supernatant (p<0.01). To confirm that IL-6 production was induced by IL-17A rather 
than any other component of the supernatant, a neutralising/blocking antibody was 
added, at a concentration sufficient to block 10ng/ml IL-17A (Figure 8.2 C), which 
inhibited IL-6 production in both supplemented cultures. The non-significant increase 
in IL-6 production by PI3Kγ-/- CD4+ supernatant-treated MDF cultures vs wild type 
derived supernatant effects in the presence of anti-IL-17A Ab may be attributable to 
higher levels of IL-17F in the PI3Kγ-/- CD4+ supernatants (see below). The significant 
(p<0.05), Student’s paired T Test) IL-17A-dependent IL-6 production by the MDF in 
response to PI3Kγ-/- CD4+ T cell supernatant indicated that the IL-17A was functional 
(Figure 8.2 D).  
8.4 Kinetics of IL-17A and IL-17F production 
It was thought that the increase in IL-17A production by PI3Kγ-/- cells might be due to 
differing kinetics of production, with a peak in WT production occurring earlier or later 
than the timepoints used in previous experiments. In order to dissect the kinetics of 
production, IL-17A was measured at 1, 4, 24, 48 and 72h in cultures of CD4+ T cells 
(Figure 8.3 A). The kinetics of production of IL-17A by PI3Kγ-/- cells mirrored that of 
WT cells, with the amount secreted increased at all timepoints. As IL-17F has been 
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γ 
Figure 8.1. Lack of PI3Kγ leads to enhanced IL-17 production in vivo and in 
vitro in response to LPS or CD3/CD28 stimulation. A. Increased IL-17A detected 
in the BAL fluid of PI3Kγ-/- mice stimulated intranasally with LPS. B. Enhanced IL-17 
release from PI3Kγ-/- over WT splenocytes cultured over time, stimulated with saline 
or LPS. C. Comparison of WT, PI3Kγ-/- and PI3Kγ kinase dead CD4+ T cells 
stimulated with plate bound anti-CD3 and anti CD28. Mean of n=3, +/- SD. D. Fold-
differences in proliferation and cytokine release in PI3Kγ-/- and WT CD4+ T cells 
stimulated with plate bound anti-CD3 and anti CD28, n=1. *These experiments 
were performed by Matt Thomas* 
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Figure 8.2. The functionality of IL-17 generated by PI3Kγ-/- T cells. 
A. Schematic of the IL-17 production assay. IL-17 in the culture media induces 
production of IL-6 by mouse dermal fibroblasts B. Concentration dependent 
responses to IL-17A and IL-17F in the MDF assay. IL-17A and IL-17F at the 
indicated concentrations were added to MDFs and 24 hours later, IL-6 in the 
supernatant was assessed by ELISA. Data representative of three independent 
experiments, error bars are SD. C. Validation of an IL-17A blocking/neutralising 
antibody. 10ng/ml IL-17A was added to MDF cultures in the absence or presence of 
1μg/ml anti-IL-17A and the IL-6 in the culture supernatant was assessed by ELISA. 
Data representative of three independent experiments, error bars are SD. D. 
Supernatant from WT or PI3Kγ-/- BALB/c CD4+ T cells, cultured as described in the 
Materials and Methods, was removed at 48hr and incubated on a WT mouse dermal 
fibroblast cell line for 24 hr. The IL-6 produced by the MDF in response to the CD4+ T 
cell supernatant was assessed by ELISA. and is shown in the first two bars. The 
component of IL-6 production that could not be neutralised by addition of an anti-IL­
17A antibody to the MDF culture when the CD4+ supernatant was added is shown in 
bars three and four. The remainder of the IL-6 production was deemed to be 
dependent upon IL-17A from the CD4+ culture supernatants and is shown in columns 
five and six. Data from three independent experiments, +/- SEM. 
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demonstrated to have a more important role in suppressing IL-17A production (382) it 
was postulated that a lack of IL-17F might be driving the increase in IL-17A. However 
levels of IL-17F in the supernatant of PI3Kγ-/- cells were also increased at all time-
points (Figure 8.3 B) ruling out the possibility of lack of IL-17F-driven suppression of 
IL-17A production. To determine whether the increased IL-17 observed in animals / 
cell cultures lacking PI3Kγ was due to expansion of a Th17-like population, cells 
activated for 48hr were cultured for 4 hours in the presence of Golgistop and then 
stained for IL-17A. No increase in the percentage of IL-17+ve cells in the PI3Kγ-/­
cultures was observed (Figure 8.3C). Instead an increase in the mean fluorescence 
of the cells was observed, similar to data published by Nagata et al. (382). Taken 
together these data indicated that PI3Kγ-/- T cells are not more susceptible to 
skewing to Th17 in vivo or in vitro but instead individual cells each produce more IL­
17 than their WT counterparts, and this increase is consistently sustained over time. 
8.5 Expression of IL-17RA and IL-17RC by PI3Kγ-/- CD4+ 
To determine whether the aberrant IL-17 levels produced by T cells lacking PI3Kγ 
were due to altered IL-17 receptor levels, expression patterns were investigated. 
Freshly isolated PI3Kγ-/- CD4+ expressed a significantly higher level (p<0.05) of IL­
17RA than their WT counterparts. IL-17RC surface expression was very low on 
freshly isolated cells with no significant difference between WT and PI3Kγ-/- cells 
(Figure 8.3 Di). Typical flow cytometry plots are shown in Figure 8.3 Dii, indicating 
that there are not distinct IL-17RA or IL-17RC positive populations, but rather that the 
mean level of expression of IL-17RA on individual cells is increased by loss of PI3Kγ. 
8.6 Involvement of PI3Kγ in IL-17 production by naïve cells 
and upon skewing 
To further investigate whether there was a change in the expansion of Th17 cells in 
the PI3Kγ-/- cultures, and also whether there was still some regulation of IL-17 
production, cells were cultured under Th17 skewing conditions. To do this, naïve 
CD4+ T cells were used. Therefore in the first experiment, naïve CD4+ were isolated 
from the spleen and cultured as previously. IL-17A and IL-17F in the supernatant 
were measured after 48hr (Figure 8.4 A) as had been done previously using pan 
CD4+ T cells. Significantly more IL-17A was generated by PI3Kγ-/- cells than WT 
cells, with a trend towards more IL-17F production, although levels were lower than 
in experiments with pan CD4+.  Again this reiterated the finding that increased IL-17 
production was not due to the presence of increased numbers of in vivo generated 
Th17s. 
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Next naïve cells were cultured for seven days under Th0 or Th17 conditions and the 
levels of IL-17 in the supernatant were quantified. Under both Th0 and Th17 
conditions the PI3Kγ-/- cells produced more IL-17A and IL-17F than their equivalent 
WT counterparts (Figure 8.4 B). However, there was no increase in the percentage of 
cells staining positive for either the characteristic Th17 chemokine receptor CCR6 
(Figure 8.4 C) or IL-17A (Figure 8.4 D). Finally, the expression of IL-17 receptors was 
characterised in both Th0 and Th17. It was observed that expression of IL-17RA was 
not altered by skewing to Th17, however, under Th0 conditions (but not Th17 
conditions) there was a marked upregulation of IL-17RA in PI3Kγ-/- cells (Figure 8.4 
E). The same trends were observed with IL-17RC, although expression levels were 
more varied and the trend did not reach significance. 
8.7 Involvement of PI3Kγ in IL-17 signalling 
The altered levels of IL-17 receptors suggested a failure of a negative feedback loop 
upon IL-17 production in PI3Kγ-/- CD4+ T cells (383). To investigate this, freshly 
isolated WT and PI3Kγ-/- CD4+ T cells were stimulated with a range of concentrations 
of IL-17A and IL-17F, and Akt phosphorylation was measured by ELISA. 
Phosphorylation of Akt was observed in response to 30ng/ml IL-17A in WT cells only 
(Figure 8.5 A), despite increased IL-17RA expression in PI3Kγ-/- cells. No 
phosphorylation of Akt was observed either in WT or PI3Kγ-/- cells in response to IL­
17F up to 100 ng/ml (Figure 8.5 B). 
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Figure 8.3. Characterisation of IL-17 production by CD4+ T cells. More IL-17A 
and IL-17F are produced by CD4+ T cells with genetic loss of PI3Kγ. ELISA detection 
of A. IL-17A and B. IL-17F from supernatants of WT or PI3Kγ-/- BALB/c CD4+ T cell 
cultures, maintained as described in Materials and Methods, at 1, 4, 24, 48 and 72hr 
timepoints. Data are from one experiment representative of three independent 
experiments. Error bars are SD. C. CD4+ cells were cultured for 48hr on CD3/CD28 
beads as described in Materials and Methods. For the final six hours cells were 
restimulated on CD3/CD28 beads in the presence of golgistop, then fixed and 
stained for IL-17 or isotype control. i. Bar graph is pooled data from three 
independent experiments, error bars are SEM. ii Flow cytometry plots are from a 
single experiment, representative of three independent experiments. D. Expression 
of the IL-17RA and IL-17RC on the surface of CD4+ freshly isolated from WT or 
PI3Kγ-/- BALB/c mice were assessed by flow cytometry. i. Bar graph is pooled data 
from three independent experiments, error bars are SEM. ii. Plots are from a single 
experiments representative of three independent experiments. 
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Figure 8.4 PI3Kγ-/- T cells skewed to Th17 still produce more IL-17A and IL-17F 
than their WT Th17 skewed counterparts. A. Naïve CD4+ were isolated from WT 
or PI3Kγ-/- BALB/c mice and cultured for 48 hours on CD3/CD28 beads and the 
concentrations of IL-17A and IL-17F in their supernatants were assessed by ELISA. 
B. Naïve cells were culutred under Th0 or Th17 conditions for six days, then 
restimulated for 16 hours and the IL-17A (Bi) and IL-17 F (Bi and ii) were assessed 
by ELISA. C. The expression of CCR6 on day 7 Th0 and Th17 skewed cells was 
assessed using flow cytometry. D. Day 7 cells were restimulated on CD3/CD28 
beads for 6 hours in the presense of golgistop, then fixed and stained for IL-17A 
which was assessed by flow cytometry. E. Expression of i. IL-17 RA and ii. IL-17RC 
was assessed by flow cytometry on the surface of day 7 Th0 and Th17 skewed cells. 
Averaged data are from at least three independent experiments, error bars are SEM. 
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Figure 8.5 Intracellular Signalling by CD4+ T cells in response to IL-17. 
PI3K signalling in response to IL-17. Phosphorylation of AKT was quantified by 
ELISA and normalised to unstimulated WT or PI3Kγ-/- CD4+ cells in response to A. IL­
17A or B. IL-17F applied for 5 minutes at the indicated concentrations. Averaged 
data are from at least three independent experiments, error bars are SEM 
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8.8 Summary 
Previous work has shown that murine T cells produce an increased amount of IL-17A 
in response to a variety of stimuli both in vitro and in vivo when PI3Kγ was knocked 
out, or a catalytically inactive mutant was knocked in. In this chapter it was 
demonstrated that 
•	 Both IL-17A and IL-17F production are increased upon knockout of PI3Kγ 
•	 There is aberrant expression of the IL-17RA and IL-17RC receptors 
•	 The IL-17A produced by PI3Kγ-/- T cells is functional 
•	 The increase in IL-17 production is not due to an expansion in the Th17 
population 
•	 Upon culture in Th17 conditions, the increase in Th17 cells is equivalent in 
WT and PI3Kγ-/- cells, however, the PI3Kγ-/- cells still produce more IL-17A 
and IL-17F 
•	 IL-17A but not IL-17F signals through PI3Kγ in murine T cells 
These results are summarised in Figure 8.6 
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Figure 8.6 Summary of the effects of PI3Kγ knockout on IL-17 signalling and 
production 
In murine T cells, loss of PI3Kγ led to a loss of IL-17A induced signalling through Akt 
and also to an increase in the expression of IL-17 receptors and increased 
production of IL-17A and IL-17F. It is possible that the IL-17A signalling through 
PI3Kγ is required to negatively regulate both receptor expression and IL-17 
production. This hypothesis will be examined in the Discussion. 
182 
Chapter 9: Discussion 
Chapter 9: Discussion 
183 
Chapter 9: Discussion 
9.1 Overview 
In this thesis the role of SHIP-1 in T lymphocyte function has been extensively 
investigated. It was shown that SHIP-1 was activated in response to a variety of 
stimuli in primary human T cells. Furthermore, expression of rCD2:SHIP protected 
Jurkats against apoptosis in response to H202 and TRAIL. Next a lentiviral delivery 
system was successfully established so that SHIP-1 expression could be modulated 
in primary human cells. Expression of rCD2:SHIP in these cells led to their death, 
however, cells in which SHIP-1 expression had been silenced were still viable, 
although they failed to proliferate. SHIP-1 silenced cells displayed an increase in 
basal PI3K activity and actin polymerisation. They also had a loss of microvilli 
expression and a decrease in basal motility. However, they were still able to migrate 
towards chemokines. Experiments using fluorescent PH domain reporters and 
staining for phosphorylated SHIP-1 also revealed only a weak localisation of both to 
the leading edge of polymerised cells. The final section examined the role of SHIP-1 
in T cell functions. Silencing of SHIP-1 led to a reduction in Th1 cytokine production 
under Th1 skewing conditions. Under Th2 skewing conditions, silencing of SHIP-1 
resulted in an increase in production of IL-4. Notably under Th0 conditions there was 
an increase in the percentage of Tregs. Finally CD8+ T cells had a tendency towards 
a decrease in cytotoxic function upon silencing of SHIP-1. These findings will now be 
discussed in more detail. 
9.2 Expression of SHIP-1 
Expression of SHIP-1 in primary T cell and T cell lines was in agreement with that 
previously reported in the literature (244). Expression of rCD2:SHIP-1 was also 
verified in stably transfected cell lines, however, the expression was deemed too 
leaky to use the “off” Jurkats as negative controls for future experiments. Since the 
generation of this cell line, more easily controlled promoter systems have been 
developed, which would be alternative options for future experiments (384, 385). 
9.3 SHIP-1 is phosphorylated in response to a variety of 
stimuli 
The first section of the results indicates that SHIP-1 is phosphorylated in response to 
a variety of stimuli. Confocal imaging of SHIP-1 verified that phosphorylation of SHIP­
1 on Y1020 may be taken as a marker for its recruitment to the cell membrane it T 
cells. Staining with the pan SHIP-1 antibody was less successful but implied that 
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SHIP-1 was distributed throughout the cytosol in controls, and recruited to the cell 
membrane upon stimulation in line with the report of others (386).  
As the phosphorylation of SHIP-1 on Y1020 can be taken as a marker of its recruitment 
to the cell membrane and hence its activity, it is clear that SHIP-1 will play a variety 
of roles in PI3K mediated signalling events. However, western blotting for 
phosphorylated Akt and phosphorylated SHIP-1 in response to a variety of stimuli 
such as chemokines and anti-CD3 indicated that SHIP-1 is differentially activated 
compared to Akt. These findings support the idea that other negative regulators of 
PI3K signalling such as PTEN and Phlpp may contribute to differential activation of 
AKT (387) and that SHIP-1 modulation of PI3K signalling directs the pathway 
towards different outcomes. However, in some cases, a lack of Akt response may 
indicate that timepoints or concentrations of chemokine were not optimal. Previously 
it has been reported that in B cells, SHIP-1 is not phosphorylated in response to 
CXCL12 stimulation (294). However, the situation may be different in T cells, or the 
phospho-specific antibody may be more sensitive than immunoprecipitation of SHIP­
1 followed by probing with 4G10 (an antibody that recognises phosphotyrosine 
residues). The strong phosphorylation of SHIP-1 observed in response to H2O2 may 
be partly due to inactivation of the (as yet unidentified) phosphatase responsible for 
the dephosphorylation of SHIP-1 by oxidizing conditions (388). Others have also 
reported that hydrogen peroxide stimulates the PI3K-dependent recruitment of 
PI(3,4)P2 binding proteins (389). It was somewhat surprising that SHIP-1 was not 
strongly phosphorylated in response to CD28 stimulation, as it has been previously 
reported to act downstream of this receptor, and PI3K is strongly activated by CD28 
signalling (335). 
The PI3K inhibitor LY294002 did not affect phosphorylation of SHIP-1 in response to 
stimuli, suggesting that phosphorylation is PI3K-independent as has been reported 
for IgE stimulated SHIP-1 phosphorylation in basophils (390). However, the Src 
kinase inhibitor PP2 was successful in reducing both basal and induced levels of 
SHIP-1 phosphorylation in response to H2O2, consistent with reports that the Src 
kinase Lyn is responsible for phosphorylation of SHIP-1 (255, 341). However, this 
phosphorylation is not essential for SHIP-1’s enzymatic activity in vitro nor for its 
association with the Src kinase Lyn at the cell membrane as inhibition of the kinase 
activity of Lyn using PP2 inhibits SHIP-1 phosphorylation but not its association with 
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Lyn (340). bpVphen was found to induce phosphorylation of both Akt and SHIP-1, 
which was indicative of its actions in raising levels of both PI(3,4,5)P3 and PI(3,4)P2 
(388). This was important to validate for later work investigating the actions of 
bpVphen on cell morphology. The identity of the band recognised by the pY1020 SHIP­
1 antibody at approximately 75kDa remains unknown. Variants of SHIP-1 with 
molecular weights this low have not been reported in the literature. It is possible that 
the antibody cross reacts with another protein with a NPXY motif. Alternatively, this 
band may be due to proteolytic cleavage of SHIP-1 after cell lysis (391). 
9.4 The role of SHIP-1 in apoptosis 
The investigation into the role of SHIP-1 in ROS and death receptor signalling yielded 
some interesting results. The finding that CD2:SHIP protected against cell death was 
in line with Gloire et al. (263), who found that expression of SHIP-1 protected 
leukaemic T cells against ROS-induced cell death. It has been reported in the 
literature that inhibition of Akt sensitises cancer cell lines to TRAIL induced apoptosis 
by increasing TRAIL-mediated cleavage of Bid. It also sensitised cells to Fas 
mediated apoptosis (392). It has also been reported that reintroduction of SHIP-1 into 
Jurkats sensitises them to Fas mediated apoptosis (264). In addition, it has been 
shown that introduction of constitutively active Akt or loss of SHIP-1 causes an 
increase in Fas expression and cell death in Francisella tularensis-infected 
macrophages (393). 
SHIP-1 is reported to be recruited to a YxxL motif on death receptors including TNF, 
TRAIL and Fas receptors and thus negatively regulate cell death (394). It may be that 
the lack of SH2 domain in the rCD2:SHIP construct, which would prevent its 
recruitment to the TNF receptor, was responsible for its inefficacy. It is not clear why 
SHIP-1 protects against death induced by TRAIL but not by TNFα. The presence of 
CD2:SHIP may alter the expression of TRAIL or TNF receptors, although this could 
be quantitated by western blotting or flow cytometry with the appropriate antibodies. 
Kim et al.  reported that SHIP-1 null HPCs are still sensitive to the suppressive 
effects of TNFα in a colony forming assay (360), i.e. that SHIP-1 probably does not 
regulate TNFα signalling. Some limitations of the CD2:SHIP molecule must be born 
in mind. Firstly it does not have the ability to cluster in the vicinity of its substrate and 
secondly it lacks the binding domains that allow SHIP-1 to perform a scaffolding 
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function for the recruitment of other molecules. However, a comparison of this 
approach with reintroduction of full length SHIP-1 would clarify these issues (334). 
9.5 Safety and efficacy of lentivirus 
As reported elsewhere it is extremely difficult to introduce siRNA into primary T cells 
using either chemical transfection or electroporation (286, 346), without 
compromising viability. Furthermore rates of transfection are low, and the effect is 
transient. These findings were repeated using one of the most up to date 
electroporation systems available, the Microporator MP-100. This resulted in a 
maximum of 8% of cells that were viable and transfected with a GFP expression 
plasmid, making it unsuitable for many experiments. This percentage was achieved 
in freshly isolated CD4+ T cells. When PBMCs were activated for 10 days in the 
presence of SEB before electroporation, less than 3% of cells were transfected and 
viable. This was despite the manufacturer’s report that 30% of PBMCs could be 
transfected. Therefore it is preferable to use a viral delivery system which can give 
higher rates of infection and also utilise shRNA. Adenoviruses and adenovirus 
associated viruses can deliver transient shRNA, but are not efficient at infecting 
primary T cells (395), whilst mouse stem cell virus (MSCV) and the Moloney murine 
leukaemia virus (MoMLV) or lentivirus (e.g. HIV, FIV or EIAV) can integrate into the 
host cell DNA. Lentiviruses are particularly advantageous as they can infect non 
dividing cells (347, 348). A variety of plasmids for lentiviral delivery of shRNA are 
now commercially available (347). In addition, the lentiviral plasmid can also be used 
to introduce DNA coding for full length proteins. 
With this in mind, it was satisfying to note that the Jurkat cell line could be infected 
with high efficacy and that the cells appeared normal, with strong expression of GFP. 
Furthermore, supernatant from infected cells was unable to infect other cells, 
indicating that the four plasmid expression system had worked effectively and made 
replication incompetent viral particles (328). Similarly, primary human T cells could 
also be infected at a very high percentage (over 85%), without any effect on viability, 
in line with reports in the literature (396). Spinoculation and use of polybrene 
enhanced infection rates. Spinoculation sediments the virus onto the cell (397) whilst 
polybrene is a polycation that is thought to increase viral infection by aiding the 
interaction of the negatively charged membrane of the virus and the target cell (327). 
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9.6 Overexpression of constitutively active SHIP-1 in primary 
cells leads to death 
It was hoped that silencing of SHIP-1 expression in primary cells would be 
complemented by a model of SHIP-1 activation in these cells. This would utilise the 
rCD2:SHIP chimeric protein, used successfully in the first results chapter and by 
others (244, 256, 294). To this end, the DNA was cloned into the lentiviral expression 
vector pCLPS, which was used previously to express GFP when validating the 
lentiviral delivery system. This was used to infect primary cells and the rat CD2 
protein was detected by flow cytometry and by western blotting (at the correct 
molecular weight to be part of the chimeric protein). Furthermore, the infected cells 
could be enriched using MACs columns. However it was observed using flow 
cytometry that three days after infection, only 30% of the population was positive for 
rCD2, whereas infection rates of over 80% had been achieved with the same vector 
encoding GFP. Furthermore, it was noted on the FSC/SSC dot plots, that there was 
an increased amount of debris and that therefore the infected cells were most likely 
dying. To ascertain this, day three post infection the cells were stained with annexin 
and propidium iodide and assessed by flow cytometry. They were found to have an 
increase in the percentage of apoptotic cells (and presumably by this stage a 
substantial proportion had already undergone apoptosis or necrosis, to judge from 
the amount of debris). This finding was confirmed by confocal microscopy, in which 
rCD2:SHIP cell cultures had a lot of debris and cells that were staining positive for 
propidium iodide. Western blotting confirmed that levels of basal or CXCL11 induced 
Akt phosphorylation were reduced by expression of rCD2:SHIP (although equal 
loading was difficult as protein quantification by Bradford assay was confounded by 
dead cells). These observations were unsurprising, given the key role of the PI3K 
pathway in cell growth and survival (290, 295, 398-400). Furthermore overexpression 
of inositol polyphosphate 5-phosphatase type IV (5ptase IV), which metabolises 
PI(4,5)P2 and PI(3,4,5)P3, suppressed cell growth, increased basal cell death by 
apoptosis and also sensitised cells to Fas mediated apoptosis (401). 
In general, interest in the PI3K pathway has focussed on its role in cancer and 
inflammation. Particularly in cancer it has been noted that a high proportion of both 
solid tumours and leukaemias exhibit mutations in the PI3K pathway (or upstream 
activators such as growth factor receptors). This can be at the level of activating 
mutations in the PI3K itself, (most commonly in PI3Kα), or in Akt, or a loss of a 
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negative regulator. In solid tumours this is PTEN, but SHIP-1 is lost in leukaemias or 
has inactivating mutations. Therefore a core principal of cancer research has been to 
develop PI3K and Akt inhibitors, some of which are showing early success in clinical 
trials. However, there is conflicting information as to whether inhibiting the PI3K 
pathway induces growth arrest or can actually initiate apoptosis or necrosis. Until 
recently, evidence had pointed towards the growth arrest, at least when PI3K 
inhibitors were given as a monotherapy (a situation that would be unlikely to be the 
case in the clinic (295, 402, 403)). However, recent research has pointed towards the 
the initiation of apoptosis by PI3K inhibitors (299). It is somewhat hard to envisage 
how a PI3K inhibitor, even if it were selective for the alpha isoform, could selective 
induce cell death or even growth inhibition in cancerous cells, without impacting upon 
normal cells, particularly upon insulin signalling. However, a theory of oncogene 
addiction has been proposed, in which cancerous cells become uniquely dependent 
upon the mutated pathway for growth and survival and are therefore much more 
susceptible to inhibition of this pathway than are wild type cells. 
This theory does not appear to hold water with the results described here, when 
inhibition of PI3K signalling by diversion of the PI(3,4,5)P3 product to PI(3,4)P2 rapidly 
induced death of cells. The fact that this was not seen in the Jurkats may be 
attributable to the relative strengths of the promoters used to drive the transcription of 
rCD2:SHIP and therefore the relative abundance of the protein in the cells. It is to be 
expected that small molecule inhibitors may not, over a sustained period, be at high 
enough intracellular concentrations to cause complete inhibition of signalling 
mechanisms. SHIP-1 has also been shown to regulate Akt localisation at the cell 
membrane as well  (404). This was confirmed in primary cells by decreased basal 
and stimulated Akt phosphorylation upon introduction of rCD2:SHIP. Nevertheless, 
some weak Akt phosphorylation can be seen in the infected cells and therefore, 
inhibition of PI3K signalling pathways may have serious consequences in primary 
cells. 
An alternative explanation is that the PI(3,4)P2 product may activate signalling 
pathways contribute to cell death or interfere with survival. Relatively little is known 
about the specific PI(3,4)P2 binding proteins (405, 406), although TAPP2 has been 
demonstrated to interact with the cytoskeletal proteins utrophin and syntrophin and to 
facilitate adhesion to fibronectin and laminin. However, TAPP2 is an unlikely culprit 
189 
Chapter 9: Discussion 
for cell death as TAPP2 expression was upregulated in aggressive B cell leukaemias 
with increased adhesion probably contributing to disease progression (407). 
As well as the rCD2:SHIP construct, others have used  retrovirus to reintroduce full 
length SHIP-1 into Jurkats and found similar effects i.e. a decrease in PI(3,4,5)P3 and 
pAkt levels. However, although there was reduced proliferation, due to slow transit 
through G1, there was not complete cell cycle arrest or apoptosis. The decreased 
proliferation was due to decreased phosphorylation of Rb and increased stability of 
p27Kip1, two regulators of cell cycle at the G1 stage (408). Alternative experimental 
strategies would be to overexpress full length SHIP-1, to clone the rCD2:SHIP into a 
lentiviral vector with a weaker promoter, or a lentiviral inducible promoter system 
(409-411) or to use a small molecule pharmacological approach. The latter option 
has been explored by other (319, 320, 323). SHIP-1 is reported to be an allosterically 
modulated enzyme (although others have questioned this (257)) and the compound 
reported in the literature facilitates its activation by binding to the allosteric binding 
site (319, 320). This compound has been reported to be anti-proliferative and 
cytotoxic against human multiple myeloma cells (323). As mentioned above (408), in 
Jurkats overexpression of WT SHIP-1 has been shown to have no effect on 
proliferation. In erythroid cells, overexpression of catalytically inactive SHIP-1 
decreases proliferation. However, overexpression of either WT SHIP-1 or a 
catalytically inactive mutant causes an increase in apoptosis, highlighting the 
important difference between the scaffold and catalytic functions of SHIP-1 and that 
PI(3,4)P2 can be crucial for proliferation (332). Since the increased apoptosis of 
SHIP-1 overexpressing cells was not caused by the 5-phosphatase activity of SHIP­
1, other regulatory domains appear to be involved in this process, like the 
noncatalytic C-terminal proline-rich region or the N-terminal SH2 domain which were 
found to be essential for the inhibitory signalling of B cells and the increased 
apoptosis observed in DA-ER cells (a murine myeloid cell line), respectively (412, 
413). Furthermore, different non-catalytic domains can have important functions, for 
example the proline rich domain is required for inhibitory signalling in B cells and the 
SH2 domain is required for some proapototic functions of SHIP-1 (412). 
Overexpression of full length SHIP-1 would have several advantages over 
rCD2:SHIP, which is somewhat flawed as although it has constitutive membrane 
localisation it does not necessarily colocalise with PI3K- containing signalling 
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complexes generating its substrate (which may be in discreet areas of the cell). 
Moreover rCD2:SHIP lacks the other binding domains of SHIP-1 that constitute its 
adapter function  (258). Whichever explanation for the death of rCD2:SHIP 
expressing T cells is correct, the fact remained that by 7 days post infection, no intact 
cells remained, and the rapid cell death made it impossible to gather further data 
from these cells, and therefore further research concentrated on silencing of SHIP-1 
expression. 
9.7 Lentiviruses expressing shRNA can be used to silence 
SHIP-1 expression in primary human T cells 
Initial experiments used CEMs to evaluate the ability of five different shRNAs to 
reduce expression of SHIP-1, and all five proved successful. The remainder of the 
experiments were conducted using primary human T cells. Use of the lentiviral 
system allowed the introduction of shRNA and RNA coding for proteins, without 
adversely affecting the viability of the cells. Infection rates of over 85% could be 
achieved, and furthermore, in the case of shRNA-encoding plasmids, the uninfected 
population could be killed using puromycin. The only parameters that were altered 
between control and shRNA control-infected cells appeared to be the percentage 
expressing CD25 and ability to skew to Th17 (see later). Assessment of SHIP-1 
silencing at both the mRNA and protein level gave confidence in the methodology. 
Lentiviral delivery systems are now the preferred method for silencing of protein 
expression in many primary cells, and even in cell lines, as they give sustained 
silencing over indefinite numbers of cell divisions, and the virus itself does not 
damage the cell. This is in contrast to other methods such as chemical transfection, 
electroporation or adenoviral infection, all of which variously damage the cell or 
induce an immune response. 
9.8 SHIP-1 silencing does not affect viability of T cells but 
reduces proliferation 
Viability of the primary cells was assessed using annexin and propidium iodide 
staining. This was performed on day nine post isolation, at which point, all uninfected 
cells had been killed on the basis of puromycin selectivity, and it was hoped that 
these dead cells would have degraded enough so as not to impinge upon the assay 
result. Furthermore, it gave time not only for SHIP-1 shRNA to be expressed by the 
cell, but also for existing SHIP-1 protein to be degraded. It was found that for both 
CD4+ and CD8+ T cells, viability was not adversely affected by silencing of SHIP-1 
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expression. The caveat of this is that some cells may have died very early on at the 
point at which SHIP-1 protein levels began to fall. 
Additionally, the viability of the cells after 6 hours in 0.1% serum was assessed, and 
found to be unaffected by SHIP-1 silencing. This gave confidence that experiments 
that required long periods in low serum or BSA (such as a neuroprobe chemotaxis 
assay) would not cause apoptosis in SHIP-1 silenced cells and thus compromise the 
results. In general, loss of SHIP-1 has not been reported to reduce viability (183), but 
instead has been implicated in the progression of several leukaemias (269-271). 
A final experiment examined the effect of exposure to TRAIL. It has been reported 
that primary T cells are insensitive to TRAIL and do not undergo apoptosis in 
response to it, possibly because they have low levels of TRAIL receptors and high 
levels of the antiapoptotic proteins TRAIL-R4 and c-FLIP (414) . Certain T cell lines 
such as CEMs also have low levels of TRAIL receptors and are reported to be 
resistant to TRAIL-induced cell death, whereas Jurkats are sensitive to this agent 
(415). Results in the previous chapter indicated that introduction of rCD2:SHIP to 
Jurkats protected them against TRAIL-induced death. Therefore it was logical that 
loss of SHIP-1 might be sufficient to confer sensitivity to primary T cells. However, it 
was found that silencing of SHIP-1 expression did not allow TRAIL to induce 
apoptosis of the primary cells. This may suggest that rCD2:SHIP has substantially 
different qualities to endogenous SHIP-1 (see later). It may also be that the multiple 
other abnormalities in Jurkats (such as a loss of PTEN) (244), mean that they 
respond differently to the presence or absence of SHIP-1 than do primary T cells. 
Reduced numbers of SHIP-1 silenced cells were recovered following selection, 
despite the fact that they had not been observed to undergo excessive apoptosis. 
Therefore cells were labelled with CFSE to observe their proliferation. Two different 
protocols were used. Firstly, cells were labelled immediately post isolation, before 
infection with lentivirus. This had the advantage of the cells being relatively uniform in 
size, and guaranteed that the shRNA cells and SHIP-1 shRNA cells would have 
started out with identical amounts of CFSE, as they were labelled as one population 
and then subsequently infected with different lentiviruses. In addition, although CFSE 
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is generally regarded as non-toxic at low concentrations and is generally suitable for 
labelling lymphocytes, it can be toxic to activated T cells and if cells are labelled with 
too much CFSE they exhibit reduced proliferation (416).  
In this assay, proliferation was observed to be reduced in SHIP-1 silenced cells 
compared to shRNA control cells. The SHIP-1 shRNA cells were still observed to 
have undergone some divisions in this assay. However, this could have been during 
the initial activation before exposure to lentivirus, or after infection when shRNA was 
present in the cell and inhibiting new production of SHIP-1 but SHIP-1 protein 
synthesised prior to infection was still present. Therefore a further assay was done to 
establish whether once a maximum amount of SHIP-1 protein had been lost, whether 
the cells would undergo proliferation. With the caveats mentioned above, the assay 
was optimised using lower concentrations of CFSE and loading in the presence of 
FCS. In addition, flow cytometry was used on a sample from each population 
immediately following CFSE loading, to verify equal staining. In this instance, no 
proliferation of SHIP-1 shRNA cells was observed, whereas a proportion of shRNA 
control cells underwent a division over the course of 48 hours. This low level of 
proliferation in the control cells is probably attributable to reduced proliferation seen 
after reactivation of previously activated cells, but a component may also be due to 
the anti-proliferative effect of CFSE, despite every effort being taken to optimise the 
protocol. 
The next experiment examined in further detail the lack of proliferation observed in 
SHIP-1 shRNA cells. Propidium iodide was used to stain fixed cells in order that their 
DNA content could be quantified by flow cytometry. It was found that by day 7, SHIP­
1 shRNA cells had undergone cell cycle arrest in G0 and/or G1, whereas shRNA 
control cells were found to be in S, G2 and M phases as well as G0/G1. These 
findings were somewhat unexpected for a number of reasons. Firstly, activating 
mutations of PI3Ks, or upstream components, are frequently detected in cancers, 
and PI3K inhibitors can reduce proliferation of primary cells and cancer cell lines, as 
well as showing some early success in the treatment of solid tumours and 
leukaemias. Secondly, PTEN is a well known tumour suppressor (417). Thirdly, some 
(269-272) studies have identified SHIP-1 as being lost in a proportion of leukaemias 
(and indeed, gene transfer of SHIP-1 into AML cells from patients, blocked their 
proliferation (418)), suggesting that it may also be a negative regulator of cell cycle 
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progression. However, others have queried whether lack of detectable SHIP-1 
expression is due to lysates being prepared using an NP-40 based lysis buffer, 
without adequate PMSF, which can allow proteolytic cleavage of SHIP-1. When an 
SDS based lysis buffer has been used instead, SHIP-1 is frequently detected (391, 
419). Furthermore, reports of the T cell specific SHIP-1 knockout mice indicated that 
loss of SHIP-1 did not affect proliferation of these T cells, either in vitro or in vivo 
(183). 
Interestingly, loss of SHIP-1 is associated with the increased proliferation seen in 
leukaemia when miR155 expression is increased. For example it has been shown 
that increased expression of miR155 silences SHIP-1 expression and encourages 
progression of preleukaemic B cells to leukaemia (420). This has also been 
demonstrated in natural killer cell leukaemias (421), whilst in macrophages, miR155 
also mediates suppression of SHIP-1 expression (50). Interestingly, silencing of 
SHIP-1 expression using a retrovirus that mimics miR155 expression leads to a 
myeloproliferative disorder (50). 
However, there are a number of possible explanations for the data found herein. 
Firstly, in SHIP-1-/- mice, the number of T cells is reported to be decreased. Some 
have attributed this to increased sensitivity of the T cells to FasL mediated apoptosis 
(264), but this is somewhat dubious. A more convincing explanation stems from the 
observation that SHIP-1-/- mice have an increase in the percentage of Tregs (184). 
Although this finding was not replicated in the T cell specific knockout mouse (183), it 
has been replicated using naive T cells from the whole animal knockout, which, in 
culture, are polarised more effectively to Tregs than their WT counterparts (186). 
Anergy and reduced proliferation are well known features of Treg cells, and therefore 
their phenotype was examined in more detail (see below). 
An alternative explanation for the failure of SHIP-1 silenced cells to proliferate may lie 
in the fact that this is the only aberrant protein in these cells. During the cell cycle, a 
number of checkpoints ensure that proliferation is regulated and that cells with 
mutations are prevented from proliferating. In particular the G1 checkpoint allows a 
G1-S transition. This checkpoint can be overcome by actions of certain oncogenes in 
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cancer, however, in general, unhealthy cells will be prevented from proceeding 
further. It is possible that high levels of PI(3,4,5)P3 present in the SHIP-1 shRNA cells 
indicate to them that they are not healthy and in order to reduced the chance of a 
leukaemia developing, these cells are prevented from proliferating. If this were the 
case then one would expect the loss of SHIP-1 that has been reported in some 
leukaemias, to occur at a late stage of oncogenesis, after the cell had acquired other 
mutations that will allow it to proceed through the G1 checkpoint. There is some 
evidence that SHIP-1 suppression is downstream of earlier oncogenic events (50). 
Furthermore, PI3K activity is key to progression through the G1 checkpoint, so a lack 
of its downstream product PI(3,4)P2 generated in the SHIP-1 shRNA cells may also 
contribute to cell cycle arrest (422). A final explanation is that the high levels of 
disordered actin polymerisation seen in the SHIP-1 shRNA cells are inhibitory upon 
cell cycle progression. Well ordered polymerisation of actin filaments has been 
shown to be key for progression to S phase (423-425).  
Since the completion of the experiments in this thesis, a recently published paper by 
Brooks et al. has shed further light of the decreased proliferation in SHIP-1-silenced 
cells (426). The authors identified 3 α-aminocholestane as an inhibitor of SHIP-1 in 
an isolated enzyme assay. They demonstrated that treatment of mice with the 
compound expanded myeloid immunoregulatory cell numbers. They also showed 
that inhibition of SHIP-1 reduced human and mouse allogenic responses in mixed 
leukocyte reactions, similar to that seen with genetic deletion of SHIP-1 (260). 
Inhibition of SHIP-1 caused increased granulocyte production, and upon irradiation 
recovery of neutrophils, platelet and red blood cell (RBC) numbers were increased by 
inhibition of SHIP-1. 
Crucially, in contrast to genetic deletion of SHIP-1 (184), inhibition did not cause 
myeloid infiltration of the lung. However, the treatment of myeloid leukaemia cell lines 
with the compound resulted in increased apoptosis and reduced proliferation, and 
this could be reduced by exogenous PI(3,4)P2. In an osteosarcoma cell line which 
lacked SHIP-1 expression, the compound had no effect. 
Previous to this reduction of SHIP-1 was thought to contribute to survival and 
proliferation of leukaemic cells (50, 244), and this was the first evidence that it might 
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be detrimental. (Counterintuitively, activation of SHIP-1 using the allosteric 
modulator was identified as inhibiting proliferation and causing apoptosis of multiple 
myeloma cells (323)). However, the reduced proliferation observed using a SHIP-1 
inhibitor correlated with the results herein using shRNA silencing of SHIP-1, and 
point to a crucial role of the phosphatase activity rather than the scaffolding/adaptor 
functions of the protein. The possible reasons for the reduced proliferation of cells 
upon silencing of SHIP-1 are summarised in Figure 9.1. 
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Figure 9.1 Model for decreased proliferation upon silencing of SHIP-1 
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9.9 PI3K signalling in the absence of stimulation and in 
response to the CD3 stimulatory antibody UCHT1 is increased 
by SHIP-1 silencing 
In addition to the verification of SHIP-1 silencing at the protein and mRNA levels, the 
effects of SHIP-1 silencing were characterised by the effect of proximal targets, both 
basally and upon stimulation. The simulation used was UCHT1, an anti-TCR 
antibody, as this had been previously found to induce strong phosphorylation of 
SHIP-1. An optimal concentration of UCHT1 was determined by examining AKT 
phosphorylation by western blot, and a concentration of 10µg/ml was decided upon. 
To this end the effect of PI(3,4,5)P3 levels was investigated, and it was found that 
silencing of SHIP-1 led to a basal increase in  PI(3,4,5)P3 levels, which were further 
increased upon TCR stimulation. This was a somewhat surprising finding, as 
previously it was thought that PTEN regulated the basal levels of PI3K activity, 
whereas SHIP-1 would influence the receptor induced PI3K response (136). 
However, close examination of western blots of phosphorylated SHIP-1 presented in 
the first results section reveals that there is a basal level of SHIP-1 phosphorylation 
which can be abrogated by use of the Src kinase inhibitor PP2. This would also 
suggest that there is some basal activity of SHIP-1. An analysis of basal levels of 
PI(3,4)P2 was also attempted, however this was not possibly due to the anti-PI(3,4)P2 
antibody cross reacting with PI(3,4,5)P3. An alternative approach would be to use a 
radioactivity based assay. However due to the methodology used to generate the 
SHIP-1 silenced cells, and their subsequent non-proliferation, it was deemed 
impractical to generate sufficient cells for this assay. 
9.10 Phosphorylation of Akt and downstream targets is 
increased by silencing of SHIP-1 
The next step was to investigate the effects of the increased PI(3,4,5)P3 levels on the 
downstream signalling targets Akt, GSK3β and p70S6K. This was performed using 
an MSD mesoscale plate. It was decide to investigate signalling in response to TCR 
stimulation over a timecourse using the optimal concentration of UCHT1 decided 
upon in the previous experiment. Again it was observed that basal phosphorylation 
was increased in all three proteins, and they responded to TCR stimulation with a 
further increase in phosphorylation, but without changes in kinetics compared to the 
controls. Again this was in agreement with the results from the PI(3,4,5)P3 assay, 
suggesting a major role for SHIP-1 in regulating basal PI3K activity. The timecourse 
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was confirmed in the novel assay (427) using a timecourse in control cells by western 
blot, which was found to be in agreement. This result was also verified by western 
blotting at single timepoints using SHIP-1 silenced cells, where again, levels of basal 
phosphorylation of Akt were found to be increased. The response to CXCL11 was 
also examined, and again the increase in Akt phosphorylation was observed to be at 
the basal state rather than further phosphorylation being induced upon receptor 
stimulation. ERK phosphorylation was also investigated as there is some evidence of 
cross regulation of MAPK pathways. There was evidence of a weak upregulation of 
basal ERK phosphorylation. It has been suggested that SHIP-1 could negatively 
regulate the MAPKp38 pathway and activation of SHIP-1 leads to a decrease in ERK 
phosphorylation (428). Furthermore, SHIP-1 has been shown to negatively regulate 
Tec, thus inhibiting the PLCγ pathway (429). SHIP-1 is thought to negatively regulate 
MAPK signalling independent of its phosphatase action on the PI3K pathway (430) 
and these results highlight the importance of SHIP-1 as an adaptor molecule. 
However, evidence from the T cell specific knockout mouse indicated that SHIP-1-/- T 
cells could signal normally in terms of ERK and Akt phosphorylation when stimulated 
with anti-CD3 or anti-CD3 plus anti-CD4. Calcium flux in response to CD3 was also 
unaffected. In contrast it was reported in using T cells from whole animal SHIP-1-/­
mice that calcium flux in response to SDF was potentiated (360).  
In agreement with findings in murine SHIP-1-/- neutrophils (293), splenocytes and 
thymocytes (360), basal polymerisation of actin was found to be increased when 
SHIP-1 was silenced in primary human T cells. Furthermore, the actin was not 
localised to discrete areas of the cell surface membrane as it was in the controls, 
lending further credence to the idea that SHIP-1 may by constitutively, if at low levels, 
present at the cell surface membrane, where it can regulate actin organisation, both 
through regulation of PI(3,4,5)P3 levels and though its specific products. For 
example, TAPP1, which is recruited to PI(3,4)P2 via its PH domain, binds 
synotrophins and controls actin polymerisation (431). This could have important 
repercussion for the cell as actin controls a range of processes from chemotaxis to 
cell division, to exocytosis. This would have serious implications for the functions of 
the cells, which were therefore investigated in the following results section. 
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9.11 Cell morphology and expression of adhesion molecules, 
but not adhesion, are altered by SHIP-1 silencing 
The finding that SHIP-1 silenced cells lacked microvilli, as determined by SEM had 
important implications. Microvilli collapse has previously been reported in the 
literature in response to chemokine stimulation, a finding replicated here using 
CXCL11. The purpose of this has been hypothesised to be to allow firm adhesion 
and flattening of the cell during chemotaxis. Initial adhesion is due to adhesion 
molecules expressed on the tips of microvilli binding to their ligands. Upon 
stimulation, a Rac1 mediated dephosphorylation of ERM proteins occurs causing the 
dissociation of actin from the cell membrane. It would be logical that PI3K could drive 
the activation of Rac1 in this circumstance and therefore that silencing of SHIP-1, 
through an increase in PI3K signalling, would lead to microvilli collapse. It was 
therefore surprising that the morphology could not be rescued with LY294002. This 
suggested that SHIP-1 might further regulate the activation of Rac though its non 
catalytic actions (Figure 9.2). For example in B-cells and possibly T-cells, SHIP-1 
binds Shc and in doing so prevents Shc’s association with Grb2. In this way SHIP-1 
inhibits Ras (432, 433) and thus could also downregulate Rac activation (434). 
Indeed, others have reported that SHIP-1 further regulates Rac activity though its 
non catalytic actions (435). 
Rac activation has previously been shown to have both PI3K dependent and 
independent components (352, 354). It has also been shown that there are complex 
feedback loops between PI3K and Rac (436). In keeping with the idea that activation 
of PI3K signalling could lead to microvilli collapse, it was seen that LY294002 on its 
own did not affect cell morphology, but that bpVphen (which leads to an increase in 
PI(3,4,5)P3 and PI(3,4)P2 (338, 437-439)), did cause moderate loss of microvilli. 
However, it was seen that SHIP-1 silenced cells could polarise normally upon 
exposure to chemokine. Images captured at a lower magnification also revealed a 
diversity of cell morphologies within each treatment group, highlighting one of the 
drawbacks of SEM and confocal microscopy in that a “representative” cell is very 
much subject to interpretation. 
To further investigate whether there was a Rac1 mediated ERM dephosphorylation 
occurring, confocal microscopy was undertaken with staining for both polymerised 
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actin and pERM. This allowed identification of pERM in microvilli tips and confirmed 
its loss from SHIP-1 silenced cells and those exposed to chemokine. The Rac1 
inhibitor NSC23766 (440, 441) was then used in an attempt to restore ERM 
phosphorylation. This was moderately successful, as determined by the confocal 
microscopy and quantified by flow cytometry, confirming that Rac1 played a part in 
the loss of ERM phosphorylation seen in SHIP-1 silenced cells. However it did not 
fully restore levels to that of control cells, not did it restore microvilli.  This leads to a 
number of possible hypotheses. Firstly the Rac inhibitor may not be at a high enough 
concentration to control Rac1 activity as tightly as in WT cells. Secondly, the Rac 
inhibitor on its own caused morphological defects in the control cells and over longer 
periods (results not shown) led to cell of an unhealthy appearance as assessed by 
flow cytometry, which may have adversely affected the cells’ ability to reconstruct 
microvilli. Thirdly other SHIP-1 dependent processed may be required for not only 
preventing the loss of the microvilli but also their construction (or reconstruction) 
(149). Certainly, this assay revealed complex underlying defects in the SHIP-1 
silenced cells under resting conditions, although again, their response to stimulation 
appeared normal. 
A lack of phosphorylated ERM in SHIP-1 silenced cells, along with an inability to 
completely recover phosphorylation using a Rac inhibitor, indicated that expression 
of ERM at the protein level could have been reduced by silencing of SHIP-1. 
However, this was ruled out by confocal microscopy and flow cytometry for the total 
protein. Confocal microscopy indicated that the majority of ERM in control cells was 
located in microvilli on the cell surface, whereas in SHIP-1 silenced cells it was 
distributed throughout the cell. The observation that ERM was membrane localised 
and enriched at the leading edge and the uropod upon chemokine stimulation, has 
been previously reported in the literature (442) and this localisation is reported to aid 
polarisation of lymphocytes. 
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Figure 9.2 Model for microvilli loss 
PI3K can activate Rac1 and lead to the dephosphorylation of ERM and hence 
microvilli collapse. SHIP-1 is an important regulator of basal PI3K activity through its 
phosphatase activity (P’tase). LY294002 can also inhibit PI3K activity and thus limit 
Rac1 activation. However, SHIP-1 can also regulate Rac1 activity through its non 
phosphatase functions (for example by competing for binding sites with other SH2 
domain containing signalling proteins).  Rac1 activity can also be inhibited by the 
compound NSC23766. 
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Following on from this it was decided to investigate further what effect the loss of 
microvilli might have on the cells, by examining the expression of two adhesion 
molecules. CD11a forms part of LFA-1, which binds to ICAM1-3, and is key in initial 
tethering of T cells during migration to sites on inflammation and in making initial 
contact with antigen presenting cells. It is capable of initiating inside out signalling 
and is also the target for Efalizumab. CD49d forms part of VLA-4 and binds to VCAM 
and fibronectin (356, 443). VLA-4 is preferentially localised to the microvilli tips and to 
membrane ruffles of lymphocytes (444, 445) and whilst there are some reports of 
LFA-1 having this localisation, it is generally agreed that it localises to the main cell 
body (446, 447). As it had been previously observed using SEM and confocal 
microscopy that microvilli were lost from the SHIP-1 silenced cells, it was therefore 
surprising that CD11a but not CD49d was downregulated, although defects in inside-
out signalling may play a role (448) (350, 351, 449) (355). Other researchers have 
shown that overexpression of full length SHIP-1 had no effect of expression of LFA-1 
but increased the activation of LFA-1, so that LFA-1-mediated adhesion to ICAM-1 
was increased in a manner which was dependent upon SHIP-1’s phosphatase 
activity (450). 
Following on from this it was important to address whether SHIP-1 silenced cells 
could adhere normally. Two different surfaces were used: fibronectin (357) is a dimer 
that can be present in the plasma or as part of the extracellular matrix and can be 
adhered to by many different integrins including VLA-4 (α4β1) (358), whilst ICAM1 
(CD54) is present of leukocytes and the endothelium and is bound by LFA-1 
(αLβ2)(359). These two adhesion molecules were selected as they are thought to be 
important at different stages of adhesion during transendothelial migration. It was 
found that, despite lower levels of LFA-1 being expressed on the surface of the 
SHIP-1 silenced T cells, there was no difference in the adhesion to either fibronectin 
or ICAM1, and there was even a trend towards increased adhesion. Furthermore, the 
ability to adhere to fibronectin was similarly enhanced in control and SHIP-1 silenced 
cells when in the presence of either CXCL11 or UCHT1. The fact that a decrease in 
LFA-1 did not affect adhesion is probably due to the fact that a loss of microvilli 
allows easy adhesion of a large surface area of the cell body. Similarly, the results in 
the previous section have indicated that signalling in response to both CXCL11 and 
UCHT1 are largely intact following silencing of SHIP-1. Obviously, in physiological 
conditions, the cells would be attempting to extravasate under flow and shear stress, 
at which point, the absence of microvilli might become more relevant (87, 451). It is 
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worth noting that higher percentages of adhesion have been reported in the literature 
(331) in response to stimulation, however the assay in its present form was adequate 
for the purpose. 
9.12 Expression of CXCR3 is unaffected by SHIP-1 silencing 
in CD4+ but is reduced in CD8+ T cells 
It was thought desirable to investigate chemotaxis in light of the morphological 
changes observed in the cells and the known involvement of PI3K and Rac signalling 
in chemotaxis (286). In the T cell specific SHIP-1 KO, it was reported that levels of 
Tbet were increased in CD4+ (183). As PI3Kγ and the transcription factor Tbet have 
also been shown to drive expression of CXCR3 in both CD4 and CD8+ T cells (452), 
it was important to verify CXCR3 expression levels before proceeding with 
chemotaxis to CXCL11. However, flow cytometric analysis did not detect an increase 
in CXCR3 levels in CD4+ (consistent with observations in the next chapter that these 
CD4+ cells are not skewed towards Th1, nor do the CD8+ show an increase in 
toxicity). However, the CD8+ T cells did show a decrease in CXCR3 expression. It is 
less clear how CXCR3 expression is modulated on CD8+ T cells, as it is not driven 
by IFNγ and STAT1 signalling as it is in CD4+ T cells (453). 
9.13 Basal motility but not chemotaxis, is reduced by SHIP-1 
silencing. 
Initial investigations into chemotaxis utilised the neuroprobe chemotaxis assay (286) 
in which cells migrate through pores in a membrane into a lower chamber with 
chemokine in it. By varying the concentration of chemokine in the chamber it is 
possible to get a classic bell shaped dose response curve. In addition, some of the 
cells will migrate in the absence of chemokine, due to their basal motility. By using a 
membrane with 5µm diameter pores, the T cells are required to actively distend as 
they move towards the chemokine, in the same way as when they pass between 
endothelial cells to exit the blood. In this assay it was noted that there was a defect in 
the basal motility of SHIP-1 silenced cells. The role of PI3K in chemotaxis has been 
debated; however it is known that PI3K signalling is biased towards the leading edge 
of chemotaxing cells where it is thought to contribute to the generation of 
pseudopods but not directional sensing (287). The reduction in basal motility found in 
SHIP-1 silenced T cells is in agreement with PTEN knockouts in Dictyostelium which 
can chemotax in response to stimuli, but lack basal motility because competition 
between emerging pseudopods cannot be resolved without PI(3,4,5)P3 gradients 
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(454, 455). Furthermore, findings were in agreement with SHIP-1-/- neutrophils, which 
were reported to have a higher level of basal actin polymerisation and a reduction in 
basal motility but to chemotax normally to fMLP. In the neutrophils, SHIP-1 was 
required to regulate polarity and motility, but not directionality (344). This was in 
contrast to finding using SHIP-1-/- T cells, which exhibited normal basal motility but 
increased chemotaxis to CXCL12 (SDF-1) (360). 
Chemotaxis is a complicated process, with PI3K signalling and other pathways 
frequently fulfilling redundant roles (456). Therefore it was not surprising that the cells 
could still detect the chemokine and move towards it in a concentration dependent 
manner. Indeed this was in agreement with the findings of others, whereby in freshly 
isolated T cells, PI3K is required for both basal migration and movement towards 
chemokine, but upon activation, only basal migration has a PI3K-dependent element 
(286) (chemotaxis of CD8+ T cells has been shown to be dependent on PI3Kγ 
(457)). 
The next assay used to investigate chemotaxis used videomicroscopy as described 
elsewhere (206). In this assay cells chemotax across a fibronectin coated surface 
towards a chemokine gradient.  It might be imagined that this would be more 
analogous to an earlier stage of chemotaxis in vivo when lymphocytes crawl or roll 
along the endothelium (451). However, this assay again replicated the findings of the 
neuroprobe assay, with a decrease in basal migration. Analysis of individual tracks 
allowed confirmation of findings in neutrophils (293) and the neuroprobe chemotaxis 
assay, as during basal motility both total and Euclidean distance were reduced as 
well as velocity. Therefore the effect of SHIP-1 silencing was on motility rather than 
directionality (i.e. the cells were not just going around in circles, which would have 
resulted in decreased Euclidean distance without affecting velocity or total path 
length). During chemotaxis to chemokine, this reduction in basal motility impinged 
upon the Euclidean distance and when the data were expressed as indices (fold 
change from respective basal figures), it was observed that the Euclidean Index was 
unaffected by silencing of SHIP-1, as had been observed with the chemotatic index 
in the Neuroprobe assay. Interestingly the accumulated distance and velocity during 
chemotaxis were not affected by silencing of SHIP-1 and therefore there were 
increases in the accumulated distance index and velocity index, possibly indicating a 
defect in directionality during chemotaxis. A logical next step for this assay would be 
to investigate under flow conditions (458) when, as mentioned previously, a lack of 
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microvilli might make a crucial difference to initial tethering the endothelial cells or 
fibronectin. 
Use of the two systems for analysing chemotaxis was of benefit because not only 
could two different chemotactic behaviours be examined, but also, a balance could 
be struck between gaining information on a large number of cells, and being able to 
observe small changes in the behaviour of individual cells. 
9.14 Localisation of fluorescent reporters and phosphorylated 
SHIP-1 
The next results section examined the localisation of PI(3,4)P2 by its ability to recruit 
a GFP tagged TAPP PH domain. It had been expected that some of the defects 
observed in the chemotaxing cells might be due to a lack of PI(3,4)P2 in the polarised 
cell. Proteins with PH domains that preferentially bind PI(3,4)P2, including TAPP1 
TAPP2 and BAM32, have been shown to have key roles in B and T cells (459). For 
example, TAPP1 binds synotrophins and controls actin polymerisation (431). 
It was somewhat surprising that the fluorescent TAPP PH domain proteins showed 
relatively weak localisation upon cell stimulation. bpVphen has  been shown by 
others to cause the generation of PI(3,4)P2 (388) and in the first results chapter, 
caused phosphorylation of SHIP-1 in primary human T cells. Therefore it would be 
expected to cause membrane recruitment of the probe. Similarly there are extensive 
reports of PI3K and SHIP-1 activity in motile cells, even when this pathway is not 
required for their movement (85).  Moreover, SHIP-1 has been reported to localise to 
the sides of the chemotaxing cell, confining PI(3,4,5)P3 to the leading edge and 
causing the accumulation of PI(3,4)P2 at the sides of the cell (293), whilst TAPP1 and 
TAPP2 are localised to membrane ruffles in lymphocytes (460). Instead these 
experiments indicated that the PI(3,4)P2 domain probe localised to the leading edge 
and emerging pseudopods. Due to the weak expression of the probes, a 1μm pinhole 
was used to capture fluorescence, and this may have been too broad to capture 
membrane localisation, particularly when cells were flattened during chemotaxis. 
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The finding that the mutant TAPP PH was excluded from the nucleus, whereas the 
WT TAPP PH appeared fairly uniform throughout the cell was unexpected. There is 
some evidence of nuclear localisation of PI(3,4,5)P3, which may explain why the AKT 
PH domain probe was not excluded from the nucleus under resting conditions (461). 
Previous work has identifies PI(3,4)P2 as being enriched at the cell surface 
membrane in response to growth factor stimulation of exposure to hydrogen 
peroxide, and it has also been identified on intracellular organelles such as the ER 
and endosomes. A small percentage was also detected on the nuclear envelope and 
in the nucleus (386). As this work was done in Swiss 3T3 cells (mouse embryonic 
fibroblasts), species and cell differences may account for the higher nuclear 
localisation of TAPP-PH seen in the primary human T cells.  However, others have 
found that whilst TAPP reporter proteins can be detected in the nucleus in resting 
cells, they translocate to the membrane upon stimulation (460). An alternative 
explanation was that the GFP or RFP may be cleaved from the wildtype PH domain. 
This could be verified by western blotting for GFP at the expected molecular weight 
for the tag and PH domain. However, low levels of transient transfection meant that 
this was not an option. The alternative would be cloning of all reporters into a 
lentiviral expression vector.  
The weak localisation of the PI(3,4)P2 domain binding probes during chemotaxis was 
further investigated using confocal microscopy to identify the localisation of 
phosphorylated SHIP-1 in  chemotaxing cells. Unexpectedly pY1020 SHIP-1 also 
lacked membrane localisation in cells exposed to CXCL11. These findings were in 
contrast to the results in the first results chapter, whereby H2O2 stimulation of CEMs 
led to a very convincing membrane localisation of phosphorylated SHIP-1. However, 
staining of phosphorylated SHIP-1 itself during chemotaxis (as opposed to its lipid 
product) has not been reported in the literature.  There was some localisation of 
SHIP-1 to emerging pseudopods, in agreement with the distribution of the TAPP PH 
domain probe. There is some evidence that once phosphorylated, Akt can detach 
from the cell surface membrane, and translocated to the cytosol or the nucleus, 
where it retains its kinase function (462-464). It could be hypothesised that a similar 
process may occur with phosphorylated SHIP-1, or alternatively it may be trafficked 
along with other proteins that are bound by its adaptor domains. 
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9.15 Silencing of SHIP-1 leads to an increased percentage of 
iTreg cells 
Exposure to lentivirus led to an increase in the percentage of cells that were CD25 
positive. CD25 in the high affinity chain of the IL-2 receptor, which is upregulated 
upon T cell activation. It is also a marker for Tregs. As lentiviruses preferentially 
infect activated and rapidly proliferating T cells, it is likely that the puromycin 
selection of infected cells has selected for cells that are CD25 positive, explaining the 
increase in the percentage of CD25 positive cells seen in with shRNA control.  The 
increase in CD25 expression per cell seen upon SHIP-1 silencing could have been 
an attempt to overcome reduced proliferation by increasing IL-2 signalling, or due to 
an increased percentage of Tregs. The situation regarding Tregs and SHIP-1 is not 
clear. In the original SHIP-1 knockout mice and increase in Tregs was observed and 
the Tregs were found to be functional. However, in the T cell specific knockout 
mouse no increase in Tregs was observed, and therefore the increase observed in 
the whole animal knockout was attributed to an attempt to inhibit the substantial 
inflammation that was caused by loss of SHIP-1 in other immune cells. However, a 
later study found an increase in T regs when naive cells from SHIP-1 knockout mice 
were culture in vitro indicating that a loss of SHIP-1 could predispose to Treg 
differentiation in a cell-intrinsic manner (194). Interestingly, there is also an increase 
in myeloid suppressor cell number in vivo upon loss of SHIP-1 (260). 
Staining for foxp3 allowed the identification of the CD25high population as being 
iTregs, whose percentage was increased three fold by silencing of SHIP-1. This is 
probably why there is a decrease in proliferation of the SHIP-1 silenced cells as 
Tregs proliferate less than other Thelper cells an also inhibit the proliferation of other 
T cells. The exact role of iTregs in the human body has not been determined. In vivo 
they develop in response to suboptimal antigen presentation or in longstanding 
inflammation. The main role of iTregs is to establish tolerance, both to external and 
self antigens. It has been hypothesised that iTregs are key to maintaining a non­
inflammatory environment in the gut and control of allergies, but may also prevent 
destruction of tumours (465). 
iTreg differentiation is driven by IL-2, and can also be facilitated by TGFβ and retinoic 
acid (466). This allows the generation of iTregs to be in balance with Th17 
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differentiation in which TGFβ directs Th17 generation but only in combination with IL­
6 (467). The balance between the two has been shown to be altered by the presence 
of SHIP-1, with SHIP-1-/- T cells being more prone to differentiation to Tregs in vitro 
and failing to become Th17s (186).  Interestingly, inhibition of the mTOR pathway 
has been shown to increase the percentage of Treg cells in culture (468). Subsets of 
iTregs can produce IL-10 and TGFβ, although these do not express foxp3. However, 
much of the mechanisms for iTreg mediated suppression remain poorly defined 
although they are generally thought to be antigen independent but contact dependent 
(469). These include CTLA-4 expression, adenosine production, transfer of cAMP to 
target cells, and LFA-1 interaction with DCs (470, 471). It has also been postulated 
that they may compete for cytokines such as IL-2, thus depriving other cells and 
contributing to their reduced proliferation and even to apoptosis (472). However it has 
been demonstrated that human iTregs do not induce apoptosis of effector T cells 
(473) and in any case this would be unlikely to be a major mechanism in the 
experimental set up used here, as IL-2 is present in high quantities. 
The results herein were therefore in keeping with those reported in murine T cells 
(186). Furthermore, the suppressive effects of Tregs probably account for the 
decrease in proliferation observed in SHIP-1 silenced cells. However, it was also 
observed that there was not a reciprocal decrease in cytokine production under Th0 
conditions, which would have been an expected outcome of having a high 
percentage of Treg cells. It has been reported that Tregs’ mechanism of suppression 
of cytokine production does not involve induction of anergy related genes in target 
cells which are known to inhibit TCR signalling (474). Therefore it is possible that 
human SHIP-1 silenced Tregs have some defects in their functions. In support of this 
was the finding that LFA-1 expression on the SHIP-1 silenced cells was in fact 
reduced, suggests that they were not fully effective in all capacities (470). 
Furthermore it has been demonstrated in several circumstances that foxp3+ cells can 
also secrete “effector” cytokines such as IL-17 (53). This possibility could be 
addressed through further dual staining experiments. It would be interesting to 
extend this study to cover skewing to Treg phenotype, and also to investigate the 
suppressive functions of these cells on target cells from the same donor.  
An insight into the role of SHIP-1 in the generation of Tregs and Thelper populations 
can be gleaned from work done on miR155. In T cells, miR155 expression is high in 
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Tregs and activated T cells, but not in resting T cells. Bic/miR155-/- murine T cells can 
skew normally to Th1 and Th2, but under non-polarising conditions, produce more IL­
4 and IL-10 but less IFNγ than WT cells (475). In Tregs expression of mir155 is 
regulated by foxp3 but conversely, a lack of miR155 causes a decrease in Treg 
numbers (476, 477). Loss of miR155 did not increase Treg activation induced cell 
death, but proliferation was decreased. These cells had a decrease in IL-2 signalling 
due to increased SOCS1 expression leading to attenuated STAT5 signalling (478). 
The fact that SHIP-1 is suppressed by miR155 contributes to an understanding of 
why high miR155 or loss of SHIP-1 both facilitate Treg generation. 
9.16 Th1 cytokines are aberrantly controlled when SHIP-1 
expression is silenced 
IFNγ is considered to be the signature Th1 cytokine, responsible for many of the 
functions of Th1 cells, including their antiviral and anti-tumour activities. In the 
literature it is reported that knockout of SHIP-1 results in an increase in skewing 
towards a Th1 phenotype, due to increased levels of T-bet, the transcription factor 
required for Th1 differentiation. In agreement with this, in human cells it was 
observed that under Th1 conditions an increased percentage of cells stained positive 
for IFNγ. It was therefore unexpected that there was a trend towards a reduction in 
the levels of IFNγ in Th1 culture supernatants by silencing of SHIP-1. One possible 
explanation of this is a defect in secretion of IFNγ by SHIP-1 silenced cells. In 
general, cytokines are not thought to be stored by T helper cells (although they are 
stored in granules in CD8+ cells), however very little is known about their 
mechanisms of trafficking to the cell surface membrane and their release. Yet SHIP-1 
has been recently identified as being present on the ER, where it facilitates 
glycosylation of CD95 (334). Similarly the non-significant reduced production of IL­
1β, IL-8 and TNFα may also be attributable to defective release. However, it may 
also be due to decreased levels of IFNγ in the culture supernatant being insufficient 
to initiate production of these cytokines. 
Defective secretion of IFNγ, rather than an inability to polarise successfully, or 
experimental error, is further supported by the observation that production of IL­
12p70, a cytokine which initiates Tbet activation and skewing to Th1 as well as 
driving IFNγ production, is normal in SHIP-1 silenced cells. No firm conclusions as to 
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the effect of SHIP-1 silencing on IL-2 production could be drawn as the levels 
produced varied so much between donors. However, it did appear to be suppressed 
in Th2 conditions compared to Th0 or Th1 conditions. 
9.17 Th2 cytokines are aberrantly controlled when SHIP-1 
expression is silenced 
Expression of IL-10 which may be produced by either Th2 or Treg populations, was 
unaffected by silencing of SHIP-1. Yet an apparent dichotomy was revealed with the 
other three Th2 cytokines, with increased production of IL-4 but a trend towards 
decreased production of IL-5 and IL-13. SHIP-1 knockout mice are prone to a Th2 
type inflammation, with extensive leukocyte infiltration into the lungs (182). However 
in a study of mice with genetic ablation of SHIP-1 confined to the T cell compartment, 
Th2 responses were decreased, as the mice were skewed towards Th1 responses 
due to raised levels of Tbet (181). Therefore it was counterintuitive that IL-4 levels 
should be raised in human knockout, although the fact that the cells have been given 
the opportunity to develop in the thymus normally may have a bearing. 
The genes for IL-4, IL-5 and IL-13 are located in a cluster on the same chromosome 
and are generally regulated together (479). However, in this case the effect also 
appeared to be promoter specific as levels of IL-5 and IL-13 were reduced. In support 
of this there is substantial evidence that IL-4, IL-5 and IL-13 are differentially 
regulated. It has been demonstrated that an NF-AT/AP-1 binding site is located in the 
IL-4 promoter, but additional elements are also required to drive IL-4 expression 
(480). Furthermore, c-maf has been shown to bind a c-maf response element in the 
IL-4 promoter (481). GATA3 has only a moderate effect on the proximal IL-4 
promoter but acts on other genomic regions to enhance IL-4 transcription (482). IL-5 
production can be driven by activation of GATA3 alone, and if GATA3 levels are 
reduced then that is sufficient to repress IL-5, but not IL-4 production (483). Other 
GATA-3 related factors are also involved in IL-5 expression (484). It has further been 
demonstrated that although IL-13 can also be induced by GATA-3, IL-13 is regulated 
by different pathway from IL-4, and that individual Th2 cells will not necessarily 
coexpress IL-4 and IL-13 (26). 
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9.18 Th17 cytokine production is aberrant upon silencing of 
SHIP-1 
The role of PI3K in Th17 generation and IL-17 production has not been extensively 
assessed. However, we have found that genetic loss of PI3Kγ or its catalytic activity 
increases production of IL-17A and IL-17F in mice (Chapter 8), but that this effect 
was not reproducible using pharmacological inhibitors of PI3Kγ despite the reported 
plasticity of Th17 populations. In addition, Locke et al. reported that genetic knockout 
of SHIP-1 in mice leads to a block in Th17 development, and a reciprocal increase in 
Treg development due to defective IL-6 signalling, which was observable in vitro. 
This is in line with the findings of others, who report that IL-6 switches the signal of 
TGFβ from differentiation of Tregs to development of Th17s (485). Clearly this runs 
counter to the findings here, however, in a T cell specific SHIP-1 knockout, 
Tarasenko et al. found no increase in IL-17 production or in abundance of Th17s 
(183). In addition Locke et al. demonstrated that the naive SHIP-1 deficient T cells 
immediately showed a decreased ability to respond to IL-6 with STAT3 
phosphorylation, indicating that SHIP-1 may play a role in the very early stages of 
skewing (186). Therefore the protocol required with human cells, whereby the cells 
are activate under skewing conditions and then infected with lentivirus, which takes 
several days to eliminate SHIP-1 at the protein level, may be too lengthy to influence 
Th17 skewing. Unfortunately, due to the endogenous presence of TGFβ in the 
culture media it would not be feasible to initiate Th17 skewing after SHIP-1 had been 
silenced, as in the absence of IL-6 it would bias towards the generation of Tregs. 
Furthermore, the exact role of TGFβ in human Th17 generation is very controversial 
(reviewed (486)) and for this reason it was not additionally supplemented to the 
culture media of Th17, although initial results in our lab have indicated that it can 
increase IL-17 production (not shown).  
Locke et al. suggest that an increase in STAT5 phosphorylation and a concomitant 
block in STAT3 phosphorylation is responsible for decreased Th17 skewing in SHIP­
1 silenced T cells (186). To further clarify the transcriptional events in the SHIP-1 
silenced human T cells, STAT3 phosphorylation was therefore examined. However 
when STAT3 phosphorylation was assessed in SHIP-1 silenced T cells there was no 
difference in levels of STAT3 phosphorylation between shRNA control cells and 
SHIP-1 shRNA treated cells. Locke et al. demonstrated that in freshly isolated murine 
T cells, loss of SHIP-1 results in reduced STAT3 phosphorylation in response to IL-6, 
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and SHIP-1 has been shown to be a key regulator of IL-6 signaling (420). However, it 
should be noted that IL-6 signalling in activated T cells is somewhat controversial, as 
some groups have reported that whilst IL-6 receptor expression is reduced on 
activated T cells, they are still present at sufficient levels to initiate STAT3 
phosphorylation (487), whereas others find that receptor levels are insufficient to 
support signalling, and that signalling relies upon soluble receptor (trans-signalling) 
(488-490). However, consistent with the notion that IL-6 receptor expression is lost 
upon activation of T cells and that responsiveness to IL-6 in these cells is due to IL-6 
trans signalling, no increase in STAT 3 phosphorylation was seen in response to IL­
6. 
9.19 CD8+ cytotoxicity is not enhanced by silencing of SHIP-1 
Under physiological conditions, CD8+ T cells that have been activated, develop the 
ability to kill other cells, i.e. they are cytotoxic T lymphocytes (CTLs). When the CTL’s 
TCR recognises a target, it rapidly releases perforins and granzymes that have been 
stored in granules, and these kill the target cell. They can also initiate Fas-mediated 
killing of target cells (491). PI3K is involved in CTL degranulation but not Fas 
mediated killing (492). It thought that it contributes to degranulation via a PKCθ/ 
RasGRP/Ras/ERK/paxillin pathway. Paxillin is an adaptor protein that facilitates 
recruitment of proteins to actin at the cell surface membrane, although its exact role 
in cytotoxicity is unclear (493). Others have shown that PI3K does not play a role in 
CTL perforin mediated lysis but instead regulate FasL expression (370). These 
results correlate better to the findings in this thesis, where short (1 hour) 
preincubations of CD8+ T cells with wortmannin, LY294002 or ZSTK474 all failed to 
alter their ability to kill target A20 cells. 
It has previously been reported in the literature that murine CD8+ T cells have 
increased cytotoxicity when SHIP-1 is knocked out. This is due to increased levels of 
Tbet leading to enhanced granzyme B activity (183). However, the same effect was 
not found when expression of SHIP-1 was silenced in human T cells. Instead, the 
percentage of target cells killed was slightly reduced. Whilst the set up of the assay 
appeared valid, with efficient killing of the cells only in the presence of both CD8+ T 
cells and UCHT1, the protocol is obviously substantially different from that used in 
murine cells and therefore the mechanisms may be different. In addition, it was 
observed that a higher proportion of the SHIP-1 silenced cells were staining positive 
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for annexin by the end of the assay. Therefore their cytotoxic function may have been 
compromised by their death. It is not clear what would have triggered the cell death, 
although it would possibly have been contents released from dying A20 target cells. 
Interestingly, in murine NK cells, it has been found that loss of SHIP-1 decreases 
cytotoxic activity (494). However, this is due to disruption of their receptor repertoire, 
with expression of an inhibitory receptor, 2B4, being favoured and the situation is 
different in human NK cells (495), where 2B4 is an activating receptor. 
9.20 Final discussion on the role of SHIP-1 
The role of PI3Ks in cell function has been extensively investigated in recent years, 
particularly as they have shown much promise as drug targets in inflammation and 
cancer. Yet SHIP-1, despite its key function in the PI3K pathway in immune cells, 
remains poorly understood, with even less attention being paid to its scaffolding 
function. Whilst a whole mouse SHIP-1 knockout and a T cell specific knockout 
mouse have been generated, and some research has been done in human 
leukaemic cell lines, this thesis is the first investigation into the role of SHIP-1 in 
primary human cells, and focuses in particular on its role in T cells. 
The first set of experiments examined and reconfirmed a variety of stimuli as 
activators of SHIP-1, and also extended previous work into the role of SHIP-1 in 
leukaemic cell lines. It was found that expression of the SHIP-1 catalytic core can 
protect against cell death in response to oxidative stress and TRAIL.  The aim of the 
second set of experiments was to investigate the role of SHIP-1 in primary cells. This 
involved the setting up and validation of a lentiviral expression system which is 
described in the first section of the results. This allowed the silencing of SHIP-1 
expression without the low efficacy and seen using chemical methods or 
electroporation. This method allowed the introduction of a constitutively active SHIP­
1 construct into T cells, which unfortunately resulted in unviable cells which were not 
suitable for further study. However, silencing of SHIP-1 yielded a considerable 
amount of data. Key findings were that silencing of SHIP-1 expression results in: 
• No change in viability 
• Decreased proliferation due to G0/G1 cell cycle arrest 
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•	 Increased levels of basal and receptor induced PI(3,4,5)P3 as well as 
increased levels of AKT, GSK3β and p70s6K phosphorylation and actin 
polymerisation 
•	 Loss of microvilli on the cell surface, probably due to Rac1-mediated ERM 
dephosphorylation 
•	 Reduced cell surface expression of CD11a but not CD49d 
•	 Reduced basal motility, without affecting on chemotaxis 
•	 Increased expression of CD25 and foxp3, i.e. increased Treg generation 
•	 Non-significant changes in ability to skew to Th1 
•	 Increased ability to produce and secrete IL-4, the signature Th2 cytokine, but 
without increased IL-5 and IL-13 
•	 Increased skewing to a Th17 phenotype 
• Reduced ability of CD8+ to kill target cells 
In addition, to complement the work on T cell chemotaxis, localisation of fluorescent 
PH domain probes was examined. However, whilst the Akt PH domain could localise 
to the cell surface membrane, the TAPP PH domain failed to do so. Therefore, an 
insight into SHIP-1’s localisation during chemotaxis was not obtained. 
Whilst some of these findings were in line with data from murine models, others, such 
as the decreased proliferation ran contrary to the findings in mice, and serve to 
highlight the fact that there are often substantial differences between the immune 
systems of mice and humans, and the importance of studying the role of proteins in 
human cells, even if the assays available are somewhat limited compared to animal 
models. 
SHIP-1 now stands at a crossroads, with the first inhibitor of SHIP-1 recently reported 
in the literature (426) and an allosteric modulator in preclinical development (320), 
and scheduled to enter clinical trials in Q1 2011. At this point it will become clear 
whether the differences between the role of SHIP-1 in murine and human T cells 
identified in this thesis will be important, or whether its key role as a modulator of 
PI3K signalling transcends species differences. 
9.21 Future work on SHIP-1 
The work in this thesis has revealed much about the roles of SHIP-1 in human T 
cells, however, there are a number of areas that were particularly interesting and 
would benefit from further study. Firstly, the finding that loss of SHIP-1 expression 
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was inhibitory on proliferation and resulted in cell cycle arrest was somewhat 
counterintuitive and would benefit from further study.  Examination of proliferation 
using a tritiated thymidine assay may aid an understanding of the process, as would 
assessment of expression and activation of cell cycle proteins key to the G1-S 
transition, such as cyclin A and cyclin E and their inhibitors. 
The role of SHIP-1 in controlling cytokine production would also benefit from being 
investigated in more detail.  In particular the defects in secretion of IFNγ, along with 
the reduction in either production or secretion of IL-5 and IL-13 should be 
investigated in more detail. There is some evidence that SHIP-1 can localise to the 
endosomes and be involved in the trafficking of proteins to the membrane, but further 
experiments would be required to verify this and to discovery whether this is the 
reason for changes in secretion patterns of cytokines. Furthermore, Th22 and Th9 
subsets of CD4+ T cells have recently been identified, and it would be interesting to 
extend the current work to include these novel cell types. 
In terms of chemotaxis, the studies herein could be expanded by cloning of a 
fluorescent PI(3,4)P2 reporter into the lentiviral expression vector in order to 
understand the localisation of SHIP-1 within the cell during chemotaxis. 
Finally, the effects of activation of SHIP-1 should be studied in more detail. The 
constitutively active construct could be successfully expressed in cell lines using a 
Tet-off promoter, but expression in primary cells using the lentiviral promoter was 
unsuccessful. Small molecule allosteric modulators of SHIP-1 activity have been 
described in the literature but are not commercially available. However some have 
questioned the presence of a second PI(3,4)P2 binding domain and others have been 
unable to show allosteric enzyme kinetics, instead demonstrating classic Michaelis-
Menten characteristics. Furthermore experience with ATP- competitive kinase 
inhibitors tells us that it is preferable to have a genetic model in parallel to a 
pharmacological approach, in order to identify possible off target effects of 
compounds. It may be possible to clone the CD2:SHIP construct into a lentiviral 
vector with a weaker promoter, but it would also be beneficial to investigate in greater 
detail the effect of overexpression of full length SHIP-1, including its adapter 
domains. 
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9.21 Discussion of the role of PI3Kγ in murine IL-17 
production 
The role of PI3Kγ has been dissected in great detail in terms of its functions in the 
immune system and inflammation and these results show a novel role for it in the 
suppression of IL-17A and IL-17F production. Previous work by Matt Thomas had 
shown that a genetic loss of PI3Kγ resulted in increased IL-17A both in vivo and in 
vitro, and in response to various stimuli despite otherwise normal cytokine production 
and proliferation. Knock in of a catalytically inactive PI3Kγ also caused increased IL­
17 production, demonstrating that the kinase function rather than the structural role 
(496) is required for control of IL-17 production. This is the first reported involvement 
of PI3Kγ in IL-17 production, despite evidence that SHIP-1 and mTOR are required 
for development of Th17s and that AKT signalling impairs their generation (186) 
(164, 497). 
It was hypothesised that IL-17A may have been produced in higher quantities by 
PI3Kγ-/- cells because it was not functional, for example due to abberant post­
translational modification (99, 498) and could not activate a negative feedback loop. 
IL-17 induces the production of IL-6, IL-8 GM-CSF, matrix metalloproteinases and 
chemokines from a variety of cells, e.g. fibroblasts, keratinocytes, eosinophils, airway 
smooth muscle and epithelial cells (30, 499). Therefore, an assay which involved the 
production of IL-6 by mouse dermal fibroblasts in response to IL-17 was used to 
measure IL-17 functionality. This ruled out the possibility of non-functional IL-17 as 
the IL-17 in the supernatant was effective in inducing IL-6 production by MDFs. 
Others have found that IL-17A and IL-17F regulate both their own and each others’ 
production (383, 500, 501). It was therefore hypothesised that an excess in IL-17A 
could be due to a decrease in IL-17F failing to suppress its production, or as an 
attempt to raise IL-17F production. However, this was found not to be the case, as IL­
17F levels were also elevated in cultures of PI3Kγ-/- T cells. 
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There is some evidence that Th17 expansion is counteracted by PI3K signalling 
(497, 502). However the kinetics of IL-17 production was the same in both WT and 
PI3Kγ-/- cells and no increased percentage of IL-17 positive cells was found by intra­
cellular staining. Therefore, despite having no more Th17 cells, PI3Kγ-/- cultures 
produced more IL-17, due to a higher output per cell. This was in line with other 
findings in IL-17RA knockout animals, where an increase in the Th17 population was 
not seen in response to ConA stimulation. Instead there was an increase in mean 
intracellular staining for IL-17 in liver cells, particularly CD4+ cells in these animals. 
In vitro these CD4+ cells secreted 10-100 times more IL-17 than WT CD4+ and also 
had an increase in IL-17F production (382).  
IL-17RA is a type 1 transmembrane protein (503) which is reported (generally on the 
basis of mRNA levels) to be ubiquitously expressed (504). Levels of surface 
expression vary considerably (505) although both CD4+ and CD8+ T cells express 
IL-17RA (506). It has been reported that IL-17RA associates with IL-17RC during IL­
17A signal transduction and that IL-17RC is an essential part of the IL-17 receptor 
signalling complex (507) in both mice and humans. However, others report that in 
mice IL-17RC binds only IL-17F and not IL-17A (508). IL-17RA and IL-17RC are 
reported to play a role in a negative feedback loop whereby IL-17F homodimers 
signal through them to reduce production of IL-17A and IL-17F by CD4+ cells (382, 
509). Similarly IL-17A has been reported to inhibit production of IL-17F (500) and of 
IL-17A itself (383). However others have postulated that that IL-17A and IL-17F are 
regulated by distinct pathways during Th17 differentiation (40) and it has recently 
been reported that TCR signalling induces IL-17A but not IL-17F signalling, by 
usitlising an Itk/NFATc1 pathway Moreover, IL-17A production could be reduced in 
WT cells by suboptimal TCR stimulation (510). 
IL-17A is reported to downregulate the IL-17RA (506), however it has also been 
reported that PI3K signalling limits the expression of IL-17 receptors (506). The 
experiments in this thesis were in agreement with the latter theory, with loss of PI3Kγ 
resulting in an increase in IL-17RA expression. Levels of IL-17RC expression in 
particular were low and in line with the findings of others. It has been hypothesized 
that the failure of splenocytes to respond to IL-17 is due to low expression of IL-17RC 
expression (506). 
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The increased levels of IL-17RA expression in freshly isolated PI3Kγ-/- cells despite 
high levels of IL-17A suggested there might be a possible defect in either the 
negative feedback loop signalling and/or internalisation of receptors. Relatively little 
is known about IL-17R signalling as the receptors bear little homology to other known 
cytokine receptors (511, 512). The IL-17RA is reported to contain a SEFs (similar 
expression to fibroblast growth factor (FGF) genes) and interleukin 17 (IL-17) 
receptor (SEFIR) domain which is hypothesised to recruit PI3K (512). Furthermore, 
IL-17 receptors have been shown to recruit Ras (513) and activate MAPK and ERK 
signalling (512) or alternatively to negatively regulate Ras activity (514) IL-17RA also 
signals to NFκB and C/EBPβ, the latter involving GSK3β signalling (515). Intriguingly, 
although PI3K signalling is generally upstream of GSK3β, in this setting PI3K 
inhibitors had no effect upon this element of IL-17RA signalling (512). Others have 
hypothesised a role for PI3K in IL-17 receptor signalling (512) with reports of JAK-
mediated PI3K signalling in response to IL-17A in human airway epithelial cells (516) 
and synovial fibroblasts (517). However, others have questioned whether IL-17 
receptors are expressed at high enough levels on T cells to initiate signalling (506). 
Therefore signalling in response to both IL-17A and IL-17F was examined. IL-17A 
induced Akt phosphorylation in WT but not PI3Kγ-/- cells, thus demonstrating a novel 
mechanism by which IL-17RA signals via PI3Kγ in response to IL-17A (although not 
IL-17F). The subsequent increased IL-17A and IL-17F levels in PI3Kγ-/- animals may 
therefore be due to a dysregulated negative feedback loop for IL-17 production 
dependent on effective signalling through the IL-17RA receptor. These findings, and 
the possible feedback loop are illustrated in Figure 9.3. 
Th17 profiles are thought to be fairly plastic (518), and the kinase-dead knock-in 
mouse reproduced the phenotype of the knockout mouse, indicating that it was the 
catalytic function of PI3Kγ that is required to regulate IL-17 production. However, the 
phenotype could not be reproduced using PI3Kγ inhibitors (data not shown) over the 
timescales used for the other experiments shown here. This might suggest that the 
mechanism is PI3Kγ mediated, and that small molecule inhibitors do not have the 
required selectivity to avoid influencing other confounding stimulatory/inhibitory 
mechanisms. In addition, it is worth noting that the defects in the Itk-/- T cell 
production of IL-17A mentioned above, could also not be rescued using 
pharmacological intervention (510), leading to the hypothesis that chromatin  
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Figure 9.3 Model of the role of PI3Kγ in IL-17 signalling and production 
In murine T cells, IL-17A signals, probably via the IL-17RA receptor, to activate 
PI3Kγ. PI3Kγ negatively regulates the expression of IL-17RA and also the production 
of both IL-17A and IL-17F, thus completing a negative feedback loop. 
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remodelling of the IL-17A locus by NFAT signalling during development may be 
important, as well as NFAT mediated IL-17A transcription (510, 519).  Hence, the 
alternative explanation is that loss of PI3Kγ during development is important in 
determining IL-17 signalling in mature T cells. This would also be in line with findings 
that loss of PI3Kγ and PI3Kδ can cause defective Th1 and Th2 responses which 
cannot be fully replicated using inhibitors and which are due to defects during 
thymocyte development (168). Genetic loss of PI3Kγ has been previously 
demonstrated to result in reduced disease severity in models of conditions such as 
asthma and arthritis (175), due to the decreased migration of leukocytes to sites of 
infection and inflammation in PI3Kγ-/- animals (174, 177). However, overexpression of 
IL-17A (10) or IL-17F (520) has been reported to induce airway inflammation. Excess 
IL-17 generation may cause pro-inflammatory complications, particularly as IL-17 can 
act upon tissue cells to induce further inflammation (378, 499). IL-17 has been 
implicated in the suppression of T cell cytotoxicity, and inhibits clearance of 
persistent viral infections (521). Similarly, IL-17 is involved in the generation of an 
autoimmune response and multiple diseases in the airway, as it has roles in both 
innate and adaptive immunity (522). Furthermore, sustained high levels of Il-17A and 
Il-17F may favour tumour development (43). One concern therefore, is that chronic 
PI3Kγ inhibition as currently being explored in a range of inflammatory disease 
settings may lead to adverse effects as a result of elevated IL-17 production. 
However, this would be unlikely, due to the inability of PI3Kγ-/- cells to migrate to sites 
of inflammation (177). 
In summary, this section of the results identified a novel mechanism of signalling 
downstream of Il-17RA in response to IL-17A (but not IL-17F) in which PI3Kγ is 
required for Akt phosphorylation. PI3Kγ was also required for maintenance of normal 
levels of IL-17 receptor expression. These defects may contribute to an increase in 
IL-17A and Il-17F levels observed both in vitro and in vivo upon knockout of PI3Kγ. 
9.23 Future work on the role of PI3Kγ in IL-17 production 
Future experiments will examine the expression of the IL-23 receptor, RORγ(t) and 
RORα in PI3Kγ-/- T cells. In addition the regulatory T cells will be charachterised by 
examination of foxp3 expression.  The activation of PI3K γ downstream of IL-17 
receptors will be investigated by western blotting and will also be examined in B cells. 
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In addition, the role of PI3Kγ in IL-17 production will be examined in human T cells 
using lentiviral delivery to silence expression of PI3Kγ. 
9.24 General conclusions 
In conclusion, the work in this thesis has examined two areas of PI3K signalling in T 
cells, firstly exploring the role of SHIP-1 in human T cells and secondly exploring the 
role of PI3Kγ in murine T cells. In both cases the findings contribute to an 
understanding of PI3K signalling which will be of relevance to the development of 
drugs targeting PI3K in the immune system. 
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